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(57) Abstract: The invention relates to agonistic anti-MET antibodies and uses thereof in the therapeutic treatment of disease. The
antibodies bind with high affinity to the human and mouse hepatocyte growth factor (HGF) receptor, also known as MET, and are
agonists of MET in both humans and mice, producing molecular and cellular effects resembling the effects of HGF binding.
ANTI-MET ANTIBODIES AND USES THEREOF
FIELD OF THE INVENTION
The present invention relates to antibodies and antigen binding fragments that bind with
high affinity to the human and mouse hepatocyte growth factor (HGF) receptor, also known
as MET. The antibodies and antigen binding fragments are agonists of MET in both
humans and mice, resulting in molecular and cellular effects resembling the effects of HGF
binding. The invention further relates to therapeutic uses of antibodies and antigen binding
fragments that are agonists of MET.
BACKGROUND
HGF is a pleiotropic cytokine of mesenchymal origin that mediates a characteristic array of
biological functions including cell proliferation, motility, differentiation and survival. The
HGF receptor, also known as MET, is expressed by a variety of tissues including all
epithelia, the endothelium, muscle cells, neuronal cells, osteoblasts, hematopoietic cells
and various components of the immune system.
HGF and MET signalling plays an essential role during embryo development, where it
guides migration of precursor cells and determines cell survival or death. In adults,
HGF/MET signalling is ordinarily quiescent and is resumed during wound healing and
tissue regeneration. Some cancers and tumours usurp HGF/MET signalling in order to
promote the survival and proliferation of the tumour in the host organism. Therefore,
inhibiting the HGF-MET axis has become a popular target for anti-cancer treatment, though
with limited success.
Due to its role in tissue healing and regeneration, recombinant HGF has also been
investigated as a treatment for a number of conditions, including degenerative diseases,
inflammatory diseases, auto-immune diseases, metabolic diseases, and transplantation-
related disorders. However, recombinant HGF has poor pharmacological properties: it
requires proteolytic activation in order to become biologically active; once activated, it has
an extremely short half-life in vivo; and its industrial manufacture is complex and
expensive.
Agonistic anti-MET antibodies which activate MET in a manner mimicking that of HGF have
been proposed as alternatives.
The following antibodies that mimic HGF activity, at least partially, have been described: (i)
the 3D6 mouse anti-human MET antibody (U.S. Patent No. 6,099,841 ) ; (ii) the 5D5 mouse
anti-human MET antibody (U.S. Patent No. 5,686,292); (iii) the NO-23 mouse anti-human
MET antibody (U.S. Patent No. 7,556,804 B2); (iv) the B7 human naive anti-human MET
antibody (U.S. Patent Application No. 2014/0193431 A1); (v) the DO-24 mouse anti-human
MET antibody (Prat et al., Mol Cell Biol. 11, 5954-5962, 1991 ; Prat et al., J Cell Sci. 111,
237-247, 1998); and (vi) the DN-30 mouse anti-human MET antibody (Prat et al., Mol Cell
Biol. 11, 5954-5962, 1991 ; Prat et al., J Cell Sci. 111, 237-247, 1998).
SUMMARY OF INVENTION
Agonistic anti-MET antibodies generated to date, for example those described in the
Background section, are frequently obtained as by-products from processes intending to
identify antagonistic molecules and are not designed explicitly to become agonistic
molecules for therapeutic use. Moreover, the most manifest limit of the prior art anti-MET
antibodies is that they have been generated in a mouse system (except for B7 that was
identified using a human na'ive phage library); as a result, it is unlikely that these antibodies
will display cross-reactivity with mouse MET. Even if a minor cross-reactivity with self-
antigens is in principle possible, these interactions have normally a very low affinity.
While the absence of cross-reactivity is not a concern for mouse models of cancer (as they
employ human xenografts), cross-reactivity of antibodies between human and mouse MET
is an important requirement for pre-clinical mouse models of regenerative medicine or non-
oncological human diseases, which require the antibody to function on mouse tissues and
cells.
Not only is it necessary for an agonistic anti-MET antibody to cross-react with mouse MET
in order for the antibody to be evaluated in pre-clinical models, but it is desirable that the
antibody binds to mouse MET with an affinity the same or similar to its affinity for human
MET, and also that the antibody elicits effects in mouse systems the same or similar to the
effects which it evokes in human systems - otherwise the experiments conducted in pre-
clinical models will not be predictive of the human situation. As demonstrated in the
Examples, none of the prior art anti-MET agonistic antibodies exhibit affinity for mouse
MET, and certainly none of the prior art antibodies exhibit the same or similar binding and
agonistic effects in both mouse and human systems.
The present application provides anti-MET agonistic antibodies made by design to bind to
both human and mouse MET with high affinities. These antibodies: (i) display agonistic
activity in both human and mouse MET biological systems - that is they induce MET
signalling - some with a potency similar or superior to that of HGF; (ii) elicit the full
spectrum of HGF-induced biological activities, thus representing valid substitutes for
recombinant HGF; (iii) exhibit superior binding to mouse MET when directly compared to
prior art antibodies; (iv) display biologically significant agonistic activity at concentrations as
low as 1 pM; (v) display a plasma half-life of several days in mice, reaching
pharmacologically saturating concentrations already at a dose of 1 µg kg, which is very low
for a therapeutic antibody; (vi) preserve renal function and kidney integrity in a mouse
model of acute kidney injury; (vii) prevent liver failure and antagonize hepatocyte damage
in a mouse model of acute liver injury; (viii) display anti-fibrotic, anti-inflammatory and pro-
regenerative activity in a mouse model of chronic liver damage; (ix) prevent weight loss,
attenuate intestinal bleeding, preserve colon integrity, suppress inflammation and promote
epithelial regeneration in a mouse model of ulcerative colitis and a mouse model of
inflammatory bowel disease; (x) promote insulin-independent uptake of glucose in a mouse
model of type I diabetes; (xi) overcome insulin resistance in a mouse model of type I I
diabetes; (xii) ameliorate fatty liver, suppress fibrosis and restore liver function in a mouse
model of non-alcoholic steatohepatitis (NASH); (xiii) accelerate wound healing in a mouse
model of diabetic ulcer; (xiv) cross-react with Rattus norvegicus MET and Macaca
fascicularis MET, thus allowing to conduct toxicological and pharmacological studies in
these two vertebrates, required prior to applying for first-in-human trials; (xv) recognise
epitopes conserved across human, mouse, rat and cynomolgus macaque, thereby
providing greater utility across animal models.
Therefore, in a first aspect, the present invention provides an antibody, or an antigen
binding fragment thereof, which binds human MET protein (hMET) with high affinity and
binds mouse MET protein (mMET) with high affinity, wherein the antibody or an antigen
binding fragment thereof is a hMET agonist and a mMET agonist. In certain embodiments,
the antibody or antigen binding fragment thereof comprises at least one heavy chain
variable domain (VH) and at least one light chain variable domain (VL), wherein said VH
and VL domain, when tested as a Fab fragment, exhibit an off-rate (k
off
measured by
Biacore) for hMET in the range of from 1 x 10~3 s 1 to 1 x 10~2 s 1 , optionally 1 x 10~3 s 1 to 6 x
10~3 s and exhibit an off-rate (k
off
measured by Biacore) for mMET in the range of from 1 x
10 3 s 1 to 1 x 10~2 s 1 , optionally 1 x 10 3 s 1 to 6 x 10 3 s 1 . In certain embodiments, the
antibody or antigen binding fragment thereof has equivalent affinity for hMET and mMET.
In certain embodiments, the antibody or antigen binding fragment thereof induces
phosphorylation of hMET and induces phosphorylation of mMET. In certain embodiments,
the antibody or antigen binding fragment induces phosphorylation of hMET with an EC
50
(as measured by phospho-MET ELISA) of less than 3.0 nM, optionally less than 2.0 nM
and induces phosphorylation of mMET with an EC
50
(as measured by phospho-MET
ELISA) of less than 3.0 nM, optionally less than 2.0 nM. In certain embodiments, the
antibody or antigen binding fragment thereof induces phosphorylation of hMET and mMET
equivalently.
In certain embodiments, the antibody or antigen binding fragment thereof exhibits high
phosphorylation potency for hMET and exhibits high phosphorylation potency for mMET. In
certain embodiments, the antibody or antigen binding fragment thereof induces
phosphorylation of hMET with an EC
50
of less than 1nM and/or an E
max
(as a percentage of
HGF-induced activation in a phospho-MET ELISA) of at least 80%.and induces
phosphorylation of mMET with an EC
50
of less than 1nM and/or an E
max
(as a percentage of
HGF-induced activation in a phospho-MET ELISA) of at least 80%. In certain alternative
embodiments, the antibody or antigen binding fragment thereof exhibits low
phosphorylation potency for hMET and exhibits low phosphorylation potency for mMET. In
certain such embodiments, the antibody or antigen binding fragment thereof induces
phosphorylation of hMET with EC
50
of 1nM-5nM and/or an E
max
(as a percentage of HGF-
induced activation in a phospho-MET ELISA) of 60-80% and induces phosphorylation of
mMET with EC
50
of 1nM-5nM and/or an E
max
(as a percentage of HGF-induced activation in
a phospho-MET ELISA) of 60-80%.
In certain embodiments, the antibody or antigen binding fragment thereof induces an HGF-
like cellular response when contacted with a human cell and induces an HGF-like cellular
response when contacted with a mouse cell. In certain embodiments, the antibody or
antigen binding fragment thereof fully induces an HGF-like cellular response when
contacted with a human cell and when contacted with a mouse cell. In certain
embodiments, full induction of HGF-like cellular response is measurable as one, any two,
or all of:
(i) in a cell scattering assay, the antibody or antigen binding fragment thereof
induces cell scattering comparable to maximal HGF-induced scattering when the antibody
or antigen binding fragment thereof is at a concentration of 0.1-1 .0 nM;
(ii) in an anti-apoptotic cell assay, the antibody or antigen binding fragment
thereof exhibits an EC
50
of less than 1.1x that of HGF, and/or with an E
max
(measured as a
% of total ATP content of non-apoptotic control cells) of greater than 90% that observed for
HGF; and/or
(iii) in a branching morphogenesis assay, cells treated with the antibody exhibit
greater than 90% of the number of branches per spheroid induced by the same (non-zero)
concentration of HGF.
In certain embodiments, the antibody or antigen binding fragment thereof partially induces
an HGF-like cellular response when contacted with a human cell and when contacted with
a mouse cell. In certain embodiments, partial induction of an HGF-like cellular response is
measurable as:
(i) in a cell scattering assay, the antibody or antigen binding fragment thereof
induces cell scattering of at least 25% that induced by 0.1 nM homologous HGF when the
antibody concentration is 1 nM or lower;
(ii) in anti-apoptotic cell assay, the antibody or antigen binding fragment thereof
exhibits an EC
50
no more than 7.0x that of HGF and/or an E
max
cellular viability of at least
50% that observed for HGF; and/or
(ii) in a branching morphogenesis assay, cells treated with the antibody exhibit
at least 25% the number of branches per spheroid induced by the same (non-zero)
concentration of HGF;
and the antibody or antigen binding fragment does not fully induce an HGF-like cellular
response.
In certain embodiments, the antibody or antigen binding fragment thereof is a HGF
competitor. In certain embodiments, the antibody or antigen binding fragment thereof
competes with hHGF binding to hMET with an IC
50
of no more than 5nM and/or an l
max
of at
least 50% and competes with mHGF binding to mMET with an IC
50
of no more than 5nM
and/or an l
max
of at least 50%. In certain embodiments, the antibody or antigen binding
fragment thereof competes with hHGF and mHGF equivalently. In certain embodiments,
the antibody or antigen binding fragment thereof is a full HGF competitor. In certain such
embodiments, the antibody or antigen binding fragment thereof competes with hHGF with
an IC
50
of less than 2 nM and/or an l
max
of greater than 90% and competes with mHGF with
an IC
50
of less than 2 nM and/or an l
max
of greater than 90%. In certain embodiments, the
antibody or antigen binding fragment thereof is a partial HGF competitor. In certain such
embodiments, the antibody or antigen binding fragment thereof competes with hHGF with
an IC
50
of 2-5nM and/or an l
max
of 50%-90% and competes with mHGF with an IC
50
of 2-
5nM and/or an l
max
of 50%-90%.
Antibodies or antigen binding fragment thereof of the invention may exhibit cross-reactivity
with MET of simian origin, such as cynomolgus monkey (Macaca cynomolgus) MET, and
may exhibit cross-reactivity with MET of rat origin (Rattus norvegicus).
Antibodies or antigen binding fragment thereof of the invention may bind an epitope of
human MET from amino acid residue 123 to223 of human MET (throughout the document,
numbering of human MET refers to GenBank sequence # X54559). Also provided are
antibodies or antigen binding fragment thereof of the invention which may bind an epitope
of human MET between amino acids 224-31 1 of human MET. Also provided are antibodies
or antigen binding fragment thereof of the invention which may bind an epitope of human
MET between amino acids 314-372 of human MET. Also provided are antibodies or
antigen binding fragment thereof of the invention which may bind an epitope of human MET
between amino acids 546-562 of human MET.
Also provided are antibodies or antigen binding fragment thereof of the invention which
may bind an epitope of human MET comprising the amino acid residue Ile367. Also
provided are antibodies or antigen binding fragment thereof of the invention which may
bind an epitope of human MET comprising the amino acid residue Asp372 of human MET.
In certain embodiments, the antibody or antigen binding fragment thereof binds an epitope
of human MET comprising the amino acid residues Ile367 and Asp372 of human MET.
Also provided are antibodies or antigen binding fragment thereof of the invention which
may bind an epitope of human MET comprising the amino acid residue Thr555 of human
MET.
The invention further provides an antibody or antigen binding fragment thereof which
comprises a heavy chain variable domain comprising H-CDR1 , H-CDR2 and H-CDR3, and
a light chain variable domain comprising L-CDR1 , L-CDR2 and L-CDR3, wherein:
H-CDR1 comprises an amino acid sequence selected from SEQ ID NO:2, 9 , 16, 23, 30, 37,
44, 5 1 , 58, 65, and 72;
H-CDR2 comprises an amino acid sequence selected from SEQ ID NO:4, 11, 18 , 25, 32,
39, 46, 53, 60, 67, and 74;
H-CDR3 comprises an amino acid sequence selected from SEQ ID NO:6, 13 , 20, 27, 34,
4 1 , 48, 55, 62, 69, and 76,
L-CDR1 comprises an amino acid sequence selected from SEQ ID NO:79, 86, 93, 100,
107, 114, 12 1 , 128, 135, 142, and 149;
L-CDR2 comprises an amino acid sequence selected from SEQ ID NO:81 , 88, 95, 102,
109, 116, 123, 130, 137, 144, and 151 ; and
L-CDR3 comprises an amino acid sequence selected from SEQ ID NO:83, 90, 97, 104,
111, 118, 125, 132, 139, 146, and1 53.
[71 G2] In one embodiment, the invention provides an antibody or antigen binding fragment
which comprises a heavy chain variable domain comprising H-CDR1 , H-CDR2 and H-
CDR3, and a light chain variable domain comprising L-CDR1 , L-CDR2 and L-CDR3,
wherein:
H-CDR1 comprises the amino acid sequence shown as SEQ ID NO:44,
H-CDR2 comprises the amino acid sequence shown as SEQ ID NO:46,
H-CDR3 comprises the amino acid sequence shown as SEQ ID NO:48,
L-CDR1 comprises the amino acid sequence shown as SEQ ID NO:121 ,
L-CDR2 comprises the amino acid sequence shown as SEQ ID NO:123, and
L-CDR3 comprises the amino acid sequence shown as SEQ ID NO:125.
[71 G2] In certain such embodiments, the heavy chain variable domain of the antibody or
fragment comprises the amino acid sequence of SEQ ID NO:1 67, or a sequence at least
90%, 95%, 97% or 99% identical thereto, and the light chain variable domain comprises the
amino acid sequence of SEQ ID NO:168, or a sequence at least 90%, 95%, 97% or 99%
identical thereto.
[71 D6] In another embodiment, the invention provides an antibody or antigen binding
fragment which comprises a heavy chain variable domain comprising H-CDR1 , H-CDR2
and H-CDR3, and a light chain variable domain comprising L-CDR1 , L-CDR2 and L-CDR3,
wherein:
H-CDR1 comprises the amino acid sequence shown as SEQ ID NO:30,
H-CDR2 comprises the amino acid sequence shown as SEQ ID NO:32,
H-CDR3 comprises the amino acid sequence shown as SEQ ID NO:34,
L-CDR1 comprises the amino acid sequence shown as SEQ ID NO:107,
L-CDR2 comprises the amino acid sequence shown as SEQ ID NO:109, and
L-CDR3 comprises the amino acid sequence shown as SEQ ID NO:1 11.
[71 D6] In certain such embodiments, the heavy chain variable domain of the antibody or
antigen binding fragment comprises the amino acid sequence of SEQ ID NO:1 63, or a
sequence at least 90%, 95%, 97% or 99% identical thereto, and the light chain variable
domain comprises the amino acid sequence of SEQ ID NO:164, or a sequence at least
90%, 95%, 97% or 99% identical thereto.
[71 G3] In a further embodiment, the invention provides an antibody or antigen binding
fragment which comprises a heavy chain variable domain comprising H-CDR1 , H-CDR2
and H-CDR3, and a light chain variable domain comprising L-CDR1 , L-CDR2 and L-CDR3,
wherein:
H-CDR1 comprises the amino acid sequence shown as SEQ ID NO:9,
H-CDR2 comprises the amino acid sequence shown as SEQ ID NO:1 1,
H-CDR3 comprises the amino acid sequence shown as SEQ ID NO:1 3 ,
L-CDR1 comprises the amino acid sequence shown as SEQ ID NO:86,
L-CDR2 comprises the amino acid sequence shown as SEQ ID NO:88, and
L-CDR3 comprises the amino acid sequence shown as SEQ ID NO:90.
[71 G3] In certain such embodiments, the heavy chain variable domain of the antibody or
antigen binding fragment comprises the amino acid sequence of SEQ ID NO:1 57, or a
sequence at least 90%, 95%, 97% or 99% identical thereto, and the light chain variable
domain comprises the amino acid sequence of SEQ ID NO:158, or a sequence at least
90%, 95%, 97% or 99% identical thereto.
In further embodiments, the invention provides an antibody or antigen binding fragment
comprising a heavy chain variable domain comprising H-CDR1 , H-CDR2 and H-CDR3, and
a light chain variable domain comprising L-CDR1 , L-CDR2 and L-CDR3, wherein H-CDR1 ,
H-CDR2 and H-CDR3 are selected from a set of CDRs (CDR1 , CDR2 and CDR3) for a Fab
shown in Table 3 , and L-CDR1 , L-CDR2 and L-CDR3 are the corresponding CDRs (CDR1 ,
CDR2 and CDR3) for the same Fab shown in Table 4 .
In certain embodiments, the heavy chain variable domain of the antibody or antigen binding
fragment comprises a VH amino acid sequence from Table 5 or a sequence at least 90%,
95%, 97% or 99% identical thereto, and the light chain variable domain comprises the
corresponding VL amino acid sequence in Table 5 or a sequence at least 90%, 95%, 97%
or 99% identical thereto.
Embodiments wherein the amino acid sequence of the VH domain exhibits less than 100%
sequence identity with a defined VH domain amino acid sequence (e.g. SEQ ID NO: x)
may nevertheless comprise heavy chain CDRs which are identical to the HCDR1 , HCDR2
and HCDR3 of the VH of SEQ ID NO: xwhilst exhibiting amino acid sequence variation
within the framework regions. For example, one or more amino acid residues of the
framework region may be substituted by an amino acid residue which occurs in the
equivalent position in a human VH domain encoded by the human germline. Likewise,
embodiments wherein the amino acid sequence of the VL domain exhibits less than 100%
sequence identity with a defined VL domain amino acid sequence (e.g. SEQ ID NO:y) may
nevertheless comprise light chain CDRs which are identical to the LCDR1 , LCDR2 and
LCDR3 of the VL of SEQ ID NO:y, whilst exhibiting amino acid sequence variation within
the framework regions. For example, one or more amino acid residues of the framework
region may be substituted by an amino acid residue which occurs in the equivalent position
in a human VL domain encoded by the human germline.
The invention also provides antibodies and antigen binding fragments comprising
humanised/germlined variants of VH and VL domains of the foregoing antibodies, plus
affinity variants and variants containing conservative amino acid substitutions, as defined
herein. Specifically provided are chimeric antibodies containing VH and VL domains of the
llama-derived Fabs described above, or human germlined variants thereof, fused to
constant domains of human antibodies, in particular human lgG1 , lgG2, lgG3 or lgG4. The
heavy and light chain variable domains of the foregoing antibodies, or germlined variants,
affinity variants or conserved variants thereof, may be included within a conventional four-
chain antibody or other antigen binding proteins, such as for example Fab, Fab', F(ab')2, bi-
specific Fabs, and Fv fragments, diabodies, linear antibodies, single-chain antibody
molecules, a single chain variable fragment (scFv) and multispecific antibodies. The heavy
chain variable domains, or germlined variant, affinity variant or conserved variant thereof,
can also be utilised as single domain antibodies.
In further aspects, the invention also provides an isolated polynucleotide which encodes an
antibody or antigen binding fragment of the invention, an expression vector comprising said
polynucleotide operably linked to regulatory sequences which permit expression of the
antibody or antigen binding fragment thereof in a host cell or cell-free expression system,
and a host cell or cell free expression system containing said expression vector. The
invention further provides a method of producing a recombinant antibody or antigen binding
fragment thereof which comprises culturing said host cell or cell free expression system
under conditions which permit expression of the antibody or antigen binding fragment and
recovering the expressed antibody or antigen binding fragment.
In a further aspect, the invention provides a pharmaceutical composition comprising an
antibody or antigen binding fragment of the invention and at least one pharmaceutically
acceptable carrier or excipient.
In a further aspect, the invention provides an antibody or antigen binding fragment of the
invention, or the pharmaceutical composition of the invention, for use in therapy.
In a further aspect, the invention provides a method of treating or preventing liver damage
in a human patient, optionally acute liver damage or chronic liver damage, which comprises
administering to a patient in need thereof a therapeutically effective amount of a MET
agonist antibody. In certain embodiments, the MET agonist antibody is an antibody or
antigen binding fragment according to the invention.
In a further aspect, the invention provides a method of treating or preventing kidney
damage in a human patient, optionally acute kidney damage, which comprises
administering to a patient in need thereof a therapeutically effective amount of a MET
agonist antibody. In certain embodiments, the MET agonist antibody is an antibody or
antigen binding fragment according to the invention.
In a further aspect, the invention provides a method of treating or preventing inflammatory
bowel disease in a human patient, optionally ulcerative colitis, which comprises
administering to a patient in need thereof a therapeutically effective amount of a MET
agonist antibody. In certain embodiments, the MET agonist antibody is an antibody or
antigen binding fragment according to the invention.
In a further aspect, the invention provides a method of treating or preventing diabetes in a
human patient, optionally type I or type I I diabetes, which comprises administering to a
patient in need thereof a therapeutically effective amount of a MET agonist antibody.
In certain embodiments, the MET agonist antibody is an antibody or antigen binding
fragment according to the invention.
In a further aspect, the invention provides a method of treating or preventing non-alcoholic
steatohepatitis in a human patient, which comprises administering to a patient in need
thereof a therapeutically effective amount of a MET agonist antibody. In certain
embodiments, the MET agonist antibody is an antibody or antigen binding fragment
according to the invention.
In a further aspect, the invention provides a method of treating or promoting wound healing
in a human patient, optionally a patient having diabetes, which comprises administering to
a patient in need thereof a therapeutically effective amount of a MET agonist antibody. In
certain embodiments, the MET agonist antibody is an antibody or antigen binding fragment
according to the invention.
DRAWINGS
Figure 1. Immune response of llamas immunized with human MET-Fc as determined
by ELISA. Human MET ECD (hMET) or mouse MET ECD (mMET) recombinant protein
was immobilized in solid phase and exposed to serial dilutions of sera from llamas before
(PRE) or after (POST) immunization. Binding was revealed using a mouse anti-llama lgG1
and a HRP-conjugated donkey anti-mouse antibody. OD, optical density; AU, arbitrary
units.
Figure 2. Schematic drawing of the human MET deletion mutants used for identifying
the domains of MET responsible for mAb binding. ECD, extra-cellular domain; aa,
amino acid; L. peptide, leader peptide; SEMA, semaphorin homology domain; PSI or P,
plexin-semaphorin-integrin homology domain; IPT, Immunoglobulin-transcription factor-
plexin homology domain. On the right, the corresponding residues of human MET are
reported according to UniProtKB # P08581 .
Figure 3. Schematic drawing of the llama-human chimeric MET proteins used for
finely mapping the epitopes recognized by anti-MET antibodies. The extracellular
portions of llama MET and human MET are composed of 931 and 932 amino acids (aa),
respectively (llama MET has a 2 aa shorter leader peptide but has an insertion after aa
163). Both receptor ectodomains comprise a leader peptide, a semaphorin homology
domain (SEMA), a plexin-semaphorin-integrin homology domain (PSI or P) and four
immunoglobulin-transcription factor-plexin homology domains (IPT). Chimeras CH1 -5 have
a N-terminal llama portion followed by a C-terminal human portion. Chimeras CH6-7 have
an N-terminal human portion followed by a C-terminal llama portion.
Figure 4. Agonistic activity of human/mouse equivalent anti-MET antibodies in
human and mouse cells as measured by Western blotting. A549 human lung
carcinoma cells and MLP29 mouse liver precursor cells were serum-starved and then
stimulated with increasing concentrations of mAbs or recombinant human HGF (hHGF;
A549) or mouse HGF (mHGF; MLP29). MET auto-phosphorylation was determined by
Western blotting using anti-phospho-MET antibodies (tyrosines 1234-1 235). The same cell
lysates were also analysed by Western blotting using anti-total human MET antibodies
(A549) or anti-total mouse MET antibodies (MLP29).
Figure 5. Biological activity of human/mouse equivalent anti-MET antibodies as
measured by a branching morphogenesis assay using LOC human kidney epithelial
cells and MLP29 mouse liver precursor cells. Cell spheroids were seeded inside a
collagen layer and then exposed to increasing concentrations of mAbs or recombinant
human HGF (LOC) or mouse HGF (MLP29). Branching morphogenesis was followed over
time by microscopy, and colonies were photographed after 5 days.
Figure 6. Comparison with prior art antibodies: human-mouse cross-reactivity.
Human or mouse MET ECD was immobilized in solid phase and exposed to increasing
concentrations of antibodies (all in a mouse lgG/λ format) in solution. Binding was revealed
by ELISA using HRP-conjugated anti-mouse Fc antibodies.
Figure 7. Comparison with prior art antibodies: MET auto-phosphorylation. A549
human lung carcinoma cells and MLP29 mouse liver precursor cells were deprived of
serum growth factors for 48 hours and then stimulated with increasing concentrations of
antibodies. After 15 minutes of stimulation, cells were lysed, and phospho-MET levels were
determined by ELISA using anti-MET antibodies for capture and anti-phospho-tyrosine
antibodies for revealing.
Figure 8. Comparison with prior art antibodies: branching morphogenesis. LOC
human kidney epithelial cell spheroids were seeded in a collagen layer and then incubated
with increasing concentrations of mAbs. Branching morphogenesis was followed over time
by microscopy, and colonies were photographed after 5 days.
Figure 9. Comparison with prior art antibodies: branching morphogenesis. MLP29
mouse liver precursor cell spheroids were seeded in a collagen layer and then incubated
with increasing concentrations of mAbs. Branching morphogenesis was followed over time
by microscopy, and colonies were photographed after 5 days.
Figure 10. Plasma stability of human/mouse equivalent anti-MET antibodies. A single
bolus of 1 mg/kg or 10 mg/kg antibody was injected i.p. and blood samples were taken
from the tail vein at 3 , 6 , 12 and 24 hours post-injection. Blood samples were processed
and antibody concentration in plasma was determined by ELISA. (A) Peak and trough
levels of injected antibodies. (B) Antibody plasma half-life was calculated by linear fitting of
the antibody concentration Ln transforms.
Figure 11. Acute liver failure model: plasma concentration of liver function markers.
Acute liver damage was induced in BALB/c mice by subcutaneous injection of a CCI4
solution. Soon after intoxication, mice were randomized into 4 arms which received a single
bolus of 7 1G3, 7 1D6, 7 1G2 or vehicle only (PBS). Antibodies were administered by i.p.
injection at a dose of 5 mg/kg. Each arm comprised three groups of mice that were
sacrificed at different times post-intoxication (12, 24 and 48 hours). Blood samples were
taken at different times post-injection (0, 12, 24 and 48 hours). At autopsy, blood and livers
were collected for analysis. Plasma levels of the hepatic markers aspartate transaminase
(AST), alanine aminotransferase (ALT) and bilirubin (BIL) was determined by standard
clinical biochemistry methods.
Figure 12. Acute liver failure model: histological examination of liver sections. Acute
liver damage was induced in BALB/c mice as described in Figure 11 legend. At autopsy,
livers were extracted and embedded in paraffin for histological analysis. Sections were
stained with hematoxylin and eosin and examined by microscopy. A representative image
for each treatment arm is shown. Magnification: 100X.
Figure 13. Chronic liver damage model: plasma concentration of liver function
markers. Liver injury and fibrosis in BALB/c mice was induced by chronic exposure to CCI4
for several weeks. Soon after the first CCI4 injection, mice were randomized into 4 arms
which received treatment with 7 1G3, 7 1D6, 7 1G2 or vehicle only (PBS), respectively.
Antibodies were administered three times a week by i.p. injection at a dose of 1 mg/kg. An
additional, fifth control arm received no CCI4 or antibody and served as healthy control.
Mice were sacrificed after 6 weeks of chronic CCI4 intoxication. At autopsy, blood and livers
were collected for analysis. Plasma levels of the hepatic markers aspartate transaminase
(AST) and alanine aminotransferase (ALT) were determined by standard clinical
biochemistry methods.
Figure 14. Chronic liver damage model: histological examination of liver sections
stained with Picro Sirius red. Liver injury and fibrosis in BALB/c mice were induced by
chronic exposure to CCI as described in Figure 13 legend. At autopsy, livers were
extracted and embedded in paraffin for immuno-histochemical analysis. Sections were
stained with Picro Sirius red. A representative image for each treatment arm is shown.
Magnification: 100X.
Figure 15. Chronic liver damage model: histological examination of liver sections
stained with anti-alpha smooth muscle actin (a-SMA) antibodies. Liver injury and
fibrosis in BALB/c mice were induced by chronic exposure to CCI as described in Figure
13 legend. At autopsy, livers were extracted and embedded in paraffin for immuno-
histochemical analysis. Sections were stained with anti-alpha smooth muscle actin (a-SMA)
antibodies. A representative image for each treatment arm is shown. Magnification: 100X.
Figure 16. Acute kidney injury model: plasma levels of renal function markers. Acute
renal failure was induced in BALB/c mice by i.p. injection of a single bolus of HgCI2. Soon
after HgCI2 intoxication, mice were randomized into 4 arms which were subjected to
treatment with 7 1G3, 7 1D6, 7 1G2 or vehicle only (PBS). Antibodies were administered by
i.p. injection every 24 hours at a dose of 5 mg/kg. Mice were sacrificed 72 hours after HgCI2
injection. At autopsy, blood and kidneys were collected for analysis. Blood urea nitrogen
(BUN) and creatinine (CRE) plasma levels were determined by standard clinical
biochemistry methods.
Figure 17. Acute kidney injury model: histological analysis of kidney sections. Acute
renal failure was induced in BALB/c mice by HgCI2 injection as described in Figure 16
legend. At autopsy, kidneys were extracted and embedded in paraffin for histological
analysis. Kidney sections were stained with hematoxylin and eosin. A representative image
for each treatment arm is shown. Magnification: 400X.
Figure 18. Ulcerative colitis model: body weight, Disease Activity Index (DAI), and
colon length. Ulcerative colitis was induced in BALB/c mice by addition of dextran sodium
sulphate (DSS) to the drinking water for 10 days. On day 10 , DSS treatment was
interrupted and mice were put back on normal water. Starting from day 1, mice were
randomized into 7 arms which received treatment with 7 1G3, 7 1D6, 7 1G2 (at a dose of 1
mg/kg or 5 mg/kg) or vehicle only (PBS). An additional, eighth control arm received no DSS
or antibody and served as healthy control. Mice were sacrificed on day 12 , i.e. 2 days after
DSS administration was interrupted. At autopsy, colons were collected, washed through,
and their length was determined using a ruler. Following measurement, colons were
embedded in paraffin and processed for histological analysis. During the whole course of
the experiment, mouse weight was monitored on a regular basis, and the clinical symptoms
of ulcerative colitis were assessed by determining faecal blood, rectal bleeding and stool
consistency. Each parameter was given a score from 0 (absence of the symptom) to 3
(maximal manifestation of the symptom). Scores relative to the single parameters were
summed together to give rise to the DAI ranging from 0 to 9 . (A) Body weight over time (%
relative to time 0). (B) DAI over time. (C) Colon length at autopsy. Data of the 1 mg/kg arms
and of the 5 mg/kg arms are shown in separate graphs for clarity.
Figure 19. Ulcerative colitis model: histological analysis of colon sections. Ulcerative
colitis was induced in BALB/c mice by exposure to dextran sodium sulphate (DSS) as
described in Figure 18 legend. At autopsy, colons were collected, measured, and then
embedded in paraffin and processed for histological analysis. Colon sections were stained
with hematoxylin and eosin, examined by microscopy, and photographed. Experimental
arm, antibody dose and magnification are indicated close to each image. Please refer to
the main text for image analysis.
Figure 20. Inflammatory bowel disease model: body weight and colon length. Colon
injury and inflammation was induced in C57BLKS/J mice by intra-rectal injection of 2,4,6-
trinitrobenzenesulfonic acid (TNBS) dissolved in ethanol. Soon after TNBS administration,
mice were randomized into 4 arms which received treatment with 7 1G3, 7 1D6, 7 1G2 or
vehicle only (PBS). An additional, fifth control arm received no TNBS or antibody and
served as healthy control. Mice were sacrificed 5 days after TNBS administration. At
autopsy, colons were collected and measured. Following measurement, colons were
embedded in paraffin and processed for histological analysis. During the whole course of
the experiment, mouse weight was measured every day. (A) Body weight over time (%
relative to time 0). (B) Colon length at autopsy.
Figure 21. Inflammatory bowel disease model: histological analysis of colon
sections. Colon injury and inflammation was induced in BALB/c mice by intra-rectal
injection of 2,4,6-trinitrobenzenesulfonic acid (TNBS) as described in Figure 20 legend. At
autopsy, colons were collected and measured. Following measurement, colons were
embedded in paraffin and processed for histological analysis. Colon sections were stained
with hematoxylin and eosin, examined by microscopy, and photographed. Please refer to
the main text for image analysis.
Figure 22. Type I diabetes model: promotion of glucose uptake and cooperation with
insulin in diabetic mice. Pancreatic β-cell degeneration was induced in BALB/c mice by
i.p. injection of streptozotocin (STZ). STZ-treated mice displayed a mean basal glycemy
two times higher compared to untreated mice. STZ-treated mice were randomized into 4
arms, which received treatment with 7 1G3, 7 1D6, 7 1G2 or vehicle only (PBS), respectively.
An additional, fifth control arm received no STZ or antibody and served as healthy control.
Blood glucose concentration in fasting conditions was monitored over time for 5 weeks. At
the end of week 5 , a glucose tolerance test (GTT) and an insulin tolerance test (ITT) were
performed. (A) Analysis over time of basal blood glucose levels in fasting conditions. (B)
GTT: following oral administration of glucose to a fasting animal, blood glucose levels are
monitored over time. (C) ITT: following i.p. injection of insulin to a partially fasting animal,
blood glucose levels are monitored over time.
Figure 23. Type I diabetes model: promotion of glucose uptake and co-operation with
insulin in cultured cells. C2C12 mouse myoblast cells were induced to differentiate into
myocytes and then incubated with human/mouse equivalent agonistic anti-MET antibodies
(71 G3, 7 1D6, 7 1G2). After 24 hours, antibody-treated cells were divided into 3 arms, which
were subjected to acute stimulation with 0 nM, 100 nM or 1000 nM human recombinant
insulin for 1 hour in the presence of the fluorescent glucose analogue 2-(N-(7-Nitrobenz-2-
oxa-1 ,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG). 2-NBDG uptake was determined by
flow cytometry. (A) Induction of 2-NBDG uptake by human/mouse equivalent agonistic anti-
MET antibodies or insulin. (B) Induction of 2-NBDG uptake by 7 1G3 in the absence or
presence of insulin. (C) Induction of 2-NBDG uptake by 7 1D6 in the absence or presence
of insulin. (D) Induction of 2-NBDG uptake by 7 1G2 in the absence or presence of insulin.
Figure 24. Type I I diabetes model: blood glucose level normalization and insulin
resistance overcoming in db/db mice. At the age of 8 weeks, female db/db mice (a
C57BLKS/J variant bearing a point mutation in the leptin receptor gene lepr) were
randomized into 4 arms that received treatment with 7 1G3, 7 1D6, 7 1G2 or vehicle only
(PBS), respectively. Antibodies were administered two times a week by i.p. injection at a
dose of 1 mg/kg. Blood glucose concentration in fasting conditions was monitored every 10
days for 7 weeks. At the end of the treatment, i.e. when mice were 15 weeks old, a glucose
tolerance test (GTT) and an insulin tolerance test (ITT) were performed using age-matched
wild-type C57BLKS/J mice as control. (A) Blood glucose concentration over time. (B) GTT:
following oral administration of glucose to a fasting animal, blood glucose levels are
monitored over time. (C) ITT: following i.p. injection of insulin to a partially fasting animal,
blood glucose levels are monitored over time.
Figure 25. Mouse model of non-alcoholic steatohepatitis (NASH): fatty liver
amelioration as determined by histology. Eight week-old female db/db mice were
randomized into 4 arms that received treatment with 7 1G3, 7 1D6, 7 1G2 or vehicle only
(PBS), respectively. Antibodies were administered two times a week by i.p. injection at a
dose of 1 mg/kg. After 8 weeks of treatment, mice were sacrificed and subjected to
autopsy. Blood was collected for analysis of hepatic function markers. Livers were
extracted, embedded in paraffin and processed for histological examination. Liver sections
were stained with hematoxylin and eosin. The cytoplasm of fatty cells appears empty and
white because lipids are washed away during alcohol processing of the specimen. A
representative image for each treatment arm is shown. Magnification: 200X.
Figure 26. Mouse model of non-alcoholic steatohepatitis (NASH): suppression of
fibrosis as determined by Picro Sirius red staining. Eight week-old female db/db mice
were randomized and treated as described in Figure 25 legend. At autopsy, livers were
processed for histological examination. Liver sections were stained with Sirius red to
highlight fibrosis. A representative image for each treatment arm is shown. Magnification:
200X.
Figure 27. Mouse model of non-alcoholic steatohepatitis (NASH): normalization of
liver function markers. Eight week-old female db/db mice were treated with purified
7 1G3, 7 1D6, 7 1G2 or vehicle only as described in Figure 25 legend. After 7 weeks of
treatment, blood was collected for analysis of the hepatic function markers. (A) Plasma
levels of aspartate transaminase (AST). (B) Plasma levels of alanine aminotransferase
(ALT).
Figure 28. Mouse model of diabetic ulcers: accelerated healing of wounds. Eight
week-old db/db diabetic mice were subjected to anaesthesia and then cut with a 0.8 cm-
wide circular punch blade for skin biopsies to create a round wound in the right posterior
flank. The entire epidermal layer was removed. The day after surgery, mice were
randomized into 4 arms that received treatment with purified 7 1G3, 7 1D6 and 7 1G2 or
vehicle only (PBS). Antibodies were delivered every second day by i.p injection at a dose of
5 mg/kg. Wound diameter was measured every day using a calliper. (A) Wound area over
time. (B) Mean re-epithelization rate as determined by averaging the daily % of wound
closure.
Figure 29. Rattus norvegicus and Macaca fascicularis cross-reactivity as determined
by ELISA. In order to test pan-species cross-reactivity, a restricted panel of antibodies
representative of both SEMA binders (71 D6, 7 1C3, 7 1D4, 7 1A3, 7 1G2) and PSI binders
(76H1 0 , 7 1G3) was selected. The 5D5 prior art antibody was used as control. Human,
mouse, rat or monkey MET ECD was immobilized in solid phase and exposed to increasing
concentrations of mAbs (in their human lgG1/A format) in solution. Binding was revealed
using HRP-conjugated anti-human Fc antibodies.
Figure 30. Amino acid sequence alignment among the MET ECD domains of from H.
sapiens, M. musculus, R. norvegicus, M. fascicularis and L. glama. (A) Sequence
alignment relative to the region recognized by the SEMA-binding antibodies (71 D6, 7 1C3,
7 1D4, 7 1A3 and 7 1G2) (human MET sequence SEQ ID NO: 239; mouse MET sequence
SEQ ID NO: 240; rat MET sequence SEQ ID NO: 241 , cyno MET sequence SEQ ID NO:
242, Llama MET sequence SEQ ID NO: 243). The amino acids identified by the human-
llama chimera approach shown in Table 12 are underlined. Within this region there are five
residues that are conserved in human and mouse MET but not in llama MET (Ala 327, Ser
336, Phe 343, lie 367, Asp 372). These amino acids are indicated with a black box and the
progressive numbers 1-5. Of these, four residues are also conserved in rat and
cynomolgus monkey MET (Ala 327, Ser 336, lie 367, Asp 372). Amino acids responsible
for binding to the SEMA-binding antibodies are indicated with an "S" (for SEMA). Amino
acids responsible for binding to 5D5/Onartuzumab are indicated with an "O" (for
Onartuzumab). (B) Sequence alignment relative to the region recognized by the PSI-
binding antibodies 76H10 and 7 1G3 (human MET sequence SEQ ID NO: 244; mouse MET
sequence SEQ ID NO: 245; rat MET sequence SEQ ID NO: 246, cyno MET sequence
SEQ ID NO: 247, Llama MET sequence SEQ ID NO: 248). The amino acids identified by
the human-llama chimera approach shown in Table 12 are underlined. Within this region
there are three residues that are conserved in human and mouse MET but not in llama
MET (Arg 547, Ser 553, Thr 555). These amino acids are indicated with a black box and
the progressive numbers 6-8. Of these, two residues are also conserved in rat and
cynomolgus monkey MET (Ser 553 and Thr 555). The amino acid responsible for binding
to the PSI-binding antibodies is indicated with a "P" (for PSI).
Figure 31. Schematic representation of the MET mutants used for fine epitope
mapping. Using human MET ECD as a template, the key residues indicated with the
progressive numbers 1-8 in Figure 30 were mutagenized in different permutations,
generating mutants A-L. Each of these mutants is fully human except for the indicated
residues, which are llama.
DETAILED DESCRIPTION
As used herein, the term "immunoglobulin" includes a polypeptide having a combination
of two heavy and two light chains whether or not it possesses any relevant specific
immunoreactivity. "Antibodies" refers to such assemblies which have significant known
specific immunoreactive activity to an antigen of interest (e.g. MET). The term "MET
antibodies" or "anti-MET antibodies" are used herein to refer to antibodies which exhibit
immunological specificity for MET protein. Antibodies and immunoglobulins comprise light
and heavy chains, with or without an interchain covalent linkage between them. Basic
immunoglobulin structures in vertebrate systems are relatively well understood.
The generic term "immunoglobulin" comprises five distinct classes of antibody that can be
distinguished biochemically. Although all five classes of antibodies are within the scope of
the present invention, the following discussion will generally be directed to the IgG class of
immunoglobulin molecules. With regard to IgG, immunoglobulins comprise two identical
light polypeptide chains of molecular weight approximately 23,000 Daltons, and two
identical heavy chains of molecular weight 53,000-70,000. The four chains are joined by
disulfide bonds in a " configuration wherein the light chains bracket the heavy chains
starting at the mouth of the " and continuing through the variable region.
The light chains of an antibody are classified as either kappa or lambda (κ, λ) . Each heavy
chain class may be bound with either a kappa or lambda light chain. In general, the light
and heavy chains are covalently bonded to each other, and the "tail" portions of the two
heavy chains are bonded to each other by covalent disulfide linkages or non-covalent
linkages when the immunoglobulins are generated by B cells or genetically engineered
host cells. In the heavy chain, the amino acid sequences run from an N-terminus at the
forked ends of the Y configuration to the C-terminus at the bottom of each chain. Those
skilled in the art will appreciate that heavy chains are classified as gamma, mu, alpha,
delta, or epsilon, (γ , µ , , δ , ε) with some subclasses among them (e.g., γ 1-γ4). It is the
nature of this chain that determines the "class" of the antibody as IgG, IgM, IgA, IgD or IgE,
respectively. The immunoglobulin subclasses (isotypes) e.g., lgG1 , lgG2, lgG3, lgG4,
lgA1 , etc. are well characterized and are known to confer functional specialization.
Modified versions of each of these classes and isotypes are readily discernible to the
skilled artisan in view of the instant disclosure and, accordingly, are within the scope of the
instant invention.
As indicated above, the variable region of an antibody allows the antibody to selectively
recognize and specifically bind epitopes on antigens. That is, the VL domain and VH
domain of an antibody combine to form the variable region that defines a three dimensional
antigen binding site. This quaternary antibody structure forms the antigen binding site
present at the end of each arm of the Y. More specifically, the antigen binding site is
defined by three complementary determining regions (CDRs) on each of the VH and VL
chains.
As used herein, the terms "MET protein" or "MET antigen" or "MET" are used
interchangeably and refer to the receptor tyrosine kinase that, in its wild-type form, binds
Hepatocyte Growth Factor (HGF). The terms "human MET protein" or "human MET
receptor" or "human MET" or "hMET" are used interchangeably to refer to human MET
(GenBank accession number: X54559), including the native human MET protein naturally
expressed in the human host and/or on the surface of human cultured cell lines, as well as
recombinant forms and fragments thereof and also naturally occurring mutant forms. The
terms "mouse MET protein" or "mouse MET receptor" or "mouse MET" or "mMET" are used
interchangeably to refer to mouse MET (GenBank accession number: NM 008591),
including the native mouse MET protein naturally expressed in the mouse host and/or on
the surface of mouse cultured cell lines, as well as recombinant forms and fragments
thereof and also naturally occurring mutant forms.
As used herein, the term "binding site" comprises a region of a polypeptide which is
responsible for selectively binding to a target antigen of interest (e.g. hMET). Binding
domains comprise at least one binding site. Exemplary binding domains include an
antibody variable domain. The antibody molecules of the invention may comprise a single
binding site or multiple (e.g., two, three or four) binding sites.
As used herein the term "derived from" a designated protein (e.g. a MET antibody or
antigen-binding fragment thereof) refers to the origin of the polypeptide. In one
embodiment, the polypeptide or amino acid sequence which is derived from a particular
starting polypeptide is a CDR sequence or sequence related thereto. In one embodiment,
the amino acid sequence which is derived from a particular starting polypeptide is not
contiguous. For example, in one embodiment, one, two, three, four, five, or six CDRs are
derived from a starting antibody. In one embodiment, the polypeptide or amino acid
sequence which is derived from a particular starting polypeptide or amino acid sequence
has an amino acid sequence that is essentially identical to that of the starting sequence, or
a portion thereof wherein the portion consists of at least 3-5 amino acids, at least 5-1 0
amino acids, at least 10-20 amino acids, at least 20-30 amino acids, or at least 30-50
amino acids, or which is otherwise identifiable to one of ordinary skill in the art as having its
origin in the starting sequence. In one embodiment, the one or more CDR sequences
derived from the starting antibody are altered to produce variant CDR sequences, e.g.
affinity variants, wherein the variant CDR sequences maintain MET binding activity.
"Camelid-Derived" — In certain preferred embodiments, the MET antibody molecules of
the invention comprise framework amino acid sequences and/or CDR amino acid
sequences derived from a camelid conventional antibody raised by active immunisation of
a camelid with a MET-derived antigen. However, MET antibodies comprising camelid-
derived amino acid sequences may be engineered to comprise framework and/or constant
region sequences derived from a human amino acid sequence (i.e. a human antibody) or
other non-camelid mammalian species. For example, a human or non-human primate
framework region, heavy chain portion, and/or hinge portion may be included in the subject
MET antibodies. In one embodiment, one or more non-camelid amino acids may be
present in the framework region of a "camelid-derived" MET antibody, e.g., a camelid
framework amino acid sequence may comprise one or more amino acid mutations in which
the corresponding human or non-human primate amino acid residue is present. Moreover,
camelid-derived VH and VL domains, or humanised variants thereof, may be linked to the
constant domains of human antibodies to produce a chimeric molecule, as extensively
described elsewhere herein.
As used herein, a "conservative amino acid substitution" is one in which the amino acid
residue is replaced with an amino acid residue having a similar side chain. Families of
amino acid residues having similar side chains have been defined in the art, including basic
side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic
acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine,
tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline,
phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine,
isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
Thus, a nonessential amino acid residue in an immunoglobulin polypeptide may be
replaced with another amino acid residue from the same side chain family. In another
embodiment, a string of amino acids can be replaced with a structurally similar string that
differs in order and/or composition of side chain family members.
As used herein, the term "heavy chain portion" includes amino acid sequences derived
from the constant domains of an immunoglobulin heavy chain. A polypeptide comprising a
heavy chain portion comprises at least one of: a CH1 domain, a hinge (e.g., upper, middle,
and/or lower hinge region) domain, a CH2 domain, a CH3 domain, or a variant or fragment
thereof. In one embodiment, an antibody or antigen binding fragment of the invention may
comprise the Fc portion of an immunoglobulin heavy chain (e.g., a hinge portion, a CH2
domain, and a CH3 domain). In another embodiment, an antibody or antigen binding
fragment of the invention may lack at least a portion of a constant domain (e.g., all or part
of a CH2 domain). In certain embodiments, at least one, and preferably all, of the constant
domains are derived from a human immunoglobulin heavy chain. For example, in one
preferred embodiment, the heavy chain portion comprises a fully human hinge domain. In
other preferred embodiments, the heavy chain portion comprises a fully human Fc portion
(e.g., hinge, CH2 and CH3 domain sequences from a human immunoglobulin).
In certain embodiments, the constituent constant domains of the heavy chain portion are
from different immunoglobulin molecules. For example, a heavy chain portion of a
polypeptide may comprise a CH2 domain derived from an lgG1 molecule and a hinge
region derived from an lgG3 or lgG4 molecule. In other embodiments, the constant
domains are chimeric domains comprising portions of different immunoglobulin molecules.
For example, a hinge may comprise a first portion from an lgG1 molecule and a second
portion from an lgG3 or lgG4 molecule. As set forth above, it will be understood by one of
ordinary skill in the art that the constant domains of the heavy chain portion may be
modified such that they vary in amino acid sequence from the naturally occurring (wild-
type) immunoglobulin molecule. That is, the polypeptides of the invention disclosed herein
may comprise alterations or modifications to one or more of the heavy chain constant
domains (CH1 , hinge, CH2 or CH3) and/or to the light chain constant region domain (CL).
Exemplary modifications include additions, deletions or substitutions of one or more amino
acids in one or more domains.
As used herein, a "chimeric" protein comprises a first amino acid sequence linked to a
second amino acid sequence with which it is not naturally linked in nature. The amino acid
sequences may normally exist in separate proteins that are brought together in the fusion
polypeptide or they may normally exist in the same protein but are placed in a new
arrangement in the fusion polypeptide. A chimeric protein may be created, for example, by
chemical synthesis, or by creating and translating a polynucleotide in which the peptide
regions are encoded in the desired relationship. Exemplary chimeric MET antibodies
include fusion proteins comprising camelid-derived VH and VL domains, or humanised
variants thereof, fused to the constant domains of a human antibody, e.g. human lgG1 ,
lgG2, lgG3 or lgG4, or fused to the constant domains of a mouse antibody, e.g. mouse
lgG1 , lgG2a, lgG2b, lgG2c or lgG3.
As used herein, the terms "variable region" and "variable domain" are used
interchangeably and are intended to have equivalent meaning. The term "variable" refers
to the fact that certain portions of the variable domains VH and VL differ extensively in
sequence among antibodies and are used in the binding and specificity of each particular
antibody for its target antigen. However, the variability is not evenly distributed throughout
the variable domains of antibodies. It is concentrated in three segments called
"hypervariable loops" in each of the VL domain and the VH domain which form part of the
antigen binding site. The first, second and third hypervariable loops of the VLambda light
chain domain are referred to herein as L 1(A), Ι_2(λ) and Ι_3(λ) and may be defined as
comprising residues 24-33 (L1 (A), consisting of 9 , 10 or 11 amino acid residues), 49-53
(Ι_2(λ) , consisting of 3 residues) and 90-96 (L3(A), consisting of 5 residues) in the VL
domain (Morea et al., Methods 20, 267-279, 2000). The first, second and third
hypervariable loops of the VKappa light chain domain are referred to herein as L 1(K), L2(K)
and L3(K) and may be defined as comprising residues 25-33 (L1 (K), consisting of 6 , 7 , 8 ,
11, 12 or 13 residues), 49-53 (L2(K), consisting of 3 residues) and 90-97 (L3(K), consisting
of 6 residues) in the VL domain (Morea et al., Methods 20, 267-279, 2000). The first,
second and third hypervariable loops of the VH domain are referred to herein as H 1 , H2
and H3 and may be defined as comprising residues 25-33 (H1 , consisting of 7 , 8 or 9
residues), 52-56 (H2, consisting of 3 or 4 residues) and 91-105 (H3, highly variable in
length) in the VH domain (Morea et al., Methods 20, 267-279, 2000).
Unless otherwise indicated, the terms L 1 , L2 and L3 respectively refer to the first, second
and third hypervariable loops of a VL domain, and encompass hypervariable loops
obtained from both Vkappa and Vlambda isotypes. The terms H 1 , H2 and H3 respectively
refer to the first, second and third hypervariable loops of the VH domain, and encompass
hypervariable loops obtained from any of the known heavy chain isotypes, including γ , ε , δ ,
a or µ.
The hypervariable loops L 1 , L2, L3, H 1 , H2 and H3 may each comprise part of a
"complementarity determining region" or "CDR", as defined below. The terms
"hypervariable loop" and "complementarity determining region" are not strictly synonymous,
since the hypervariable loops (HVs) are defined on the basis of structure, whereas
complementarity determining regions (CDRs) are defined based on sequence variability
(Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health
Service, National Institutes of Health, Bethesda, MD, 1991 ) and the limits of the HVs and
the CDRs may be different in some VH and VL domains.
The CDRs of the VL and VH domains can typically be defined as comprising the following
amino acids: residues 24-34 (CDRL1), 50-56 (CDRL2) and 89-97 (CDRL3) in the light
chain variable domain, and residues 3 1-35 or 3 1-35b (CDRH1 ) , 50-65 (CDRH2) and 95-
102 (CDRH3) in the heavy chain variable domain; (Kabat et al., Sequences of Proteins of
Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health,
Bethesda, MD, 1991 ) . Thus, the HVs may be comprised within the corresponding CDRs
and references herein to the "hypervariable loops" of VH and VL domains should be
interpreted as also encompassing the corresponding CDRs, and vice versa, unless
otherwise indicated.
The more highly conserved portions of variable domains are called the framework region
(FR), as defined below. The variable domains of native heavy and light chains each
comprise four FRs (FR1 , FR2, FR3 and FR4, respectively), largely adopting a β-sheet
configuration, connected by the three hypervariable loops. The hypervariable loops in each
chain are held together in close proximity by the FRs and, with the hypervariable loops
from the other chain, contribute to the formation of the antigen-binding site of antibodies.
Structural analysis of antibodies revealed the relationship between the sequence and the
shape of the binding site formed by the complementarity determining regions (Chothia et
al., J. Mol. Biol. 227, 799-817, 1992; Tramontano et al., J. Mol. Biol, 2 15 , 175-182, 1990).
Despite their high sequence variability, five of the six loops adopt just a small repertoire of
main-chain conformations, called "canonical structures". These conformations are first of all
determined by the length of the loops and secondly by the presence of key residues at
certain positions in the loops and in the framework regions that determine the conformation
through their packing, hydrogen bonding or the ability to assume unusual main-chain
conformations.
As used herein, the term "CDR" or "complementarity determining region" means the
non-contiguous antigen combining sites found within the variable region of both heavy and
light chain polypeptides. These particular regions have been described by Kabat et al., J.
Biol. Chem. 252, 6609-6616, 1977, by Kabat et al., Sequences of Proteins of
Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health,
Bethesda, MD, 1991 , by Chothia et al., J. Mol. Biol. 196, 901-91 7 , 1987, and by MacCallum
et al., J. Mol. Biol. 262, 732-745, 1996, where the definitions include overlapping or subsets
of amino acid residues when compared against each other. The amino acid residues
which encompass the CDRs as defined by each of the above cited references are set forth
for comparison. Preferably, the term "CDR" is a CDR as defined by Kabat based on
sequence comparisons.
Table 1: CDR definitions.
1Residue numbering follows the nomenclature of Kabat et al., supra
Residue numbering follows the nomenclature of Chothia et al., supra
3Residue numbering follows the nomenclature of MacCallum et al., supra
As used herein, the term "framework region" or "FR region" includes the amino acid
residues that are part of the variable region, but are not part of the CDRs (e.g., using the
Kabat definition of CDRs). Therefore, a variable region framework is between about 100-
120 amino acids in length but includes only those amino acids outside of the CDRs. For
the specific example of a heavy chain variable domain and for the CDRs as defined by
Kabat et al., framework region 1 corresponds to the domain of the variable region
encompassing amino acids 1-30; framework region 2 corresponds to the domain of the
variable region encompassing amino acids 36-49; framework region 3 corresponds to the
domain of the variable region encompassing amino acids 66-94, and framework region 4
corresponds to the domain of the variable region from amino acids 103 to the end of the
variable region. The framework regions for the light chain are similarly separated by each
of the light claim variable region CDRs. Similarly, using the definition of CDRs by Chothia
et al. or McCallum et al. the framework region boundaries are separated by the respective
CDR termini as described above. In preferred embodiments the CDRs are as defined by
Kabat.
In naturally occurring antibodies, the six CDRs present on each monomeric antibody are
short, non-contiguous sequences of amino acids that are specifically positioned to form the
antigen binding site as the antibody assumes its three dimensional configuration in an
aqueous environment. The remainder of the heavy and light variable domains show less
inter-molecular variability in amino acid sequence and are termed the framework regions.
The framework regions largely adopt a β-sheet conformation and the CDRs form loops
which connect, and in some cases form part of, the β-sheet structure. Thus, these
framework regions act to form a scaffold that provides for positioning the six CDRs in
correct orientation by inter-chain, non-covalent interactions. The antigen binding site
formed by the positioned CDRs defines a surface complementary to the epitope on the
immunoreactive antigen. This complementary surface promotes the non-covalent binding
of the antibody to the immunoreactive antigen epitope. The position of CDRs can be
readily identified by one of ordinary skill in the art.
As used herein, the term "hinge region" includes the portion of a heavy chain molecule
that joins the CH1 domain to the CH2 domain. This hinge region comprises approximately
25 residues and is flexible, thus allowing the two N-terminal antigen binding regions to
move independently. Hinge regions can be subdivided into three distinct domains: upper,
middle, and lower hinge domains (Roux et al., J. Immunol. 16 1, 4083-4090, 1998). MET
antibodies comprising a "fully human" hinge region may contain one of the hinge region
sequences shown in Table 2 below.
Table 2 : Human hinge sequences.
gG Upper hinge Middle hinge Lower hinge
EPKSCDKTHT APELLGGP
CPPCP
IgGl (SEQ ID (SEQ ID
(SEQ ID NO:228)
NO: 227) NO: 229 )
ELKTPLGDTTHT APELLGGP
CPRCP (EPKSCDTPPPCPRCP)
IgG3 (SEQ ID (SEQ ID
(SEQ ID NO:231)
NO :230) NO: 232)
ESKYGPP APEFLGGP
CPSCP
IgG4 (SEQ ID (SEQ ID
(SEQ ID NO:234)
NO :233) NO: 235)
ERK APPVAGP
IgG42 CCVECPPPCP
(SEQ ID (SEQ ID
(SEQ ID NO:237)
NO :236) NO:238)
As used herein the term "CH2 domain" includes the portion of a heavy chain molecule that
extends, e.g., from about residue 244 to residue 360 of an antibody using conventional
numbering schemes (residues 244 to 360, Kabat numbering system; and residues 231-
340, EU numbering system; Kabat et al., Sequences of Proteins of Immunological Interest,
5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD ( 1991). The
CH2 domain is unique in that it is not closely paired with another domain. Rather, two
linked branched carbohydrate chains are interposed between the two CH2 domains of an
intact native IgG molecule. It is also well documented that the CH3 domain extends from
the CH2 domain to the C-terminal of the IgG molecule and comprises approximately 108
residues.
As used herein, the term "fragment" refers to a part or portion of an antibody or antibody
chain comprising fewer amino acid residues than an intact or complete antibody or
antibody chain. The term "antigen-binding fragment" refers to a polypeptide fragment of
an immunoglobulin or antibody that binds antigen or competes with intact antibody (i.e.,
with the intact antibody from which they were derived) for antigen binding (i.e., specific
binding to hMET and mMET). As used herein, the term "fragment" of an antibody molecule
includes antigen-binding fragments of antibodies, for example, an antibody light chain
variable domain (VL), an antibody heavy chain variable domain (VH), a single chain
antibody (scFv), a F(ab')2 fragment, a Fab fragment, an Fd fragment, an Fv fragment, and
a single domain antibody fragment (DAb). Fragments can be obtained, e.g., via chemical
or enzymatic treatment of an intact or complete antibody or antibody chain or by
recombinant means.
As used herein the term "valency" refers to the number of potential target binding sites in a
polypeptide. Each target binding site specifically binds one target molecule or specific site
on a target molecule. When a polypeptide comprises more than one target binding site,
each target binding site may specifically bind the same or different molecules (e.g., may
bind to different ligands or different antigens, or different epitopes on the same antigen).
The subject binding molecules have at least one binding site specific for hMET.
As used herein, the term "specificity" refers to the ability to bind (e.g., immunoreact with) a
given target, e.g., hMET, mMET. A polypeptide may be monospecific and contain one or
more binding sites which specifically bind a target or a polypeptide may be multispecific
and contain two or more binding sites which specifically bind the same or different targets.
In one embodiment, an antibody of the invention is specific for more than one target. For
example, in one embodiment, a multispecific binding molecule of the invention binds hMET
and a second target molecule. In this context, the second target molecule is a molecule
other than hMET or mMET.
The term "epitope" refers to the portion(s) of an antigen (e.g. human MET) that contact an
antibody. Epitopes can be linear, i.e., involving binding to a single sequence of amino
acids, or conformational, i.e., involving binding to two or more sequences of amino acids in
various regions of the antigen that may not necessarily be contiguous. The antibodies
provided herein may bind to different (overlapping or non-overlapping) epitopes within the
extracellular domain of the human MET protein.
As used herein the term "synthetic" with respect to polypeptides includes polypeptides
which comprise an amino acid sequence that is not naturally occurring. For example, non-
naturally occurring polypeptides which are modified forms of naturally occurring
polypeptides (e.g., comprising a mutation such as an addition, substitution or deletion) or
which comprise a first amino acid sequence (which may or may not be naturally occurring)
that is linked in a linear sequence of amino acids to a second amino acid sequence (which
may or may not be naturally occurring) to which it is not naturally linked in nature.
As used herein the term "engineered" includes manipulation of nucleic acid or polypeptide
molecules by synthetic means (e.g. by recombinant techniques, in vitro peptide synthesis,
by enzymatic or chemical coupling of peptides or some combination of these techniques).
Preferably, the antibodies of the invention are engineered, including for example,
humanized and/or chimeric antibodies, and antibodies which have been engineered to
improve one or more properties, such as antigen binding, stability/half-life or effector
function.
As used herein, the term "modified antibody" includes synthetic forms of antibodies which
are altered such that they are not naturally occurring, e.g., antibodies that comprise at least
two heavy chain portions but not two complete heavy chains (such as, domain deleted
antibodies or minibodies); multispecific forms of antibodies (e.g., bispecific, trispecific, etc.)
altered to bind to two or more different antigens or to different epitopes on a single antigen;
heavy chain molecules joined to scFv molecules and the like. ScFv molecules are known
in the art and are described, e.g., in US patent 5,892,01 9 . In addition, the term "modified
antibody" includes multivalent forms of antibodies (e.g., trivalent, tetravalent, etc.,
antibodies that bind to three or more copies of the same antigen). In another embodiment,
a modified antibody of the invention is a fusion protein comprising at least one heavy chain
portion lacking a CH2 domain and comprising a binding domain of a polypeptide
comprising the binding portion of one member of a receptor ligand pair.
The term "modified antibody" may also be used herein to refer to amino acid sequence
variants of a MET antibody of the invention. It will be understood by one of ordinary skill in
the art that a MET antibody of the invention may be modified to produce a variant MET
antibody which varies in amino acid sequence in comparison to the MET antibody from
which it was derived. For example, nucleotide or amino acid substitutions leading to
conservative substitutions or changes at "non-essential" amino acid residues may be made
(e.g., in CDR and/or framework residues). Amino acid substitutions can include
replacement of one or more amino acids with a naturally occurring or non-natural amino
acid.
As used herein, the term "humanising substitutions" refers to amino acid substitutions in
which the amino acid residue present at a particular position in the VH or VL domain of a
MET antibody of the invention (for example a camelid-derived MET antibody) is replaced
with an amino acid residue which occurs at an equivalent position in a reference human VH
or VL domain. The reference human VH or VL domain may be a VH or VL domain
encoded by the human germline. Humanising substitutions may be made in the framework
regions and/or the CDRs of a MET antibody, defined herein.
As used herein the term "humanised variant" refers to a variant antibody which contains
one or more "humanising substitutions" compared to a reference MET antibody, wherein a
portion of the reference antibody (e.g. the VH domain and/or the VL domain or parts
thereof containing at least one CDR) has an amino acid sequence derived from a non-
human species, and the "humanising substitutions" occur within the amino acid sequence
derived from a non-human species.
The term "germlined variant" is used herein to refer specifically to "humanised variants" in
which the "humanising substitutions" result in replacement of one or more amino acid
residues present at a particular position (s) in the VH or VL domain of a MET antibody of
the invention (for example a camelid-derived MET antibody) with an amino acid residue
which occurs at an equivalent position in a reference human VH or VL domain encoded by
the human germline. It is typical that for any given "germlined variant", the replacement
amino acid residues substituted into the germlined variant are taken exclusively, or
predominantly, from a single human germline-encoded VH or VL domain. The terms
"humanised variant" and "germlined variant" are often used interchangeably herein.
Introduction of one or more "humanising substitutions" into a camelid-derived (e.g. llama
derived) VH or VL domain results in production of a "humanised variant" of the camelid
(llama)-derived VH or VL domain. If the amino acid residues substituted in are derived
predominantly or exclusively from a single human germline-encoded VH or VL domain
sequence, then the result may be a "human germlined variant" of the camelid (llama)-
derived VH or VL domain.
As used herein, the term "affinity variant" refers to a variant antibody which exhibits one or
more changes in amino acid sequence compared to a reference MET antibody of the
invention, wherein the affinity variant exhibits an altered affinity for hMET and/or mMET in
comparison to the reference antibody. Preferably the affinity variant will exhibit improved
affinity for hMET and/or mMET, as compared to the reference MET antibody. The
improvement may be apparent as a lower K for hMET and/or for mMET, or a slower off-
rate for hMET and/or for mMET. Affinity variants typically exhibit one or more changes in
amino acid sequence in the CDRs, as compared to the reference MET antibody. Such
substitutions may result in replacement of the original amino acid present at a given
position in the CDRs with a different amino acid residue, which may be a naturally
occurring amino acid residue or a non-naturally occurring amino acid residue. The amino
acid substitutions may be conservative or non-conservative.
As used herein, antibodies having "high human homology" refers to antibodies
comprising a heavy chain variable domain (VH) and a light chain variable domain (VL)
which, taken together, exhibit at least 90% amino acid sequence identity to the closest
matching human germline VH and VL sequences. Antibodies having high human
homology may include antibodies comprising VH and VL domains of native non-human
antibodies which exhibit sufficiently high % sequence identity to human germline
sequences, including for example antibodies comprising VH and VL domains of camelid
conventional antibodies, as well as engineered, especially humanised or germlined,
variants of such antibodies and also "fully human" antibodies.
In one embodiment the VH domain of the antibody with high human homology may exhibit
an amino acid sequence identity or sequence homology of 80% or greater with one or more
human VH domains across the framework regions FR1 , FR2, FR3 and FR4. In other
embodiments the amino acid sequence identity or sequence homology between the VH
domain of the polypeptide of the invention and the closest matching human germline VH
domain sequence may be 85% or greater, 90% or greater, 95% or greater, 97% or greater,
or up to 99% or even 100%.
In one embodiment the VH domain of the antibody with high human homology may contain
one or more (e.g. 1 to 10) amino acid sequence mis-matches across the framework regions
FR1 , FR2, FR3 and FR4, in comparison to the closest matched human VH sequence.
In another embodiment the VL domain of the antibody with high human homology may
exhibit a sequence identity or sequence homology of 80% or greater with one or more
human VL domains across the framework regions FR1 , FR2, FR3 and FR4. In other
embodiments the amino acid sequence identity or sequence homology between the VL
domain of the polypeptide of the invention and the closest matching human germline VL
domain sequence may be 85% or greater 90% or greater, 95% or greater, 97% or greater,
or up to 99% or even 100%.
In one embodiment the VL domain of the antibody with high human homology may contain
one or more (e.g. 1 to 10) amino acid sequence mis-matches across the framework regions
FR1 , FR2, FR3 and FR4, in comparison to the closest matched human VL sequence.
Before analysing the percentage sequence identity between the antibody with high human
homology and human germline VH and VL, the canonical folds may be determined, which
allows the identification of the family of human germline segments with the identical
combination of canonical folds for H 1 and H2 or L 1 and L2 (and L3). Subsequently the
human germline family member that has the highest degree of sequence homology with
the variable region of the antibody of interest is chosen for scoring the sequence homology.
Procedures for determining the closest matching human germline, and determining %
sequence identity/homology, are well-known to the skilled person.
Antibodies with high human homology may comprise hypervariable loops or CDRs having
human or human-like canonical fold structures. In one embodiment at least one
hypervariable loop or CDR in either the VH domain or the VL domain of the antibody with
high human homology may be obtained or derived from a VH or VL domain of a non-
human antibody, for example a conventional antibody from a species of Camelidae, yet
exhibit a predicted or actual canonical fold structure which is substantially identical to a
canonical fold structure which occurs in human antibodies. In one embodiment, both H 1
and H2 in the VH domain of the antibody with high human homology exhibit a predicted or
actual canonical fold structure which is substantially identical to a canonical fold structure
which occurs in human antibodies.
Antibodies with high human homology may comprise a VH domain in which the
hypervariable loops H 1 and H2 form a combination of canonical fold structures which is
identical to a combination of canonical structures known to occur in at least one human
germline VH domain. It has been observed that only certain combinations of canonical fold
structures at H 1 and H2 actually occur in VH domains encoded by the human germline. In
an embodiment H 1 and H2 in the VH domain of the antibody with high human homology
may be obtained from a VH domain of a non-human species, e.g. a Camelidae species, yet
form a combination of predicted or actual canonical fold structures which is identical to a
combination of canonical fold structures known to occur in a human germline or somatically
mutated VH domain. In non-limiting embodiments H 1 and H2 in the VH domain of the
antibody with high human homology may be obtained from a VH domain of a non-human
species, e.g. a Camelidae species, and form one of the following canonical fold
combinations: 1-1 , 1-2, 1-3, 1-6, 1-4, 2-1 , 3-1 and 3-5. An antibody with high human
homology may contain a VH domain which exhibits both high sequence identity/sequence
homology with human VH, and which contains hypervariable loops exhibiting structural
homology with human VH.
It may be advantageous for the canonical folds present at H 1 and H2 in the VH domain of
the antibody with high human homology, and the combination thereof, to be "correct" for
the human VH germline sequence which represents the closest match with the VH domain
of the antibody with high human homology in terms of overall primary amino acid sequence
identity. By way of example, if the closest sequence match is with a human germline VH3
domain, then it may be advantageous for H 1 and H2 to form a combination of canonical
folds which also occurs naturally in a human VH3 domain. This may be particularly
important in the case of antibodies with high human homology which are derived from non-
human species, e.g. antibodies containing VH and VL domains which are derived from
camelid conventional antibodies, especially antibodies containing humanised camelid VH
and VL domains.
Thus, in one embodiment the VH domain of the MET antibody with high human homology
may exhibit a sequence identity or sequence homology of 80% or greater, 85% or greater,
90% or greater, 95% or greater, 97% or greater, or up to 99% or even 100% with a human
VH domain across the framework regions FR1 , FR2 , FR3 and FR4, and in addition H 1 and
H2 in the same antibody are obtained from a non-human VH domain (e.g. derived from a
Camelidae species, preferably llama), but form a combination of predicted or actual
canonical fold structures which is the same as a canonical fold combination known to occur
naturally in the same human VH domain.
In other embodiments, L 1 and L2 in the VL domain of the antibody with high human
homology are each obtained from a VL domain of a non-human species (e.g. a camelid-
derived VL domain), and each exhibits a predicted or actual canonical fold structure which
is substantially identical to a canonical fold structure which occurs in human antibodies.
L 1 and L2 in the VL domain of an antibody with high human homology may form a
combination of predicted or actual canonical fold structures which is identical to a
combination of canonical fold structures known to occur in a human germline VL domain.
In non-limiting embodiments L 1 and L2 in the VLambda domain of an antibody with high
human homology (e.g. an antibody containing a camelid-derived VL domain or a
humanised variant thereof) may form one of the following canonical fold combinations: 11-
7 , 13-7(A,B,C), 14-7(A,B), 12-1 1, 14-1 1 and 12-12 (as defined in Williams et al., J. Mol.
Biol. 264, 220-232, 1996, and as shown on
http://www.bioc.uzh.ch/antibody/Sequences/Germlines/VBase_hVL.html). In non-limiting
embodiments L 1 and L2 in the Vkappa domain may form one of the following canonical fold
combinations: 2-1 , 3-1 , 4-1 and 6-1 (as defined in Tomlinson et al., EMBO J. 14 , 4628-
4638, 1995 and as shown on
http://www.bioc.uzh.ch/antibody/Sequences/Germlines/VBase_hVK.html). In a further
embodiment, all three of L 1 , L2 and L3 in the VL domain of an antibody with high human
homology may exhibit a substantially human structure. It is preferred that the VL domain of
the antibody with high human homology exhibits both high sequence identity/sequence
homology with human VL, and also that the hypervariable loops in the VL domain exhibit
structural homology with human VL.
In one embodiment, the VL domain of a MET antibody with high human homology may
exhibit a sequence identity of 80% or greater, 85% or greater, 90% or greater, 95% or
greater, 97% or greater, or up to 99% or even 100% with a human VL domain across the
framework regions FR1 , FR2 , FR3 and FR4, and in addition hypervariable loop L 1 and
hypervariable loop L2 may form a combination of predicted or actual canonical fold
structures which is the same as a canonical fold combination known to occur naturally in
the same human VL domain.
It is, of course, envisaged that VH domains exhibiting high sequence identity/sequence
homology with human VH, and also structural homology with hypervariable loops of human
VH will be combined with VL domains exhibiting high sequence identity/sequence
homology with human VL, and also structural homology with hypervariable loops of human
VL to provide antibodies with high human homology containing VH/VL pairings (e.g.
camelid-derived VH/VL pairings) with maximal sequence and structural homology to
human-encoded VH/VL pairings.
Procedures for evaluating camelid-derived (e.g. llama-derived) CDRs, VH domains or VL
domains for the presence of human-like canonical fold structures are described in WO
2010/001251 and WO 201 1/080350, the contents of which are incorporated herein in their
entirety by reference.
As used herein, the term "affinity" or "binding affinity" should be understood based on the
usual meaning in the art in the context of antibody binding, and reflects the strength and/or
stability of binding between an antigen and a binding site on an antibody or antigen binding
fragment thereof.
The anti-MET antibodies provided herein are characterised by high affinity binding to
human MET (hMET), and also high affinity binding with mouse MET (mMET). Binding
affinity for hMET and mMET may be assessed using standard techniques known to
persons of skill in the art.
In one embodiment, binding affinity of a Fab clone comprising a defined VH/VL pairing may
be assessed using surface plasmon resonance, e.g. using the Biacore™ system. Fab
clones comprising VH/VL pairings of the antibodies and antigen binding fragments of the
invention typically exhibit an off-rate for hMET measured by Biacore™ in the range of from
1 x 10 3 to 1 x 10~2 s~1 , optionally 1 x 10 3 to 6 x 10 3 s~1 . An off-rate within this range may be
taken as an indication that the Fab, and a corresponding bivalent mAb, exhibit high affinity
binding to hMET. Similarly, the Fab clones comprising VH/VL pairings of the antibodies,
and antigen binding fragments of the invention typically exhibit an off-rate for mMET
measured by Biacore™, as described in the accompanying examples, in the range of from
1 x 10 3 to 1 x 10~2 s 1 , optionally 1 x 10 3 to 6 x 10 3 s 1 . An off-rate within this range may be
taken as an indication that the Fab, and a corresponding bivalent mAb, exhibit high affinity
binding to mMET. Therefore, Fabs that exhibit off-rates for both human and murine MET
falling within the stated ranges show high affinity binding for hMET, and high affinity binding
for mMET - that is, the Fabs are cross-reactive between hMET and mMET. Bivalent mAbs
comprising two Fabs that (individually) exhibit off-rates for human and murine MET within
the stated ranges are also taken to exhibit high affinity binding to human MET and high
affinity binding to murine MET.
Binding affinity may also be expressed as the dissociation constant for a particular
antibody, or the K . The lesser the K value, the stronger the binding interaction between
an antibody and its target antigen. K may be determined, for example, by combining the
Kon and K 0 ff rate determined by SPR measurement. Typically, antibodies and antigen
binding fragments of the invention, when measured as mAbs, exhibit a K for mMET and
for hMET of less than 0.1 nMol/L.
Binding affinity to human and murine MET can also be assessed using a cell-based system
as described in the accompanying examples, in which mAbs are tested for binding to
mammalian cell lines that express MET, for example using ELISA or flow cytometry. High
affinity for hMET or mMET may be indicated, for example, by an EC
50
of no more than 0.5
nM in an ELISA such as that described in Example 3 .
As summarised above, the invention relates, at least in part, to antibodies, and antigen
binding fragments thereof, that bind to hMET and mMET with high affinity. The properties
and characteristics of the MET antibodies, and antibody fragments, according to the
invention will now be described in further detail.
The high affinity hMET and mMET cross-reactive antibodies and antigen binding fragments
described herein are MET agonists. As used herein, MET agonists induce (partially or fully)
MET signalling when binding to the MET receptor. MET agonist antibodies and antigen
binding fragments according to the invention are agonists of hMET and mMET. Agonist
activity on binding of hMET or mMET by the antibodies described herein may be indicated
by molecular and/or cellular responses that (at least partially) mimic the molecular and
cellular responses induced upon homologous HGF-MET binding (i.e. human HGF binding
hMET, mouse HGF binding mMET). Antibodies stimulating such a response are also
referred to herein as "anti-MET agonists", "agonist antibodies" and grammatical variations
thereof. Similarly, antibodies partially or fully stimulating such responses are referred to
herein as "partial MET agonists" or "partial agonists", or "full MET agonists" or "full
agonists", respectively. It is emphasised that antibodies and antigen binding fragments of
the invention induce MET signalling in both human and mouse systems - that is, they are
agonists of hMET and mMET. Thus the following discussion applies both to the response
induced by binding of hMET by the antibodies and antigen binding fragments of the
invention, and to the response induced by binding of mMET by the antibodies and antigen
binding fragments of the invention.
MET agonism by antibodies and antigen binding fragments of the invention may be
indicated by molecular responses such as phosphorylation of the MET receptor and/or
cellular responses, for example those detectable in a cell scattering assay, an anti-
apoptosis assay and/or a branching morphogenesis assay. These molecular and cellular
responses are further described below:
(i) Phosphorylation of the MET receptor. In this context, a MET agonist antibody or
antigen binding fragment phosphorylates MET when binding of the antibody or antigen
binding fragment causes auto-phosphorylation of MET in the absence of receptor-ligand
binding - that is, binding of the antibody or antigen binding fragment to human hMET
results in phosphorylation of hMET in the absence of hHGF and binding of the antibody or
antigen binding fragment to mMET results in phosphorylation of mMET in the absence of
mHGF. Phosphorylation of MET may be determined by assays known in the art, for
example Western Blotting or phospho-MET ELISA (as described in Example 6 and in
Basilico et al., J Clin Invest. 124, 3 172-31 86, 201 4). Antibodies and antigen binding
fragments described herein may exhibit "high phosphorylation potency" or "low
phosphorylation potency" for hMET and may exhibit "high phosphorylation potency" or "low
phosphorylation potency" for mMET. In this context, an antibody or antigen binding
fragment exhibits "high phosphorylation potency" when the antibody or fragment exhibits a
potency for mMET with an EC
50
similar to HGF (<1 nM) and/or an E AX of at least 80% (as a
percentage of maximal HGF-induced activation) and exhibits a potency for hMET with an
EC5o similar to HGF (<1 nM) and/or an E AX of at least 80% (as a percentage of maximal
HGF-induced activation). An antibody or antigen binding fragment exhibits "low
phosphorylation potency" when the antibody exhibits a potency for mMET with an EC
50
of
1nM-5nM and/or an E
MAX
of 60-80% (as a percentage of maximal HGF-induced activation)
and exhibits a potency for hMET with an EC
50
of 1nM-5nM and/or an E
MAX
of 60-80% (as a
percentage of maximal HGF-induced activation).
(ii) Inducing HGF-like cellular responses. MET agonism can be measured using
assays such as the cell scattering assay, the anti-apoptosis assay and/or the branching
morphogenesis assay described in the present Examples. In this context, MET agonist
antibodies or antigen binding fragments according to the invention induce a response in
cellular assays such as these that resembles (at least partially) the response observed
following exposure to homologous HGF. For example, a MET agonist may be indicated by:
an increase in cell scattering in response to the antibody compared to cells exposed to a
control antibody (e.g. lgG1); a protective potency against drug-induced apoptosis with an
EC
50
of less than 32 nM and/or an E
max
cellular viability of greater than 20% compared to
untreated cells; and/or an increase in the number of branches per spheroid in cell spheroid
preparations exposed to the antibody or antigen binding fragment.
Antibodies and antigen binding fragments described herein may "fully induce" or "partially
induce" HGF-like cellular responses when contacted with a human cell and may "fully
induce" or "partially induce" HGF-like cellular responses when contacted with a mouse cell,
depending on the assay employed.
In this context, "full induction" of HGF-like cellular responses by an antibody or fragment
may be measurable as:
in a cell scattering assay, the antibody or antigen binding fragment induces an
increase in cell scattering at least equivalent to 0.1 nM homologous HGF when the
antibody concentration is 0.1-1 nM;
in an anti-apoptosis assay, the antibody or antigen binding fragment exhibits an
EC 50 no more than . 1x that of HGF and/or an Emax cellular viability of greater than 90% that
observed for HGF; and/or
in a branching morphogenesis assay, cells treated with the antibody or antigen
binding fragment exhibit greater than 90% of the number of branches per spheroid induced
by the same (non-zero) concentration of HGF.
In this context, if an antibody or antigen binding fragment does not "fully induce" HGF-like
cellular responses as defined above, "partial induction" of HGF-like cellular responses may
be measurable as:
in a cell scattering assay, the antibody or antigen binding fragment induces a level
of cell scattering at least 25% that induced by 0.1 nM homologous HGF when the antibody
concentration is 1 nM or lower;
in an anti-apoptosis assay, the antibody or antigen binding fragment exhibits an
EC
50
no more than 7.0x that of HGF and/or an E
max
cellular viability of at least 50% that
observed for HGF;
in a branching morphogenesis assay, cells treated with the antibody or antigen
binding fragment exhibit at least 25% the number of branches per spheroid induced by the
same (non-zero) concentration of HGF.
As already described, antibodies and antigen binding fragments according to the invention
are hMET agonists and mMET agonists. Thus, in embodiments wherein the antibodies
induce (partially or fully) HGF-like cellular responses, the HGF-like cellular responses are
(partially or fully) induced when the antibody or antigen binding fragment is contacted with
a human cell and are (partially or fully) induced when the antibody or antigen binding
fragment is contacted with a mouse cell.
Binding region mapping (Example 4) demonstrates that the anti-MET antibodies of the
invention recognize epitopes of MET either in the PSI domain of MET or in the SEMA
domain of MET. Therefore, in certain embodiments, the antibodies or antigen binding
fragments of the invention recognize an epitope in the PSI domain of MET, preferably
human MET. In certain alternative embodiments, the antibodies or antigen binding
fragments of the invention recognize an epitope the SEMA domain of MET, preferably
human MET.
In certain embodiments, antibodies or antigen binding fragments recognizing an epitope in
the SEMA domain recognize an epitope located on a blade of the SEMA β-propeller. In
certain embodiments, the epitope is located on blade 4 or 5 of SEMA β-propeller. In certain
such embodiments, the epitope is located between amino acids 314-372 of human MET. In
certain embodiments, the epitope is located on blades 1-4 or 1-3 of the SEMA β-propeller.
In certain embodiments, the epitope is located between amino acids 27-313 of human
MET, or between amino acids 27-225 of human MET.
In certain embodiments, antibodies or antigen binding fragments recognizing an epitope in
the PSI domain of MET recognise an epitope located between amino acids 5 16-545 of
MET, preferably human MET. In certain embodiments, antibodies or antigen binding
fragments recognizing an epitope in the PSI domain of MET recognise an epitope located
between amino acids 546-562 of MET, preferably human MET.
In certain aspects, the antibodies described herein recognize epitopes in the extracellular
domain of MET that comprise one or more amino acid residues conserved across human
and mouse MET. In preferred embodiments antibodies described herein recognize
epitopes in the extracellular domain of MET that comprise one or more amino acid residues
conserved across human MET, mouse MET, rat MET and simian (e.g. cynomolgus) MET.
In certain embodiments, antibodies of the invention recognize an epitope of human MET
located in the region from amino acid residue123 to residue 223 of human MET. In certain
embodiments, antibodies of the invention recognize an epitope of human MET located in
the region from amino acid residue 224 to residue 3 11 of human MET. In certain
embodiments, antibodies of the invention recognize an epitope of human MET located in
the region from amino acid residue 314 to residue 372 of human MET. In certain
embodiments, antibodies of the invention recognize an epitope of human MET located in
the region from amino acid residue 546 to residue 562 of human MET.
In certain embodiments antibodies or antigen binding fragments of the invention recognize
an epitope of human MET comprising the amino acid residue Ile367. In certain
embodiments antibodies or antigen binding fragments of the invention recognize an epitope
of human MET comprising the amino acid residue Asp372 of human MET. In certain
embodiments antibodies or antigen binding fragments of the invention recognize an epitope
of human MET comprising the amino acid residues Ile367 and Asp372.
In certain such embodiments, antibodies or antigen binding fragments of the invention
recognize an epitope of human MET located in the region from amino acid residue 314 to
residue 372 of human MET, wherein the epitope comprises the amino acid residue Ile367.
In certain such embodiments, antibodies or antigen binding fragments of the invention
recognize an epitope of human MET located in the region from amino acid residue 314 to
residue 372 of human MET, wherein the epitope comprises the amino acid residue
Asp371 . In certain such embodiments, antibodies or antigen binding fragments of the
invention recognize an epitope of human MET located in the region from amino acid
residue 314 to residue 372 of human MET, wherein the epitope comprises the amino acid
residues Ile367 and Asp372.
In certain embodiments antibodies or antigen binding fragments of the invention bind an
epitope of human MET comprising the amino acid residue Thr555 of human MET.
In certain such embodiments, antibodies or antigen binding fragments of the invention
recognize an epitope of human MET located in the region from amino acid residue546 to
residue 562 of human MET, wherein the epitope comprises the amino acid residue Thr555.
It will be appreciated that an antibody or antigen binding fragment thereof can recognize an
epitope made up of a number of amino acid residues. The epitope may be linear,
conformational or a combination. Where an epitope is specified as being in a certain region
of amino acids, the epitope may be formed of one or more amino acids in that region that
are contacted by the antibody or fragment. Therefore, it will be appreciated that in certain
embodiments of the invention, the antibodies or fragments thereof can recognize an
epitope made up of multiple amino acid residues (consecutive or non-consecutive) within
the region specified (e.g. from amino acid 314-372, or 546 to 562), provided the recognized
epitope includes the specified amino acid residue (e.g. Ile367, Asp372, Thr555). Methods
for determining the residues recognized as part of the epitope of an antibody are familiar to
the skilled person and include, for example, those described in Examples 4 and 26.
As the anti-MET antibodies and antigen binding fragments of the invention bind epitopes
overlapping or close to the binding domain recognised by HGF, the antibodies and antigen
binding fragments are able to (at least partially) compete with HGF for binding of the
homologous MET (i.e. compete with human HGF for hMET binding and compete with
mouse HGF for mMET binding). That is, the antibodies or antigen binding fragments
directly or indirectly prevent HGF from binding the homologous MET in a binding assay, for
example an ELISA such as that described in Example 5 . Therefore, in certain
embodiments, the MET antibodies and antigen binding fragments of the invention compete
with mouse and human HGF for binding of the homologous MET. An antibody or antigen
binding fragment that competes with HGF in this way is also referred to herein as a "HGF
competitor". Assays to determine whether an antibody or antigen binding fragment
competes with HGF for MET binding are well known to the skilled person - for example, in
a competition ELISA an HGF competitor may exhibit an IC
50
of no more than 5nM and/or
an l
max
(maximum percentage competition at saturation) of at least 50%. Antibodies and
antigen binding fragments of the invention compete with mouse HGF for mMET binding
and human HGF for hMET binding.
An antibody or antigen binding fragment of the invention may "fully compete" or "partially
compete" with HGF for homologous MET binding. In this context, a "full competitor" may be
an antibody or antigen binding fragment that in a competition assay, for example an ELISA,
exhibits an IC
50
of less than 2 nM and/or an l
max
of at least 90%. In certain embodiments, a
"full competitor" exhibits an IC5o of less than 1 nM and/or an lmax of greater than 90%. A
"partial competitor" may be an antibody or antigen binding fragment that in a competition
assay, for example an ELISA, exhibits an IC5o of 2-5 nM and/or an lmax of 50-90%. The
given values apply to competition with mouse HGF and human HGF for binding of the
homologous MET.
As already described, the antibodies and antigen binding fragments of the invention are
advantageous due to their ability to recognise both human and mouse MET. The antibodies
or antigen binding fragments thereof described herein are particularly advantageous when
they exhibit equivalent properties when binding to mMET and to hMET. This equivalence
allows the antibodies to be analysed in pre-clinical murine models of disease with an
expectation that the antibodies will exhibit the same or similar properties in a human
context.
Therefore, in certain embodiments, the antibodies and binding fragments of the invention
exhibit equivalent binding affinity for hMET and mMET. In this context, "equivalent binding
affinity" is taken as meaning the affinity of the antibody or antigen binding fragment for
hMET is 0.5-1 .5 times the affinity of that antibody for mMET. In certain embodiments,
antibodies and antigen binding fragments of the invention exhibit an affinity for hMET 0.8-
1.2 times the affinity of that antibody or antigen binding fragment for mMET.
By way of clarification and example, antibodies or antigen binding fragments having
equivalent affinity for mMET and hMET may, when measured as a Fab fragment, exhibit an
off-rate for hMET that is 0.5-1 .5 times that as the off-rate exhibited for mMET. For example,
an antibody having equivalent affinity for mMET and hMET which exhibits an off-rate of 2.6
x 10 3 s 1 for mMET would exhibit an off-rate for hMET of 1.3-3.9 x 10 3 s 1 . By way of further
example, antibodies or antigen binding fragments having equivalent affinity for mMET and
hMET may exhibit an EC
50
for hMET (determined for example by ELISA or flow cytometry)
of 0.5-1 .5 times the EC
50
of that antibody or fragment for mMET. For example, an antibody
having equivalent affinity for mMET and hMET which exhibits an EC
50
for mMET of 0.1
nMol/L would exhibit an EC
50
for hMET of 0.05-0.1 5 nMol/L.
In certain embodiments, the antibodies and antigen binding fragments of the invention are
equivalent agonists of mMET and of hMET. In this context, "equivalence" is taken as
meaning the level of MET agonism induced upon binding of hMET is 0.5-1 .5 times that of
the level of signalling induced upon binding of mMET. In certain embodiments, antibodies
and antigen binding fragments of the invention induce MET signalling upon binding of
hMET 0.8-1 .2 times that of the level of signalling induced upon binding of mMET.
In certain embodiments, the antibodies or antigen binding fragments of the invention are
equivalent mMET and hMET agonists when measured by at least one assay of MET
agonism described herein. For example, the antibodies or antigen binding fragments of the
invention may induce equivalent phosphorylation of MET, exhibit equivalent protective
efficacies against drug-induced apoptosis, and/or induce equivalent levels of branching in a
branching morphogenesis assay. In certain embodiments, the antibodies or antigen binding
fragments exhibit equivalent MET agonism when measured by all of the described assays.
By way of clarification, equivalent phosphorylation of MET by an antibody of the invention
might be detectable as the EC
50
for that antibody for hMET being 0.5-1 .5x the EC
50
for
mMET. For example, if the EC
50
for mMET is 2.9 nM, that antibody would equivalently
induce hMET phosphorylation if the EC
50
for hMET is in the range of 1.45-4.35 nM.
Similarly, equivalent MET agonism indicated in an anti-apoptosis assay may be detectable
as the E
max
in human cells being 0.5-1 .5x the E
max
in mouse cells. For example, if the E
max
in mouse cells was 37.5%, that antibody would be an equivalent hMET agonist if the E
max
for human cells is in the range of 18.75-56.25%. Equivalent MET agonism indicated in a
branching morphogenesis assay may be detectable as the number of branches observed
following exposure of human cell spheroids to the antibody being 0.5-1 .5x the number of
branches observed following exposure of mouse cell spheroids to the same (non-zero)
concentration of the antibody. For example, if the number of branches exhibited by mouse
cells following exposure to 0.5 nM antibody was 14, that antibody would be an equivalent
hMET agonist if the number of branches exhibited by human cells following exposure to 0.5
nM antibody is in the range of 7-21 .
Similarly, equivalent agonism of hMET and mMET may be indicated by equivalent cell
scattering. The nature of the output of such an assay means application of a 0.5-1 .5 factor
is not appropriate. In a cell scattering assay, equivalent agonism of hMET and mMET may
be indicated by the cell scattering score for human cells exposed to an antibody being +/- 1
the cell scattering score for mouse cells exposed to the same antibody at the same (non
zero) concentration. For example, if mouse cells exposed to 0.33 nM of an antibody
exhibited a cell scattering score of 2 , the antibody would be an equivalent agonist of hHGF
if human cells exposed to 0.33 nM of the same antibody exhibited a cell scattering score of
1-3.
In certain embodiments, the antibodies and antigen binding fragments of the invention
exhibit equivalent HGF competition between mMET and hMET. In this context, "equivalent
HGF competition" is taken as meaning the level of competition exhibited by the antibody or
antigen binding fragment with human HGF for hMET is 0.5-1 .5 times the level of
competition exhibited by the antibody or antigen binding fragment with mouse HGF for
mMET. In certain embodiments, antibodies and antigen binding fragments of the invention
exhibit a level for competition with human HGF 0.8-1 .2 times the level of competition
exhibited by that antibody or antigen binding fragment with mouse HGF for mMET.
By way of example, equivalent competition by an antibody with human HGF and mouse
HGF might be detectable as the IC50 for that antibody competing with human HGF-hMET
binding being 0.5-1 .5 times the IC50 for that antibody competing with mouse HGF-mMET
binding. For example, if the IC50 for mHGF-mMET binding is 0.34 nM, an antibody
competes with hHGF and mHGF equivalently if the IC50 for hHGF-hMET binding is in the
range of 0.1 7-0.51 nM.
In certain embodiments, the antibodies and antigen binding fragments of the invention are
cross-reactive with rat MET and/or macaque MET. Cross-reactivity with one or both of rat
and macaque MET has the advantage that toxicology studies can be conducted in rat
and/or macaque model systems. In this regard, whether or not an antibody exhibits cross-
reactivity with a cynomolgus or rat MET can be determined by ELISA, such as that
described in the accompanying example 25.
The antibodies or antigen binding fragments thereof described herein may comprise at
least one hypervariable loop or complementarity determining region obtained from a VH
domain or a VL domain of a species in the family Camelidae. In particular, the antibody or
antigen binding fragment may comprise VH and/or VL domains, or CDRs thereof, obtained
by active immunisation of outbred camelids, e.g. llamas, with a human MET antigen.
By "hypervariable loop or complementarity determining region obtained from a VH domain
or a VL domain of a species in the family Camelidae" is meant that hypervariable loop (HV)
or CDR has an amino acid sequence which is identical, or substantially identical, to the
amino acid sequence of a hypervariable loop or CDR which is encoded by a Camelidae
immunoglobulin gene. In this context "immunoglobulin gene" includes germline genes,
immunoglobulin genes which have undergone rearrangement, and also somatically
mutated genes. Thus, the amino acid sequence of the HV or CDR obtained from a VH or
VL domain of a Camelidae species may be identical to the amino acid sequence of a HV or
CDR present in a mature Camelidae conventional antibody. The term "obtained from" in
this context implies a structural relationship, in the sense that the HVs or CDRs of the MET
antibody embody an amino acid sequence (or minor variants thereof) which was originally
encoded by a Camelidae immunoglobulin gene. However, this does not necessarily imply
a particular relationship in terms of the production process used to prepare the MET
antibody.
Camelid-derived MET antibodies may be derived from any camelid species, including inter
alia, llama, dromedary, alpaca, vicuna, guanaco or camel.
MET antibodies comprising camelid-derived VH and VL domains, or CDRs thereof, are
typically recombinantly expressed polypeptides, and may be chimeric polypeptides. The
term "chimeric polypeptide" refers to an artificial (non-naturally occurring) polypeptide which
is created by juxtaposition of two or more peptide fragments which do not otherwise occur
contiguously. Included within this definition are "species" chimeric polypeptides created by
juxtaposition of peptide fragments encoded by two or more species, e.g. camelid and
human.
Camelid-derived CDRs may comprise one of the CDR sequences shown in Tables 3 and 4
below.
In one embodiment the entire VH domain and/or the entire VL domain may be obtained
from a species in the family Camelidae. In specific embodiments, the camelid-derived VH
domain may comprise the amino acid sequence shown as SEQ ID NOs:1 55, 157, 159,
16 1, 163, 165, 167, 169, 17 1 , 173, or 175, whereas the camelid-derived VL domain may
comprise the amino acid sequence shown as SEQ ID NOs: 156, 158, 160, 162, 164, 166,
168, 170, 172, 174, or 176. The camelid-derived VH domain and/or the camelid-derived
VL domain may then be subject to protein engineering, in which one or more amino acid
substitutions, insertions or deletions are introduced into the camelid amino acid sequence.
These engineered changes preferably include amino acid substitutions relative to the
camelid sequence. Such changes include "humanisation" or "germlining" wherein one or
more amino acid residues in a camelid-encoded VH or VL domain are replaced with
equivalent residues from a homologous human-encoded VH or VL domain.
Isolated camelid VH and VL domains obtained by active immunisation of a camelid (e.g.
llama) with a human MET antigen can be used as a basis for engineering MET antibodies
according to the invention. Starting from intact camelid VH and VL domains, it is possible
to engineer one or more amino acid substitutions, insertions or deletions which depart from
the starting camelid sequence. In certain embodiments, such substitutions, insertions or
deletions may be present in the framework regions of the VH domain and/or the VL
domain. The purpose of such changes in primary amino acid sequence may be to reduce
presumably unfavourable properties (e.g. immunogenicity in a human host (so-called
humanization), sites of potential product heterogeneity and or instability (glycosylation,
deamidation, isomerisation, etc.) or to enhance some other favourable property of the
molecule (e.g. solubility, stability, bioavailability, etc.). In other embodiments, changes in
primary amino acid sequence can be engineered in one or more of the hypervariable loops
(or CDRs) of a Camelidae VH and/or VL domain obtained by active immunisation. Such
changes may be introduced in order to enhance antigen binding affinity and/or specificity,
or to reduce presumably unfavourable properties, e.g. immunogenicity in a human host (so-
called humanization), sites of potential product heterogeneity and or instability,
glycosylation, deamidation, isomerisation, etc., or to enhance some other favourable
property of the molecule, e.g. solubility, stability, bioavailability, etc.
Thus, in one embodiment, the invention provides a variant MET antibody which contains at
least one amino acid substitution in at least one framework or CDR region of either the VH
domain or the VL domain in comparison to a camelid-derived VH or VL domain, examples
of which include but are not limited to the camelid VH domains comprising the amino acid
sequences shown as SEQ ID NOs:1 55, 157, 159, 16 1 , 163, 165, 167, 169, 17 1, 173, or
175, and the camelid VL domains comprising the amino acid sequences show as SEQ ID
NO: 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, or 176.
In certain embodiments, there are provided "chimeric" antibody molecules comprising
camelid-derived VH and VL domains (or engineered variants thereof) and one or more
constant domains from a non-camelid antibody, for example human-encoded constant
domains (or engineered variants thereof). In such embodiments it is preferred that both the
VH domain and the VL domain are obtained from the same species of camelid, for example
both VH and VL may be from llama (prior to introduction of engineered amino acid
sequence variation). In such embodiments both the VH and the VL domain may be derived
from a single animal, particularly a single animal which has been actively immunised with a
human MET antigen.
The invention can, in certain embodiments, encompass chimeric camelid/human
antibodies, and in particular chimeric antibodies in which the VH and VL domains are of
fully camelid sequence (e.g. Llama or alpaca) and the remainder of the antibody is of fully
human sequence. MET antibodies can include antibodies comprising "humanised" or
"germlined" variants of camelid-derived VH and VL domains, or CDRs thereof, and
camelid/human chimeric antibodies, in which the VH and VL domains contain one or more
amino acid substitutions in the framework regions in comparison to camelid VH and VL
domains obtained by active immunisation of a camelid with a human MET antigen. Such
"humanisation" increases the % sequence identity with human germline VH or VL domains
by replacing mis-matched amino acid residues in a starting Camelidae VH or VL domain
with the equivalent residue found in a human germline-encoded VH or VL domain.
The invention can, in certain embodiments, encompass chimeric camelid/mouse
antibodies, and in particular chimeric antibodies in which the VH and VL domains are of
fully camelid sequence (e.g. Llama or alpaca) and the remainder of the antibody is of fully
mouse sequence.
MET antibodies and antigen binding fragments of the invention may also be CDR-grafted
antibodies in which CDRs (or hypervariable loops) derived from a camelid antibody, for
example a camelid MET antibody raised by active immunisation with human MET protein,
or otherwise encoded by a camelid gene, are grafted onto a human VH and VL framework,
with the remainder of the antibody also being of fully human origin. Such CDR-grafted
MET antibodies may contain CDRs having the amino acid sequences shown in Tables 3
and 4 below.
Camelid-derived MET antibodies include variants wherein the hypervariable loop(s) or
CDR(s) of the VH domain and/or the VL domain are obtained from a conventional camelid
antibody raised against human MET, but wherein at least one of said (camelid-derived)
hypervariable loops or CDRs has been engineered to include one or more amino acid
substitutions, additions or deletions relative to the camelid-encoded sequence. Such
changes include "humanisation" of the hypervariable loops/CDRs. Camelid-derived
HVs/CDRs which have been engineered in this manner may still exhibit an amino acid
sequence which is "substantially identical" to the amino acid sequence of a camelid-
encoded HV/CDR. In this context, "substantial identity" may permit no more than one, or
no more than two amino acid sequence mis-matches with the camelid-encoded HV/CDR.
Particular embodiments of the MET antibody may contain humanised variants of the CDR
sequences shown in Tables 3 and 4 .
Camelid (e.g. llama) conventional antibodies provide an advantageous starting point for the
preparation of antibodies with utility as human therapeutic agents due to the following
factors, discussed in US 12/497,239 which is incorporated herein by reference:
1) High % sequence homology between camelid VH and VL domains and their human
counterparts;
2) High degree of structural homology between CDRs of camelid VH and VL domains
and their human counterparts (i.e. human-like canonical fold structures and human-like
combinations of canonical folds).
The camelid (e.g. llama) platform also provides a significant advantage in terms of the
functional diversity of the MET antibodies which can be obtained.
The utility of MET antibodies comprising camelid VH and/or camelid VL domains for human
therapy can be improved still further by "humanisation" of natural camelid VH and VL
domains, for example to render them less immunogenic in a human host. The overall aim
of humanisation is to produce a molecule in which the VH and VL domains exhibit minimal
immunogenicity when introduced into a human subject, whilst retaining the specificity and
affinity of the antigen binding site formed by the parental VH and VL domains.
One approach to humanisation, so-called "germlining", involves engineering changes in the
amino acid sequence of a camelid VH or VL domain to bring it closer to the germline
sequence of a human VH or VL domain.
Determination of homology between a camelid VH (or VL) domain and human VH (or VL)
domains is a critical step in the humanisation process, both for selection of camelid amino
acid residues to be changed (in a given VH or VL domain) and for selecting the appropriate
replacement amino acid residue(s).
An approach to germlining of camelid conventional antibodies has been developed based
on alignment of a large number of novel camelid VH (and VL) domain sequences, typically
somatically mutated VH (or VL) domains which are known to bind a target antigen, with
human germline VH (or VL) sequences, human VH (and VL) consensus sequences, as
well as germline sequence information available for llama pacos.
This procedure, described in WO 201 1/080350, contents of which are incorporated by
reference, can be applied to (i) select "camelid" amino acid residues for replacement in a
camelid-derived VH or VL domain or a CDR thereof, and (ii) select replacement "human"
amino acid residues to substitute in, when humanising any given camelid VH (or VL)
domain. This approach can be used to prepare humanised variants of camelid-derived
CDRs having the amino acid sequences shown in Tables 3 and 4 and also for germlining of
camelid-derived VH and VL domains having the sequences shown in Table 5 .
MET antibodies can take various different embodiments in which both a VH domain and a
VL domain are present. The term "antibody" herein is used in the broadest sense and
encompasses, but is not limited to, monoclonal antibodies (including full length monoclonal
antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), so
long as they exhibit the appropriate immunological specificity for a human MET protein and
for a mouse MET protein. The term "monoclonal antibody" as used herein refers to an
antibody obtained from a population of substantially homogeneous antibodies, i.e., the
individual antibodies comprising the population are identical except for possible naturally
occurring mutations that may be present in minor amounts. Monoclonal antibodies are
highly specific, being directed against a single antigenic site. Furthermore, in contrast to
conventional (polyclonal) antibody preparations which typically include different antibodies
directed against different determinants (epitopes) on the antigen, each monoclonal
antibody is directed against a single determinant or epitope on the antigen.
"Antibody fragments" comprise a portion of a full length antibody, generally the antigen
binding or variable domain thereof. Examples of antibody fragments include Fab, Fab',
F(ab')2, bi-specific Fab's, and Fv fragments, diabodies, linear antibodies, single-chain
antibody molecules, a single chain variable fragment (scFv) and multispecific antibodies
formed from antibody fragments (see Holliger and Hudson, Nature Biotechnol. 23:1 126-
1136, 2005, the contents of which are incorporated herein by reference).
In non-limiting embodiments, the MET antibodies provided herein may comprise CH1
domains and/or CL domains, the amino acid sequence of which is fully or substantially
human. If the MET antibody is intended for human therapeutic use, it is typical for the
entire constant region of the antibody, or at least a part thereof, to have fully or
substantially human amino acid sequence. Therefore, one or more or any combination of
the CH1 domain, hinge region, CH2 domain, CH3 domain and CL domain (and CH4
domain if present) may be fully or substantially human with respect to its amino acid
sequence. Such antibodies may be of any human isotype, for example lgG1 .
Advantageously, the CH1 domain, hinge region, CH2 domain, CH3 domain and CL domain
(and CH4 domain if present) may all have fully or substantially human amino acid
sequence. In the context of the constant region of a humanised or chimeric antibody, or an
antibody fragment, the term "substantially human" refers to an amino acid sequence
identity of at least 90%, or at least 92%, or at least 95%, or at least 97%, or at least 99%
with a human constant region. The term "human amino acid sequence" in this context
refers to an amino acid sequence which is encoded by a human immunoglobulin gene,
which includes germline, rearranged and somatically mutated genes. Such antibodies may
be of any human isotype, with human lgG4 and lgG1 being particularly preferred.
Also provided are MET antibodies comprising constant domains of "human" sequence
which have been altered, by one or more amino acid additions, deletions or substitutions
with respect to the human sequence, excepting those embodiments where the presence of
a "fully human" hinge region is expressly required.
The presence of a "fully human" hinge region in the MET antibodies of the invention may
be beneficial both to minimise immunogenicity and to optimise stability of the antibody.
The MET antibodies provided herein may be of any isotype. Antibodies intended for
human therapeutic use will typically be of the IgA, IgD, IgE IgG, IgM type, often of the IgG
type, in which case they can belong to any of the four sub-classes lgG1 , lgG2a and b,
lgG3 or lgG4. Within each of these sub-classes it is permitted to make one or more amino
acid substitutions, insertions or deletions within the Fc portion, or to make other structural
modifications, for example to enhance or reduce Fc-dependent functionalities.
In non-limiting embodiments, it is contemplated that one or more amino acid substitutions,
insertions or deletions may be made within the constant region of the heavy and/or the light
chain, particularly within the Fc region. Amino acid substitutions may result in replacement
of the substituted amino acid with a different naturally occurring amino acid, or with a non-
natural or modified amino acid. Other structural modifications are also permitted, such as
for example changes in glycosylation pattern (e.g. by addition or deletion of N- or O-linked
glycosylation sites). Depending on the intended use of the MET antibody, it may be
desirable to modify the antibody of the invention with respect to its binding properties to Fc
receptors, for example to modulate effector function.
In certain embodiments, the MET antibodies may comprise an Fc region of a given
antibody isotype, for example human lgG1 , which is modified in order to reduce or
substantially eliminate one or more antibody effector functions naturally associated with
that antibody isotype. In non-limiting embodiments, the MET antibody may be substantially
devoid of any antibody effector functions. In this context, "antibody effector functions"
include one or more or all of antibody-dependent cellular cytotoxicity (ADCC), complement-
dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP).
The amino acid sequence of the Fc portion of the MET antibody may contain one or more
mutations, such as amino acid substitutions, deletions or insertions, which have the effect
of reducing one or more antibody effector functions (in comparison to a wild type
counterpart antibody not having said mutation). Several such mutations are known in the
art of antibody engineering. Non-limiting examples, suitable for inclusion in the MET
antibodies described herein, include the following mutations in the Fc domain of human
lgG4 or human lgG1 : N297A, N297Q, LALA (L234A, L235A), AAA (L234A, L235A, G237A)
or D265A (amino acid residues numbering according to the EU numbering system in
human lgG1).
Monoclonal antibodies or antigen-binding fragments thereof that "cross-compete" with the
MET antibodies disclosed herein are those that bind human MET at site(s) that are
identical to, or overlapping with, the site(s) at which the present MET antibodies bind and
bind mouse MET at site(s) that are identical to, or overlapping with, the site(s) at which the
present MET antibodies bind. Competing monoclonal antibodies or antigen-binding
fragments thereof can be identified, for example, via an antibody competition assay. For
example, a sample of purified or partially purified human MET can be bound to a solid
support. Then, an antibody compound or antigen binding fragment thereof of the present
invention and a monoclonal antibody or antigen-binding fragment thereof suspected of
being able to compete with such invention antibody compound are added. One of the two
molecules is labelled. If the labelled compound and the unlabelled compound bind to
separate and discrete sites on MET, the labelled compound will bind to the same level
whether or not the suspected competing compound is present. However, if the sites of
interaction are identical or overlapping, the unlabelled compound will compete, and the
amount of labelled compound bound to the antigen will be lowered. If the unlabelled
compound is present in excess, very little, if any, labelled compound will bind. For
purposes of the present invention, competing monoclonal antibodies or antigen-binding
fragments thereof are those that decrease the binding of the present antibody compounds
to MET by about 50%, about 60%, about 70%, about 80%, about 85%, about 90%, about
95%, or about 99%. Details of procedures for carrying out such competition assays are
well known in the art and can be found, for example, in Harlow and Lane, Antibodies, A
Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York,
1988, 567-569, 1988, ISBN 0-87969-314-2. Such assays can be made quantitative by
using purified antibodies. A standard curve is established by titrating one antibody against
itself, i.e., the same antibody is used for both the label and the competitor. The capacity of
an unlabelled competing monoclonal antibody or antigen-binding fragment thereof to inhibit
the binding of the labelled molecule to the plate is titrated. The results are plotted, and the
concentrations necessary to achieve the desired degree of binding inhibition are compared.
The invention also provides polynucleotide molecules encoding the MET antibodies of the
invention, also expression vectors containing a nucleotide sequences which encode the
MET antibodies of the invention operably linked to regulatory sequences which permit
expression of the antigen binding polypeptide in a host cell or cell-free expression system,
and a host cell or cell-free expression system containing this expression vector.
Polynucleotide molecules encoding the MET antibodies of the invention include, for
example, recombinant DNA molecules. The terms "nucleic acid", "polynucleotide" or a
"polynucleotide molecule" as used herein interchangeably and refer to any DNA or RNA
molecule, either single- or double-stranded and, if single-stranded, the molecule of its
complementary sequence. In discussing nucleic acid molecules, a sequence or structure
of a particular nucleic acid molecule may be described herein according to the normal
convention of providing the sequence in the 5' to 3' direction. In some embodiments of the
invention, nucleic acids or polynucleotides are "isolated". This term, when applied to a
nucleic acid molecule, refers to a nucleic acid molecule that is separated from sequences
with which it is immediately contiguous in the naturally occurring genome of the organism in
which it originated. For example, an "isolated nucleic acid" may comprise a DNA molecule
inserted into a vector, such as a plasmid or virus vector, or integrated into the genomic
DNA of a prokaryotic or eukaryotic cell or non-human host organism. When applied to
RNA, the term "isolated polynucleotide" refers primarily to an RNA molecule encoded by an
isolated DNA molecule as defined above. Alternatively, the term may refer to an RNA
molecule that has been purified/separated from other nucleic acids with which it would be
associated in its natural state (i.e., in cells or tissues). An isolated polynucleotide (either
DNA or RNA) may further represent a molecule produced directly by biological or synthetic
means and separated from other components present during its production.
For recombinant production of a MET antibody according to the invention, a recombinant
polynucleotide encoding it may be prepared (using standard molecular biology techniques)
and inserted into a replicable vector for expression in a chosen host cell, or a cell-free
expression system. Suitable host cells may be prokaryote, yeast, or higher eukaryote cells,
specifically mammalian cells. Examples of useful mammalian host cell lines are monkey
kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney
line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen.
Virol. 36:59-74, 1977); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster
ovary cells/-DHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216, 1980); mouse
Sertoli cells (TM4; Mather, Biol. Reprod. 23:243-252, 1980); mouse myeloma cells SP2/0-
AG14 (ATCC CRL 1581 ; ATCC CRL 8287) or NS0 (HPA culture collections no. 851 10503);
monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76,
ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney
cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung
cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary
tumour (MMT 060562, ATCC CCL51 ) ; TRI cells (Mather et al., Annals N.Y. Acad. Sci.
383:44-68, 1982); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2), as well
as DSM's PERC-6 cell line. Expression vectors suitable for use in each of these host cells
are also generally known in the art.
It should be noted that the term "host cell" generally refers to a cultured cell line. Whole
human beings into which an expression vector encoding an antigen binding polypeptide
according to the invention has been introduced are explicitly excluded from the definition of
a "host cell".
In an important aspect, the invention also provides a method of producing a MET antibody
of the invention which comprises culturing a host cell (or cell free expression system)
containing polynucleotide (e.g. an expression vector) encoding the MET antibody under
conditions which permit expression of the MET antibody, and recovering the expressed
MET antibody. This recombinant expression process can be used for large scale
production of MET antibodies according to the invention, including monoclonal antibodies
intended for human therapeutic use. Suitable vectors, cell lines and production processes
for large scale manufacture of recombinant antibodies suitable for in vivo therapeutic use
are generally available in the art and will be well known to the skilled person.
The MET antibodies provided herein have utility in therapy, in particular the therapeutic
treatment of disease, in particular conditions that benefit from stimulation of MET function,
including but not limited to degenerative diseases, inflammatory diseases, autoimmune
diseases, metabolic diseases, transplantation-related disorders, and wound healing. In this
regard, the MET antibodies provided herein are examples of a broader class of MET
agonists, for example HGF, having therapeutic utility in the treatment of said conditions.
Hepatocytes express MET and are the principal target of HGF, which promotes their
proliferation and protects them from apoptosis. The MET antibodies which induce MET
signalling are shown herein (Examples 16 and 17) to protect hepatocytes in mouse models
of liver damage, both acute liver damage and chronic damage. As already described
herein, antibodies of the invention exhibit equivalent properties in a human system as in a
mouse system and, thus, can be expected to confer similar protective effects in the context
of human liver damage. Therefore, in one aspect the invention provides a method of
treating or preventing liver damage in a human patient which comprises administering to a
patient in need thereof a therapeutically effective amount of a MET antibody which induces
MET signalling. In certain embodiments, the method is a method of treating or preventing
acute liver damage. In certain embodiments, the method is a method of treating or
preventing chronic liver damage. In certain embodiments, the antibody is an antibody as
described herein.
Kidney epithelial cells express significant levels of MET and are sensitive to HGF
stimulation. MET antibodies which induce MET signalling are shown herein (Example 18)
to confer protection in a mouse model of acute kidney damage. As already described
herein, antibodies of the invention exhibit equivalent properties in a human system as in a
mouse system and, thus, can be expected to confer similar protective effects in the context
of human kidney damage. Therefore, in one aspect the invention provides a method of
treating or preventing kidney damage in a human patient which comprises administering to
a patient in need thereof a therapeutically effective amount of a MET antibody which
induces MET signalling. In certain embodiments, the method is a method of treating or
preventing acute kidney damage. In certain embodiments, the antibody is an antibody as
described herein.
It is also demonstrated herein (Examples 19 and 20) that administration of MET antibodies
which induce MET signalling provides effective treatment in mouse models of inflammatory
bowel disease (IBD), for example in ulcerative colitis. Therefore, in one aspect the
invention provides a method of treating or preventing IBD in a human patient, which
comprises administering to a patient in need thereof a therapeutically effective amount of a
MET antibody which induces MET signalling. In certain embodiments, the method is a
method of treating or preventing ulcerative colitis. In certain embodiments, the antibody is
an antibody as described herein.
It is further demonstrated herein that administration of MET antibodies which induce MET
signalling is able to restore metabolic function in diabetes, including both type I and type I I
diabetes (Examples 2 1 and 22). In particular, in a model of type I diabetes (Example 21),
MET antibodies are shown to promote glucose uptake. Furthermore, administration of MET
antibodies with insulin resulted in a synergistic effect on glucose uptake. In a model of type
I I diabetes (Example 22), MET antibodies are shown to normalise glucose control and to
reduce insulin resistance. Therefore, in one aspect the invention provides a method of
treating or preventing diabetes in a human patient, which comprises administering to a
patient in need thereof a therapeutically effective amount of a MET antibody which induces
MET signalling. In certain embodiments, the method is a method of treating or preventing
type I diabetes. In certain such embodiments, the method further comprises the
administration of insulin to the patient. In certain embodiments, the method is a method of
treating type I I diabetes. In certain embodiments, the antibody is an antibody as described
herein.
It is further demonstrated herein that administration of MET antibodies which induce MET
signalling is able to reduce the extent of fatty liver in a mouse model of non-alcoholic
steatohepatitis (NASH) (Example 23). In particular, MET antibodies were able to reduce the
number of fatty cells and the level of fibrosis. Therefore, in one aspect the invention
provides a method of treating or preventing NASH in a human patient, which comprises
administering to a patient in need thereof a therapeutically effective amount of a MET
antibody which induces MET signalling. In certain embodiments, the antibody is an
antibody as described herein.
It is further demonstrated herein that administration of MET antibodies which induce MET
signalling is able to promote wound healing (Example 24). Moreover, MET antibodies were
able to promote wound healing in diabetic mice, which exhibit impaired wound healing.
Therefore, in one aspect the invention provides a method of promoting wound healing in a
human patient, which comprises administering to a patient in need thereof a therapeutically
effective amount of a MET antibody which induces MET signalling. In certain embodiments,
the human patient has diabetes, optionally type I diabetes. In certain embodiments, the
antibody is an antibody as described herein.
Examples
The invention will be further understood with reference to the following non-limiting
experimental examples.
Example 1: Immunization of llamas
Immunizations of llamas and harvesting of peripheral blood lymphocytes (PBLs) as well as
the subsequent extraction of RNA and amplification of antibody fragments were performed
as described (De Haard et al., J. Bact. 187:4531 -4541 , 2005). Two adult llamas {Lama
glama) were immunized by intramuscular injection of a chimeric protein consisting of the
extracellular domain (ECD) of human MET fused to the Fc portion of human lgG1 (MET-Fc;
R&D Systems). Each llama received one injection per week for six weeks, for a total of six
injections. Each injection consisted in 0.2 mg protein in Freund's Incomplete Adjuvant in
the neck divided over two spots.
Blood samples of 10 ml were collected pre- and post-immunization to investigate the
immune response. Approximately one week after the last immunization, 400 ml of blood
was collected and PBLs were obtained using the Ficoll-Paque method. Total RNA was
extracted by the phenol-guanidine thiocyanate method (Chomczynski et al., Anal. Biochem.
162:1 56-1 59, 1987) and used as template for random cDNA synthesis using the
SuperScriptTM III First-Strand Synthesis System kit (Life Technologies). Amplification of
the cDNAs encoding the VH-CH1 regions of llama lgG1 and VL-CL domains (κ and λ) and
subcloning into the phagemid vector pCB3 was performed as described (de Haard et al., J
Biol Chem. 274:1 821 8-1 8230, 1999). The E. coli strain TG1 (Netherland Culture Collection
of Bacteria) was transformed using recombinant phagemids to generate 4 different Fab-
expressing phage libraries (one λ and one κ library per immunized llama). Diversity was in
the range of 10 -109.
The immune response to the antigen was investigated by ELISA. To this end, we obtained
the ECDs of human MET (UniProtKB # P08581 ; aa 1-932) and of mouse MET (UniProtKB
# P 16056.1 ; aa 1-931) by standard protein engineering techniques. Human or mouse MET
ECD recombinant protein was immobilized in solid phase (100 ng/well in a 96-well plate)
and exposed to serial dilutions of sera from llamas before (day 0) or after (day 45)
immunization. Binding was revealed using a mouse anti-llama lgG1 (Daley et al., Clin.
Vaccine Immunol. 12 , 2005) and a HRP-conjugated donkey anti-mouse antibody (Jackson
Laboratories). As shown in Figure 1, both llamas displayed an immune response against
human MET ECD. Consistent with the notion that the extracellular portion of human MET
displays 87% homology with its mouse orthologue, a fairly good extent of cross-reactivity
was also observed with mouse MET ECD.
Example 2 : Selections and screenings of Fabs binding to both human and mouse MET
Fab-expressing phages from the libraries described above were produced according to
standard phage display protocols. For selection, phages were first adsorbed to immobilized
recombinant human MET ECD, washed, and then eluted using trypsin. After two cycles of
selection with human MET ECD, two other cycles were performed in the same fashion
using mouse MET ECD. In parallel, we also selected phages alternating a human MET
ECD cycle with a mouse MET ECD cycle, for a total of four cycles. Phages selected by the
two approaches were pooled together and then used to infect TG1 E. coli. Individual
colonies were isolated and secretion of Fabs was induced using IPTG (Fermentas). The
Fab-containing periplasmic fraction of bacteria was collected and tested for its ability to
bind human and mouse MET ECD by Surface Plasmon Resonance (SPR). Human or
mouse MET ECD was immobilized on a CM-5 chip using amine coupling in sodium acetate
buffer (GE Healthcare). The Fab-containing periplasmic extracts were loaded into a
BIACORE 3000 apparatus (GE Healthcare) with a flow rate of 30 µ Ι/min. The Fab off-rates
(k
off
) were measured over a two minute period. Binding of Fabs to human and mouse MET
was further characterized by ELISA using MET ECD in solid phase and periplasmic crude
extract in solution. Because Fabs are engineered with a MYC flag, binding was revealed
using HRP-conjugated anti-MYC antibodies (ImTec Diagnostics).
Fabs that bound to both human and mouse MET in both SPR and ELISA were selected
and their corresponding phages were sequenced (LGC Genomics). Cross-reactive Fab
sequences were divided into families based on VH CDR3 sequence length and content. VH
families were given an internal number not based on IMTG (International Immunogenetics
Information System) nomenclature. Altogether, we could identify 11 different human/mouse
cross-reactive Fabs belonging to 8 VH families. The CDR and FR sequences of heavy
chain variable regions are shown in Table 3 . The CDR and FR sequences of light chain
variable regions are shown in Table 4 . The full amino acid sequences of heavy chain and
light chain variable regions are shown in Table 5 . The full DNA sequences of heavy chain























































































































































































































































The various Fab families and their ability to bind human and mouse MET are shown in
Table 7 .
Table 7 : Fabs binding to both human MET (hMET) and mouse MET (mMET). Fabs are
grouped in families based on their VH CDR3 sequence. Binding of Fabs to human and
mouse MET ECD was determined by Surface Plasmon Resonance (SPR) and by ELISA.
SPR values represent the koff (s~1 ) . ELISA values represent the Optical Density (OD) at
450 nm (AU, arbitrary units). Both SPR and ELISA were performed using crude periplasmic
extracts. Fab concentration in the extract was not determined. Values are the mean of
three independent measurements.
Example 3 : Chimerization of Fabs into mAbs
The cDNAs encoding the VH and VL (κ or λ) domains of selected Fab fragments were
engineered into two separate pUPE mammalian expression vectors (U-protein Express)
containing the cDNAs encoding CH1 , CH2 and CH3 of human lgG1 or the human CL (κ or
λ) , respectively. The full amino acid sequences of llama-human chimeric antibody heavy












































































Production (by transient transfection of mammalian cells) and purification (by protein A
affinity chromatography) of the resulting chimeric llama-human lgG1 molecules was
outsourced to U-protein Express. Binding of chimeric mAbs to MET was determined by
ELISA using hMET or mMET ECD in solid phase and increasing concentrations of
antibodies (0-20 nM) in solution. Binding was revealed using HRP-conjugated anti-human
Fc antibodies (Jackson Immuno Research Laboratories). This analysis revealed that all
chimeric llama-human antibodies bound to human and mouse MET with picomolar affinity,
displaying an EC
50
comprised between 0,06 nM and 0,3 nM. Binding capacity (E
MAX
) varied
from antibody to antibody, possibly due to partial epitope exposure in the immobilized





in Table 9 .
Table 9 : Binding of chimeric mAbs to human and mouse MET as determined by
ELISA using immobilized MET ECD in solid phase and increasing concentrations (0-
20 nM) of antibodies in solution. EC
50
values are expressed as nMol/L. E
MAX
values are
expressed as Optical Density (OD) at 450 nm (AU, arbitrary units).
We also analysed whether chimeric anti-MET antibodies bound to native human and
mouse MET in living cells. To this end, increasing concentrations of antibodies (0-1 00 nM)
were incubated with A549 human lung carcinoma cells (American Type Culture Collection)
or MLP29 mouse liver precursor cells (a gift of Prof. Enzo Medico, University of Torino,
Strada Provinciale 142 km 3.95, Candiolo, Torino, Italy; Medico et al., Mol Biol Cell 7 , 495-
504, 1996), which both express physiological levels of MET. Antibody binding to cells was
analysed by flow cytometry using phycoerythrin-conjugated anti-human lgG1 antibodies
(eBioscience) and a CyAn ADP analyser (Beckman Coulter). As a positive control for
human MET binding, we used a commercial mouse anti-human MET antibody (R&D
Systems) and phycoerythrin-conjugated anti-mouse lgG1 antibodies (eBioscience). As a
positive control for mouse MET binding we used a commercial goat anti-mouse MET
antibody (R&D Systems) and phycoerythrin-conjugated anti-goat lgG1 antibodies
(eBioscience). All antibodies displayed dose-dependent binding to both human and mouse
cells with an EC50 varying between 0,2 nM and 2,5 nM. Consistent with the data obtained in
ELISA, maximal binding (EMAX) varied depending on antibody, but was similar in human
and mouse cells. These results indicate that the chimeric llama-human antibodies
recognize membrane-bound MET in its native conformation in both human and mouse
cellular systems. EC50 and EMAX values are shown in Table 10.
Table 10: Binding of chimeric mAbs to human and mouse cells as determined by
flow cytometry using increasing concentrations (0-50 nM) of antibodies. EC50 values
are expressed as nMol/L. E AX values are expressed as % relative to control.
Example 4 : Receptor regions responsible for antibody binding
In order to map the receptor regions recognized by antibodies binding to both human and
mouse MET (herein after referred to as human/mouse equivalent anti-MET antibodies), we
measured their ability to bind to a panel of engineered proteins derived from human MET
generated as described (Basilico et al, J Biol. Chem. 283, 21267-21227, 2008). This panel
included (Figure 2): the entire MET ECD (Decoy MET); a MET ECD lacking IPT domains 3
and 4 (SEMA-PSI-IPT 1-2); a MET ECD lacking IPT domains 1-4 (SEMA-PSI); the isolated
SEMA domain (SEMA); a fragment containing IPT domains 3 and 4 (IPT 3-4). Engineered
MET proteins were immobilized in solid phase and exposed to increasing concentrations of
chimeric antibodies (0-50 nM) in solution. Binding was revealed using HRP-conjugated
anti-human Fc antibodies (Jackson Immuno Research Laboratories). As shown in Table
11, this analysis revealed that 7 mAbs recognize an epitope within the SEMA domain, while
the other 4 recognize an epitope within the PSI domain.
Table 11: Binding of human/mouse equivalent anti-MET antibodies to the panel of
MET deletion mutants described in Figure 2. The MET domain responsible for antibody
binding is indicated in the last column to the right.
To more finely map the regions of MET responsible for antibody binding, we exploited the
absence of cross-reactivity between our antibodies and llama MET (the organism used for
generating these immunoglobulins). To this end, we generated a series of llama-human
and human-llama chimeric MET proteins spanning the entire MET ECD as described
(Basilico et al., J Clin Invest. 124, 3172-31 86, 2014). Chimeras (Figure 3) were
immobilized in solid phase and then exposed to increasing concentrations of mAbs (0-20
nM) in solution. Binding was revealed using HRP-conjugated anti-human Fc antibodies
(Jackson Immuno Research Laboratories). This analysis unveiled that 5 SEMA-binding
mAbs (71 D6, 7 1C3, 7 1D4, 7 1A3, 7 1G2) recognize an epitope localized between aa 314-
372 of human MET, a region that corresponds to blades 4-5 of the 7-bladed SEMA β-
propeller (Stamos et al., EMBO J. 23, 2325-2335, 2004). The other 2 SEMA-binding mAbs
(74C8, 72F8) recognize an epitope localized between aa 123-223 and 224-31 1,
respectively, corresponding to blades 1-3 and 1-4 of the SEMA β-propeller. The PSI-
binding mAbs (76H10, 7 1G3, 76G7, 7 1G12) did not appear to display any significant
binding to any of the two PSI chimeras. Considering the results presented in Table 11,
these antibodies probably recognize an epitope localized between aa 546 and 562 of
human MET. These results are summarized in Table 12.
Table 12: Mapping of the epitopes recognized by human/mouse equivalent anti-MET
antibodies as determined by ELISA. Human MET ECD (hMET) or llama MET ECD
(IMET) as well as the llama-human MET chimeric proteins described in Figure 3 (CH1-7)
were immobilized in solid phase and then exposed to increasing concentrations of mAbs.
Epitope
mAb hMET IMET CHI CH2 CH3 CH4 CH5 CH6 CH7
(aa)
76H10 + - + + + + + - - 546-562
71G3 + - + + + + + - - 546-562
71D6 + - + + + - - + + 314-372
71C3 + - + + + - - + + 314-372
71D4 + - + + + - - + + 314-372
71A3 + - + + + - - + + 314-372
71G2 + - + + + - - + + 314-372
76G7 + - + + + + + - - 546-562
71G12 + - + + + + + - - 546-562
74C8 + - + - - - - + + 123-223
72F8 + - + + - - - + + 224-311
Example 5 : HGF competition assays
The above analysis suggests that the epitopes recognized by some of the human/mouse
equivalent anti-MET antibodies may overlap with those engaged by HGF when binding to
MET (Stamos et al., EMBO J. 23, 2325-2335, 2004; Merchant et al. , Proc Natl Acad Sci
USA 110 , E2987-2996, 2013; Basilico et al., J Clin Invest. 124, 3172-3 186, 2014) . To
investigate along this line, we tested the competition between mAbs and HGF by ELISA.
Recombinant human and mouse HGF (R&D Systems) were biotinylated at the N-terminus
using NHS-LC-biotin (Thermo Scientific). MET-Fc protein , either human or mouse (R&D
Systems), was immobilized in solid phase and then exposed to 0.3 nM biotinylated HGF,
either human or mouse, in the presence of increasing concentrations of antibodies (0-1 20
nM) . HGF binding to MET was revealed using HRP-conjugated streptavidin (Sigma-
Aldrich). As shown in Table 13 , this analysis allowed to divide human/mouse equivalent
anti-MET mAbs into two groups: full HGF competitors (71 D6, 7 1C3, 7 1D4, 7 1A3, 7 1G2),
and partial HGF competitors (76H 10 , 7 1G3, 76G7, 7 1G12 , 74C8, 72F8).
Table 13 : Ability of human/mouse equivalent anti-MET antibodies to compete with
HGF for binding to MET as determined by ELISA. A MET-Fc chimeric protein (either
human or mouse) was immobilized in solid phase and exposed to a fixed concentration of
biotinylated HGF (either human or mouse), in the presence of increasing concentrations of
antibodies. HGF binding to MET was revealed using HRP-conjugated streptavidin .
Antibody-HGF competition is expressed as IC50 (the concentration that achieves 50%
competition) and I AX (the maximum % competition reached at saturation).
hHGF on h ET mHGF on mMET
mAb
ICso (nM) ( ) ICso (nM) (%)
76H10 1.86 64 .22 2 .01 62 .71
71G3 0 .49 63.16 0.53 62.87
71D6 0.29 98.34 0.34 90 .54
71C3 1 .42 93 .64 1 .56 89.23
71D4 0.34 95.62 0.40 91 .34
71A3 0 .51 93.37 0 .54 87 .74
71G2 0.23 97 .84 0.26 91.86
76G7 1 .47 69.42 1 .56 62 .52
71G12 3.87 51 .39 4 .05 50 .67
74C8 0.43 76.89 0 .49 71 .55
72F8 0 .45 77 .34 0.52 72.79
As a general rule, SEMA binders displaced HGF more effectively than PSI binders. In
particular, those antibodies that recognize an epitope within blades 4 and 5 of the SEMA β-
propeller were the most potent HGF competitors (71 D6, 7 1C3, 7 1D4, 7 1A3, 7 1G2). This
observation is consistent with the notion that SEMA blade 5 contains the high affinity
binding site for the a-chain of HGF (Merchant et al., Proc Natl Acad Sci USA 110 , E2987-
2996, 2013). The PSI domain has not been shown to participate directly with HGF, but it
has been suggested to function as a 'hinge' regulating the accommodation of HGF
between the SEMA domain and the IPT region (Basilico et al., J Clin Invest. 124, 3172-
3 186, 2014). It is therefore likely that mAbs binding to PSI (76H10, 7 1G3, 76G7, 71G12)
hamper HGF binding to MET by interfering with this process or by steric hindrance, and not
by direct competition with the ligand. Finally, blades 1-3 of the SEMA β-propeller have been
shown to be responsible for low-affinity binding of the β-chain of HGF, which plays a central
role in MET activation but only partially contributes to the HGF-MET binding strength
(Stamos et al., EMBO J. 23, 2325-2335, 2004). This could explain why mAbs binding to
that region of MET (74C8, 72F8) are partial competitors of HGF.
Example 6 : MET activation assays
Due to their bivalent nature, immunoglobulins directed against receptor tyrosine kinases
may display receptor agonistic activity, mimicking the effect of natural ligands. To
investigate along this line, we tested the ability of human/mouse equivalent anti-MET
antibodies to promote MET auto-phosphorylation in a receptor activation assay. A549
human lung carcinoma cells and MLP29 mouse liver precursor cells were deprived of
serum growth factors for 48 hours and then stimulated with increasing concentrations (0-5
nM) of antibodies or recombinant HGF (A549 cells, recombinant human HGF, R&D
Systems; MLP29 cells, recombinant mouse HGF, R&D Systems). After 15 minutes of
stimulation, cells were washed twice with ice-cold phosphate buffered saline (PBS) and
then lysed as described (Longati et al., Oncogene 9 , 49-57, 1994). Protein lysates were
resolved by electrophoresis and then analysed by Western blotting using antibodies
specific for the phosphorylated form of MET (tyrosines 1234-1 235), regardless of whether
human or mouse (Cell Signaling Technology). The same lysates were also analysed by
Western blotting using anti-total human MET antibodies (Invitrogen) or anti-total mouse
MET antibodies (R&D Systems). This analysis revealed that all human/mouse equivalent
antibodies display MET agonistic activity. As shown in Figure 4 , some antibodies promoted
MET auto-phosphorylation to an extent comparable to that of HGF (71 G3, 7 1D6, 7 1C3,
7 1D4, 7 1A3, 7 1G2, 74C8). Some others (76H10, 76G7, 71G12, 72F8) were less potent,
and this was particularly evident at the lower antibody concentrations. No clear correlation
between MET activation activity and HGF-competition activity was observed.
To obtain more quantitative data, the agonistic activity of antibodies was also characterized
by phospho-MET ELISA. To this end, A549 and MLP29 cells were serum-starved as above
and then stimulated with increasing concentrations (0-25 nM) of mAbs. Recombinant
human (A549) or mouse (MLP29) HGF was used as control. Cells were lysed and
phospho-MET levels were determined by ELISA as described (Basilico et al., J Clin Invest.
124, 3172-3186, 2014). Briefly, 96 well-plates were coated with mouse anti-human MET
antibodies or rat anti-mouse MET antibodies (both from R&D Systems) and then incubated
with cell lysates. After washing, captured proteins were incubated with biotin-conjugated
anti-phospho-tyrosine antibodies (Thermo Fisher), and binding was revealed using HRP-
conjugated streptavidin (Sigma-Aldrich).
The results of this analysis are consistent with the data obtained by Western blotting. As
shown in Table 14, 7 1G3, 7 1D6, 7 1C3, 7 1D4, 7 1A3, 7 1G2 and 74C8 potently activated
MET, while 76H10, 76G7, 71G1 2 and 72F8 caused a less pronounced effect. In any case,
all antibodies displayed a comparable effect in human and in mouse cells.
Table 14: Agonistic activity of human/mouse equivalent anti-MET antibodies in
human and mouse cells as measured by ELISA. A549 human lung carcinoma cells and
MLP29 mouse liver precursor cells were serum-starved and then stimulated with increasing
concentrations of mAbs. Recombinant human HGF (hHGF; A549) or mouse HGF (mHGF;
MLP29) was used as control. Cell lysates were analysed by ELISA using anti-total MET
antibodies for capture and anti-phospho-tyrosine antibodies for revealing. Agonistic activity





A549 cells M P29 cells
mAb
EC50 (nM) M X (%) EC50 (nM) M X ( )
76H10 1 .77 61.23 2 .91 64. 10
71G3 0.41 95.72 0 .37 97. 81
71D6 0 .32 101.57 0.21 114.56
71C3 0 .35 86. 19 0 .33 98 .85
71D4 0 .59 84 .63 0 .51 95.34
71A3 0 .31 86.56 0.26 95. 95
71G2 0 .37 101 .35 0.25 109. 87
76G7 1 .86 62 .34 1 .19 71.45
71G12 2 .48 70 .61 2 .01 75.39
74C8 0 .52 87 .63 0.41 102. 15
72F8 1 .51 69 .74 0 .79 66. 82
HGF 0 .19 100. 00 0.23 100. 00
Example 7 : Scatter assay
To evaluate whether the agonistic activity of human/mouse equivalent anti-MET antibodies
could translate into biological activity, we performed scatter assays with both human and
mouse epithelial cells. To this end, HPAF-II human pancreatic adenocarcinoma cells
(American Type Culture Collection) and MLP29 mouse liver precursor cells were stimulated
with increasing concentrations of recombinant HGF (human or mouse; both from R&D
Systems) and cell scattering was determined 24 hours later by microscopy as described
previously (Basilico et al., J Clin Invest. 124, 3172-3186, 2014). This preliminary analysis
revealed that HGF-induced cell scattering is linear until it reaches saturation at
approximately 0.1 nM in both cell lines. Based on these HGF standard curves, we
elaborated a scoring system ranging from 0 (total absence of cell scattering in the absence
of HGF) to 4 (maximal cell scattering in the presence of 0.1 nM HGF). HPAF-II and MLP29
cells were stimulated with increasing concentrations of human/mouse equivalent anti-MET
antibodies, and cell scattering was determined 24 hours later using the scoring system
described above. As shown in Table 15, this analysis revealed that all mAbs tested
promoted cell scattering in both the human and the mouse cell systems, with substantially
overlapping results on both species. 7 1D6 and 7 1G2 displayed the very same activity as
HGF; 7 1G3 and 7 1A3 were just slightly less potent than HGF; 7 1C3 and 74C8 required a
substantially higher concentration in order to match the activity of HGF; 7 1D4, 76G7,
7 1G12 and 72F8 did not reach saturation in this assay.
Table 15: Biological activity of human/mouse equivalent anti-MET antibodies as
measured in a cell-based scatter assay. HPAF-II human pancreatic adenocarcinoma
cells and MLP29 mouse liver precursor cells were stimulated with increasing
concentrations of human/mouse equivalent anti-MET antibodies, and cell scattering was
determined 24 hours later using the scoring system described in the text (0, absence of cell
scattering; 4 , maximal cell scattering).
HPAF-II human pancreatic adenocarcinoma cells
MLP29 mouse liver precursor cells
Example 8 : Protection against drug-induced apoptosis
Several lines of experimental evidence indicate that HGF display a potent anti-apoptotic
effect on MET-expressing cells (reviewed by Nakamura et al., J Gastroenterol Hepatol. 26
Suppl 1, 188-202, 201 1) . To test the potential anti-apoptotic activity of human/mouse
equivalent anti-MET antibodies, we performed cell-based drug-induced survival assays.
MCF10A human mammary epithelial cells (American Type Culture Collection) and MLP29
mouse liver precursor cells were incubated with increasing concentrations of staurosporine
(Sigma Aldrich). After 48 hours, cell viability was determined by measuring total ATP
concentration using the Cell Titer Glo kit (Promega) with a Victor X4 multilabel plate reader
(Perkin Elmer). This preliminary analysis revealed that the drug concentration that induced
about 50% cell death is 60 nM for MCF10A cells and 100 nM for MLP29 cells. Next, we
incubated MCF1 0A cells and MLP29 cells with the above determined drug concentrations
in the presence of increasing concentrations (0-32 nM) of anti-MET mAbs or recombinant
HGF (human or mouse; both from R&D Systems). Cell viability was determined 48 hours
later as described above. The results of this analysis, presented in Table 16, suggest that
human/mouse equivalent antibodies protected human and mouse cells against
staurosporine-induced cell death to a comparable extent. While some mAbs displayed a
protective activity similar or superior to that of HGF (71 G3, 7 1D6, 7 1G2), other molecules
displayed only partial protection (76H1 0 , 7 1C3, 7 1D4, 7 1A3, 76G7, 7 1G12, 74C8, 72F8),
either in the human or in the mouse cell system.
Table 16: Biological activity of human/mouse equivalent anti-MET antibodies as
measured by a cell-based drug-induced apoptosis assay. MCF10A human mammary
epithelial cells and MLP29 mouse liver precursor cells were incubated with a fixed
concentration of staurosporine in the the presence of increasing concentrations of anti-MET
mAbs or recombinant HGF (human or mouse), and total ATP content was determined 48
hours later. Cell viability was calculated as % total ATP content relative to cells treated with
neither staurosporine nor antibodies, and is expressed as EC
50
and E AX-
Example 9 : Branching morphogenesis assay
As discussed in the Background section, HGF is a pleiotropic cytokine which promotes the
harmonic regulation of independent biological activities, including cell proliferation, motility,
invasion, differentiation and survival. The cell-based assay that better recapitulates all of
these activities is the branching morphogenesis assay, which replicates the formation of
tubular organs and glands during embryogenesis (reviewed by Rosario and Birchmeier,
Trends Cell Biol. 13 , 328-335, 2003). In this assay, a spheroid of epithelial cells is seeded
inside a 3D collagen matrix and is stimulated by HGF to sprout tubules which eventually
form branched structures. These branched tubules resemble the hollow structures of
epithelial glands, e.g. the mammary gland, in that they display a lumen surrounded by
polarized cells. This assay is the most complete HGF assay that can be run in vitro.
In order to test whether human/mouse equivalent anti-MET antibodies displayed agonistic
activity in this assay, we seeded LOC human kidney epithelial cells (Michieli et al. Nat
Biotechnol. 20, 488-495, 2002) and MLP29 mouse liver precursor cells in a collagen layer
as described (Hultberg et al., Cancer Res. 75, 3373-3383, 2015), and then exposed them
to increasing concentrations of mAbs or recombinant HGF (human or mouse, both from
R&D Systems). Branching morphogenesis was followed over time by microscopy, and
colonies were photographed after 5 days. Representative images are shown in Figure 5 .
Quantification of branching morphogenesis activity was obtained by counting the number of
branches for each spheroid. As shown in Table 17, all antibodies tested induced dose-
dependent formation of branched tubules. However, consistent with the data obtained in
MET auto-phosphorylation assays and cell scattering assays, 7 1D6, 7 1A3 and 7 1G2
displayed the most potent agonistic activity, similar or superior to that of recombinant HGF.
Table 17: Branching morphogenesis assay. Cell spheroids preparations of LOC human
kidney epithelial cells or MLP29 mouse liver precursor cells were seeded in a collagen
layer and then incubated with increasing concentrations (0, 0.5, 2.5 and 12.5 nM) of mAbs
or recombinant HGF (LOC, human HGF; MLP29, mouse HGF). Branching morphogenesis
was followed over time by microscopy, and colonies were photographed after 5 days.
Branching was quantified by counting the number of branches for each spheroid (primary
branches plus secondary branches).
LOC cells
mAb 0 nM 0.5 nM 2.5 nM 12.5 nM
76H10 3.3 ± 1.5 7.3 ± 0.6 11.7 ± 1.5 16.7 ± 1.5
71G3 3.0 ± 1.0 13.7 ± 1.5 19.0 ± 2.6 22 .3 ± 2.1
71D6 3.0 ± 1.0 29.0 ± 2.0 29.0 ± 2.6 32.7 ± 1.5
71C3 3.3 ± 0.6 8.7 ± 1.5 12.7 ± 2.1 15.7 ± 2.1
71D4 3.0 ± 1.0 9.0 ± 2.6 15.7 ± 1.2 18.7 ± 1.5
71A3 3.0 ± 1.7 24.0 ± 4.6 30.3 ± 3.2 31.3 ± 1.5
71G2 3.7 ± 1.5 25.3 ± 2.1 29.3 ± 3.5 31.7 ± 3.5
76G7 2.7 ± 0.6 6.7 ± 0.6 13.3 ± 4.2 16.3 ± 5.7
71G12 3.3 ± 0.6 7.0 ± 2.6 15.3 ± 5.5 16.0 ± 4.6
74C8 3.0 ± 1.0 10.3 ± 4.2 17.0 ± 4.6 18.7 ± 4.9
72F8 3.3 ± 1.5 9.0 ± 3.5 12.3 ± 2.1 16.0 ± 3.0
hHGF 3.0 ± 1.0 18.0 ± 2 27.7 ± 2.5 20.3 ± 2.1
MLP29 cells
Example 10: Human-mouse equivalent agonistic anti-MET antibodies offer ample
opportunity to modulate MET activity
Based on the biochemical and biological assays described thus far, we made a
comprehensive analysis aimed at comparing antibody functions. The performance of the
various mAbs measured in the assays conducted is summarized in Table 18. By analysing
this table it emerges that human-mouse equivalent agonistic anti-MET antibodies display a
wide array of biochemical and biological activities, offering ample opportunity to modulate
MET activity in a custom fashion. Depending on the translational or clinical application of
choice, antibodies can be selected among those identified that fully or partially compete
with HGF, that potently or mildly cause MET activation, that strongly or weekly promote cell
invasiveness, or that vigorously or softly antagonize apoptosis. From this perspective,
agonistic antibodies are much more versatile and plastic compared to HGF, as they allow
for more graduated response to be induced compared to the on-or-off nature of HGF.
From a pharmacological viewpoint, the possibility of eliciting selective biological activities
downstream MET can be quite useful. For example, certain applications in the field of
oncology benefit of ligands that disassociate the trophic properties of HGF from its pro-
invasive activity (Michieli et al., Nat Biotechnol. 20, 488-495, 2002). Other applications in
the field of hepatology ideally require factors that protect hepatocytes against apoptosis
without promoting cell invasion (Takahara et al., Hepatology, 47, 201 0-2025, 2008). In yet
other applications in the field of muscular dystrophy, differentiation of myoblasts into
myocytes requires shut-down of HGF-induced proliferation on one hand and protection
against differentiation-associated apoptosis on the other (Cassano et al., PLoS One 3 ,
e3223, 2008). In all these applications and in other similar cases, one could envision to
employ partial agonistic mAbs that displace endogenous HGF on one hand and elicit mild
MET activation on the other, thus enhancing certain biological activities of HGF while
reducing others.
Conversely, diverse applications in the field of regenerative medicine require potent pro-
survival signals and rapid tissue repair in order to prevent irreversible cellular damage or
degeneration. For example, this situation is found in the case of sudden liver failure, acute
kidney injury, or severe pancreatitis (reviewed by Nakamura et al., J Gastroenterol Hepatol.
26 Suppl 1, 188-202, 201 1) . In all these applications and in other similar cases, one would
prefer to employ full agonistic mAbs that push as potently as possible tissue healing and
regeneration. HGF competition does not really play a role in this case because fully
agonistic mAbs are as potent -if not more potent- than HGF and can reach
pharmacological concentrations logarithms higher than the physiological levels at which the
endogenous ligand is found.
In yet other pathological situations that involve non-canonical, less characterized functions
of HGF, such as those that involve the immune system (inflammatory diseases, auto
immune disorders, transplantation-related complications), the hematopoietic system (stem
cell mobilization, hematopoiesis) and the nervous system (nerve growth, neuronal
degeneration), the role of the HGF/MET pathway is still poorly studied. While several lines
of experimental evidence suggest that recombinant HGF or HGF gene therapy ameliorate
these disorders in preclinical models (reviewed by Nakamura et al., J Gastroenterol
Hepatol. 26 Suppl 1, 188-202, 201 1) , we do not have enough information for determining
whether all functions of HGF or only part of them are beneficial. For these therapeutic
applications as well, the possibility of finely tuning MET activity with a highly diverse panel
of MET-agonistic antibodies is potentially advantageous compared to HGF (without
mentioning the numerous pharmacological problems implicit in the use of recombinant
HGF as a drug discussed in the Summary of the Invention section).
In conclusion, we suggest that all human-mouse equivalent anti-MET antibodies identified
can be potentially useful for therapeutic application, whether fully or partially competing
with HGF, and whether fully or partially activating the MET receptor.
Table 18: Major biochemical and biological characteristics of human/mouse
equivalent anti-MET antibodies. This table summarizes the ability of each mAb to bind to
purified MET ECD (ELISA), to recognize native MET on MET-expressing cells (FACS), to
compete with HGF for MET binding (HGF competition), to activate MET in receptor auto-
phosphorylation assays (MET activation), to promote cell scattering (Scatter assay), to
protect cells against drug-induced apoptosis (Survival assay), and to promote branching
morphogenesis of epithelial cell spheroids (Branching morphogenesis). For each assay,
the score is based on the relative activity of any given mAb with respect to the other
antibodies (+, lower 50%; ++, upper 50%). Since all antibodies displayed similar activities in
human and mouse systems, only one score per assay is shown.
Example 11: Constant region swapping does not alter the biochemical and biological
features of human/mouse eguivalent antibodies
Since the aim of the invention is to generate and identify agonistic anti-MET antibodies that
work equally well in human and mouse systems, we sought to determine whether swapping
of the human heavy chain and light chain constant regions with the corresponding mouse
constant regions affected the major biochemical and biological activities of a representative
panel of antibodies. To this end, we selected 3 representative molecules from the panel of
human/mouse equivalent antibodies (71 G3, partial competitor of HGF and partial agonist in
biological assays; 7 1D6 and 7 1G2, full competitors of HGF and full agonists in biological
assays). The VH and VL regions of 7 1G3, 7 1D6 and 7 1G2 were mounted onto mouse
lgG1/A antibody frames. The sequences of all mouse immunoglobulin variants are available
in public databases such as the ImMunoGeneTics information system (www.imqt.org ) .
Fusion with the desired variable regions can be achieved by standard genetic engineering
procedures. The full amino acid sequences of the heavy chain and light chains of the
generated llama-mouse chimeric antibodies are shown in Table 19.
Table 19: Full heavy chain and light chain amino acid sequences of llama-mouse
chimeric mAbs binding to both human and mouse MET.
Clone Heavy chain (VH—CHI—CH2—CH3 ) SEQ ID Light chain (VL-CL) SEQ ID
NO. NO.


















































Production and purification of recombinant immunoglobulins can be obtained by transient
transfection in mammalian cells and affinity chromatography, respectively, following well
established protocols. Thereafter, we compared the biochemical and biological activities of
7 1G3, 7 1D6 and 7 1G2 in the mouse format with those of the same antibodies in the human
format.
We evaluated the ability of the antibodies to bind to purified human or mouse MET ECD by
ELISA, to recognize native MET on human or mouse cells by FACS, to induce scattering of
human and mouse epithelial cells, and to promote branching morphogenesis in collagen.
The results of this analysis, summarized in Table 20, reveal that swapping the human with
the mouse constant regions does not substantially affect any of the properties analysed.
Table 20: Constant region swapping does not alter the biochemical and biological
features of human/mouse equivalent antibodies. Three representative agonistic
antibodies (71 G3, 7 1D6 and 7 1G2) in either mouse or human format were subjected to
several in vitro assays aimed at characterizing their major biochemical and biological
properties.
Example 12: Comparison with prior art antibodies: human-mouse cross-reactivity
As discussed in detail in the Background section, a few other studies have already
described agonistic anti-MET antibodies that mimic HGF activity, at least partially. At the
time of writing, these include: (i) the 3D6 mouse anti-human MET antibody (U.S. Patent No.
6,099,841); (ii) the 5D5 mouse anti-human MET antibody (U.S. Patent No. 5,686,292); (iii)
the NO-23 mouse anti-human MET antibody (U.S. Patent No. 7,556,804 B2); (iv) the B7
human naive anti-human MET antibody (U.S. Patent Application No. 2014/0193431 A1);
(v) the DO-24 mouse anti-human MET antibody (Prat et al., Mol Cell Biol. 11, 5954-5962,
1991 ; Prat et al., J Cell Sci. 111, 237-247, 1998); and (vi) the DN-30 mouse anti-human
MET antibody (Prat et al., Mol Cell Biol. 11, 5954-5962, 1991 ; Prat et al., J Cell Sci. 111,
237-247, 1998).
We obtained all prior art agonistic anti-MET antibodies as follows. The 3D6 hybridoma was
purchased from the American Type Culture Collection (Cat. No. ATCC-HB-1 2093). The
3D6 antibody was purified from the hybridoma conditioned medium by standard affinity
chromatography protocols.
The cDNA encoding the variable regions of the 5D5 antibody, the bivalent progenitor of the
antagonistic anti-MET antibody Onartuzumab (Merchant et al., Proc Natl Acad Sci USA
110, E2987-2996, 201 3), were synthesized based on the VH and VL sequences published
in US Patent No. 7,476,724 B2. The obtained DNA fragments were fused with mouse
constant lgG1/A domains and produced as bivalent monoclonal antibodies by standard
protein engineering protocols.
The NO-23 antibody was obtained from Prof. Maria Prat, University of Novara, Italy
(inventor of NO-23; U.S. Patent No. 7,556,804 B2). The NO-23 antibody can also be
obtained by requesting the corresponding hybridoma to the international depositary
authority Interlab Cell Line Collection (ICLC) at the Advanced Biotechnology Center (ABC)
in Genova, Italy (Clone No. ICLC 03001 ) .
The cDNA encoding the variable regions of the B7 antibody were synthesized based on the
VH and VL sequences published in US Patent Application No. 2014/01 93431 A 1 . The
obtained DNA fragments were fused with mouse constant lgG1/A domains and produced
as bivalent monoclonal antibodies as described above.
The DO-24 and DN-30 antibodies were obtained from Prof. Maria Prat, University of
Novara, Italy (who first identified and characterized DO-24 and DN-30; Prat et al., Mol Cell
Biol. 11, 5954-5962, 1991 ; Prat et al., J Cell Sci. 111, 237-247, 1998). The DO-24 antibody,
now discontinued, has been commercially available for years from Upstate Biotechnology.
The DN-30 antibody can also be obtained by requesting the corresponding hybridoma to
the international depositary authority Interlab Cell Line Collection (ICLC) at the Advanced
Biotechnology Center (ABC) in Genoa, Italy (Clone No. ICLC PD 05006).
Because the vast majority of animal models of human diseases employ the mouse as a
host, cross-reactivity with the mouse antigen is an essential pre-requisite for an antibody
the biological activity of which needs to be validated in pre-clinical systems. Since all
antibodies of the prior art were generated in a mouse (except for B7 that was identified
using a human na'ive phage library), it is unlikely that these molecules display cross-
reactivity with mouse MET. Even if a minor cross-reactivity with self-antigens is in principle
possible, these interactions have normally a very low affinity.
As detailed in U.S. Patent No. 6,099,841 , the 3D6 antibody does not bind to mouse MET
and the inventors had to use ferrets and minks to demonstrate that their antibody has in
vivo activity. It is clear that these animal models do not represent ideal systems for
modelling human diseases nor their use in preclinical medicine has been established.
Furthermore, the inventors do not provide any quantitative data relative to the difference in
antibody affinity and activity between human systems and ferret or mink systems.
The 5D5 antibody and its derivatives were explicitly shown not to bind to mouse MET
(Merchant et al., Proc Natl Acad Sci USA 110 , E2987-2996, 201 3). No information is
available about its cross-reactivity with other preclinical species.
Likewise, U.S. Patent Application No. 2014/0193431 A 1 provides no information relative to
cross-reactivity of the B7 antibody with mouse MET or that of other species.
U.S. Patent No. 7,556,804 B2 claims that the NO-23 antibody cross-reacts with mouse, rat
and dog MET, but no quantitative experimental evidence is provided in support of this
statement. The inventors use a single saturating dose of NO-23 to immuno-precipitate MET
from lysates of mouse, rats, human or dog cells, and then incubate the immuno-
precipitated proteins with radioactive 3 P-ATP. After radiolabeling, the incorporated 3 P-ATP
is visualized by autoradiography. This method is extremely sensitive and by no mean
quantitative; it is not possible to tell to what percentage of cross-reactivity the bands on the
gel correspond to.
Similarly, the DO-24 antibody is suggested to cross-react with mouse MET because a DO-
24-containing Matrigel pellet promotes blood vessel recruitment when implanted in the
abdominal cavity of a mouse (Prat et al., J Cell Sci. 111, 237-247, 1998). However, this
could also be due to increased inflammation and no direct evidence that DO-24 interacts
with mouse MET is provided. In a different study, a single saturating dose of DO-24 (20
nM) is shown to cause auto-phosphorylation of MET in the rat cardiac muscle cell line H9c2
and in the mouse cardiac muscle cell line HL-5 (Pietronave et al., Am J Physiol Heart Circ
Physiol. 298, H 1 155-65, 2010; Fig. 1). In the same experiment, a much lower dose of
recombinant HGF (0.5 nM) is shown to cause MET phosphorylation to a comparable
extent. As the authors themselves acknowledge in the Discussion section, these results
suggest that DO-24 is dramatically less potent than HGF in these rodent cell lines. Since
DO-24 is claimed by the same authors to be a full agonistic mAb that matches HGF activity
in human cell models (Prat et al., J Cell Sci. 111, 237-247, 1998), then it should be
concluded that DO-24 does not elicit the same efficacy or potency in human and in mouse
cells. Furthermore, it should be noted that the experiments shown by Pietronave et al. are
not quantitative and are not useful to extract information on the degree of cross-reactivity
that occurs between DO-24 and mouse or rat MET, the measurement of which would
require a head-to-head dose-response study, like the one that we did (see below). In a third
work, a mixture of the DO-24 and DN-30 antibodies is used to immuno-precipitate MET
from mouse mesenchymal stem cell lysates (Forte et al., Stem Cells. 24, 23-33, 2006).
Both the presence of DN-30 and the assay type (immuno-precipitation from cell lysates)
prevent to obtain precise information on the ability of DO-24 to interact with native mouse
MET. In conclusion, no experimental evidence whatsoever exists that the DO-24 antibody
elicits comparable biological responses in human and in mouse cells.
Finally, the DN-30 antibody was explicitly shown not to interact with mouse MET (Prat et
al., J Cell Sci. 111, 237-247, 1998; and suppl. material of Petrelli et al., Proc Natl Acad Sci
USA 103, 5090-9095, 2006).
In order to directly determine whether -and to what extent- the prior art agonistic anti-MET
antibodies cross-reacted with mouse MET, and to compare them to our human/mouse
equivalent anti-MET antibodies, we performed an ELISA assay. Since all prior art
antibodies were obtained or engineered with a mouse lgG/λ format, we employed the
mouse lgG/λ version of 7 1G3, 7 1D6 and 7 1G2. Human or mouse MET ECD was
immobilized in solid phase ( 100 ng/well in a 96-well plate) and exposed to increasing
concentrations of antibodies (0-40 nM) in solution. Binding was revealed using HRP-
conjugated anti-mouse Fc antibodies (Jackson Immuno Research Laboratories). As shown
in Table 2 1 , this analysis revealed that, while the prior art antibodies bound to human MET
with a K ranging from 0.059 nM (B7) to 4.935 nM (3D6), none of them displayed any
affinity for mouse MET, even at a concentration as high as 40 nM. Among the antibodies
tested, only 7 1G3, 7 1D6 and 7 1G2 bound to both human and mouse MET, and they did so
with indistinguishable affinities and capacities. The entire binding profile of all antibodies is
shown in Figure 6 .
Table 2 1 : Binding affinity and capacity of anti-MET antibodies for human and mouse
MET as determined by ELISA. Affinity is expressed as EC
50
(nMol/L). Capacity is
expressed as E AX (optical density at 450 nm; n.c, not converged). See Figure 6 for the
entire binding profiles.
Example 13: Comparison with prior art antibodies: MET auto-phosphorylation
In order to compare the agonistic activity of the prior art antibodies with that of
human/mouse equivalent anti-MET antibodies, we performed a MET auto-phosphorylation
experiment using both human and mouse cells. A549 human lung carcinoma cells and
MLP29 mouse liver precursor cells were deprived of serum growth factors for 48 hours and
then stimulated with increasing concentrations of antibodies (0-25 nM). After 15 minutes of
stimulation, cells were washed twice with ice-cold phosphate buffered saline (PBS) and
then lysed as described (Longati et al., Oncogene 9 , 49-57, 1994). Phospho-MET levels
were determined by ELISA as described (Basilico et al., J Clin Invest. 124, 3172-3186,
2014) using anti-MET antibodies for capture (R&D Systems) and anti-phospho tyrosines for
revealing (R&D Systems).
This analysis revealed two major differences between prior art antibodies and the
human/mouse equivalent anti-MET antibodies described in the present document. First,
consistent with the results obtained in binding experiments, only 7 1G3, 7 1D6 and 7 1G2
could promote MET auto-phosphorylation in both human and mouse cells. The prior art
antibodies, including DO-24 and NO-23, induced MET activation in human cells only; no
activity on mouse cells could be detected in the system that we analyzed. Second, all prior
art antibodies invariably displayed lower agonistic activity compared to 7 1G3, 7 1D6 and
7 1G2. The most agonistic prior art mAbs were 5D5 and B7, which displayed an activity
slightly lower than 7 1G3, 7 1D6 and 7 1G2. The least agonistic prior art mAb was 3D6. The
other molecules displayed intermediate activity. The results of this analysis are shown in
Figure 7 .
Example 14: Comparison with prior art antibodies: branching morphogenesis
In order to compare the biological activity of prior art antibodies with that of human/mouse
equivalent anti-MET antibodies, we performed a branching morphogenesis assay. This
assay recapitulates all the relevant biological activities of HGF including cell proliferation,
scattering, differentiation and survival. LOC human kidney epithelial cells and MLP29
mouse liver precursor cells were seeded in a collagen layer as described above and then
incubated with increasing concentrations of mAbs or recombinant HGF (human or mouse,
both from R&D Systems). Branching morphogenesis was followed over time by
microscopy, and colonies were photographed after 5 days. Quantification of branching
morphogenesis activity was achieved by counting the number of branched tubules
sprouting from each spheroid and is shown in Table 22. Representative images of
spheroids are shown in Figure 8 (LOC cells) and in Figure 9 (MLP29 cells).
Table 22: Branching morphogenesis assay. Cell spheroids preparations of LOC human
kidney epithelial cells or MLP29 mouse liver precursor cells were seeded in a collagen
layer and then incubated with increasing concentrations (0, 0.04, 0.2, 1, and 5 nM) of mAbs
or recombinant human HGF (LOC) or mouse HGF (MLP29). Branching morphogenesis
was followed over time by microscopy, and colonies were photographed after 5 days.
Branching was quantified by counting the number of branches for each spheroid (primary
branches plus secondary branches).
LOC cells
MLP29 cells
The data presented lead to the following observations. In human cells, 7 1D6, 7 1G2 and
5D5 displayed an activity comparable to that of human HGF; 7 1G3, 3D6, B7 and DO-24
behaved as partial agonists; NO-23 and DN-30 displayed very little agonistic activity. In
mouse cells, only 7 1G3, 7 1D6 and 7 1G2 effectively induced the formation of branched
tubules; all the other antibodies -consistent with their inability to bind to mouse MET in
ELISA- did not induce branching morphogenesis at all.
We conclude that the prior art antibodies, in contrast to human/mouse equivalent anti-MET
antibodies, elicit different biological activities in human and mouse systems.
Example 15: Plasma half-life of human/mouse equivalent anti-MET antibodies
Next, we moved the selected human/mouse equivalent anti-MET antibodies forward to in
vivo studies. As a preliminary analysis, we determined their peak and trough levels in mice.
To this end, we injected affinity purified 7 1G3, 7 1D6 and 7 1G2 (in their mouse lgG/λ
format) into 7 week-old female BALB/c mice (Charles River) by i.p. injection. A single bolus
of 1 mg/kg or 10 mg/kg was injected and blood samples were taken from the tail vein at 3 ,
6 , 12 and 24 hours post-injection. Blood samples were processed and antibody
concentration in plasma was determined by ELISA. Standard 96-well plates were coated
with human MET ECD (100 ng/well) as described in Example 1 and then exposed to
increasing dilutions of mouse plasma to capture anti-MET antibodies. After repeated
washing with PBS, the presence of anti-MET antibodies was revealed using a HRP-
conjugated donkey anti-mouse antibody (Jackson Laboratories). To quantify bound
antibody, we set up a standard curve of purified 7 1G3, 7 1D6 and 7 1G2 in the same
conditions.
The results of this analysis are shown in Figure 10. The antibody concentrations in plasma
were similar for all the antibodies tested and directly proportional to the amount of protein
injected. After 24 hours, antibody concentration in plasma was approximately 15 nM for the
1 mg/kg bolus and 250 nM for the 10 mg/kg bolus. Considering that the agonistic activity of
these antibodies in the most demanding assay (the branching morphogenesis assay)
reaches saturation at a concentration of 5 nM or lower, we can safely conclude that the
plasma levels of antibodies obtained by i.p. injection are relevant from a biologic viewpoint
with boluses as low as 1 mg/kg.
Furthermore, we also calculated the plasma half-life of injected antibodies. This was
achieved by transforming the antibody concentration to natural logarithm (Ln), fitting the
data into a line and then calculating the slope of the line. This analysis led to estimate that
the half-lives of 7 1G3, 7 1D6 and 7 1G2 are very similar and correspond approximately to 3
days for the 1 mg/kg bolus and 9 days for the 10 mg/kg bolus. This is a significantly higher
stability compared to that of recombinant HGF which has been reported to have a half-life
of 2.4 minutes in rodents (Ido et al., Hepatol Res. 30, 175-1 8 1 , 2004). The whole panel of
plasma stability data is summarized in Table 23.
These data suggest that human/mouse equivalent anti-MET antibodies could
advantageously substitute recombinant HGF in all clinical applications that require systemic
administration of HGF.
Table 23. Plasma stability of human/mouse equivalent antibodies. A single bolus ( 1
mg/kg or 10 mg/kg) of affinity purified 7 1G3, 7 1D6 and 7 1G2 was administered to 7 week-
old female BALB/c mice by i.p. injection. Blood samples were taken from the tail vein at 3 ,
6 , 12 and 24 hours post-injection, and antibody concentration in plasma was determined by
ELISA. Plasma half-life was calculated by linear fitting of the natural logarithm transforms of
antibody concentrations.
Example 16: In vivo activity: Protection against acute liver damage
Hepatocytes express MET and are the principal target of HGF, which promotes their
proliferation and protects them against apoptosis (reviewed by Nakamura et al., J
Gastroenterol Hepatol. 1, 188-202, 201 1) . We therefore tested whether human/mouse
equivalent agonistic anti-MET antibodies displayed protective activity in mouse models of
acute liver failure. To this end, we injected a single dose of CCI4 (0.2 ml of a 10% solution
in olive oil; both from Sigma-Aldrich) into the subcutaneous compartment of 7 week-old
female BALB/c mice (Charles River). Soon after CCI4 injection, mice were randomized into
4 arms of 6 mice each which received a single bolus of purified 7 1G3, 7 1D6, 7 1G2 or
vehicle only (PBS). Antibodies were administered by i.p. injection at a dose of 5 mg/kg.
Blood samples were taken at different times post-injection (0, 12 , 24 and 48 hours). An
additional, fifth control arm contained 6 mice that received no CCI4 or antibody and were
sacrificed at the end of the experiment. At autopsy, blood and livers were collected for
analysis. Plasma levels of the hepatic markers aspartate transaminase (AST), alanine
aminotransferase (ALT) and bilirubin (BIL) were determined by standard clinical
biochemistry methods. Livers were embedded in paraffin and processed for histological
analysis using standard protocols.
As shown in Figure 1 1 , CCI4 injection in control mice caused a rapid and dramatic increase
in the levels of all three blood parameters analysed, which reached a peak 12-24 hours
post-intoxication. In the control arm, CCI4 injection caused AST, ALT and bilirubin levels to
rise 286, 761 and 13 times, respectively. In all antibody arms, these increases were
significantly reduced (71 G3, 53%, 62%, and 46%; 7 1D6, 37%, 34% and 48%; 7 1G2, 50%,
39% and 54%, respectively). The most potent antibody in terms of hepatic protection was
7 1D6.
Histological examination of livers at autopsy revealed that CCI4 caused marked tissue
damage around the central vein of each hepatic module, characterized by eosinophilic
staining and a large cytoplasm, typical of suffering hepatocytes. Cell-cell interactions
appeared loose allowing for infiltration of red blood cells leaking from the damaged vessels.
In the antibody-treated arms, these peri-central damaged areas were smaller and displayed
less signs of sufferance, as evidenced by a less eosinophilic staining, normal cytoplasm
size and decreased blood cell infiltration. Representative images of liver sections stained
with hematoxylin and eosin are shown in Figure 12.
These results suggest that human/mouse equivalent agonistic anti-MET antibodies could
be used in the clinic to treat acute disorders of the liver characterized by rapid development
of hepatic dysfunction, which typically lead to abnormal liver biochemical values, jaundice,
coagulopathy, cerebral edema and encephalopathy. These pathological conditions include
-but are not limited to- paracetamol overdose, idiosyncratic reactions to medications (e.g.
tetracycline), drug abuse (ecstasy, cocaine), viral infections (hepatitis A, B, E).
Example 17: In vivo activity: Protection against chronic liver damage
We also tested whether human/mouse equivalent agonistic anti-MET antibodies displayed
therapeutic effects in a mouse model of chronic liver damage. In fact, HGF is known to
have anti-fibrotic activity in the liver (reviewed by Matsumoto and Nakamura, Ciba Found
Symp. 2 12 , 198-21 1; discussion 2 11-214, 1997). To this end, 7 week-old female BALB/c
mice (Charles River) were chronically exposed to CCI4 for several weeks. The first week,
mice were injected subcutaneously for two times with 0.1 ml of a 5% solution of CCI in
olive oil (both from Sigma-Aldrich). The following weeks, the dose of CCI4 was increased
(0.1 ml of a 10% solution in olive oil), while the frequency of injection was maintained
unchanged (twice a week). Soon after the first injection, mice were randomized into 4 arms
of 7 mice each which received treatment with purified 7 1G3, 7 1D6, 7 1G2 or vehicle only
(PBS), respectively. Antibodies were administered three times a week by i.p. injection at a
dose of 1 mg/kg. An additional, fifth control arm contained 7 mice that received no CCI4 or
antibody and served as healthy control. Mice were sacrificed after 6 weeks of chronic CCI4
intoxication. At autopsy, blood and livers were collected for analysis. Plasma levels of the
hepatic markers aspartate transaminase (AST) and alanine aminotransferase (ALT) were
determined by standard clinical biochemistry methods. Livers were embedded in paraffin
and processed for histological analysis using standard protocols.
As shown in Figure 13, chronic exposure to CCI4 in control mice led to impaired liver
function as determined by higher AST and ALT plasma levels. In contrast to the acute
model which causes a sharp but transient burst in liver marker levels, chronic CCI
intoxication induced a more moderate increase of AST and ALT levels, approximately 5
times compared to untreated mice. Remarkably, antibody treatment could completely
prevent the increase in AST concentration, actually lowering it below the basal levels.
Antibodies could also significantly prevent the burst in ALT levels, although not as
spectacularly as observed for AST.
Liver sections were stained by various techniques aimed at detecting fibrotic tissue,
including Masson's trichrome, Picro Sirius red and anti-alpha smooth muscle actin (a-SMA)
antibodies. Staining with hematoxylin and eosin was also performed in order to examine
general histology architecture. This analysis revealed that chronic CCI4 treatment caused
the formation of a remarkable amount of fibrotic tissues in the inter-lobular space,
specifically characterized by positivity to Picro Sirius red and anti-alpha smooth muscle
actin (a-SMA) antibody staining. The fibrotic tissue formed a sort of 'ribbon' that linked the
portal triads, evidencing the hexagonal shape of the hepatic units. Remarkably, liver
sections derived from animals who received both CCI and agonistic anti-MET antibodies
displayed much milder fibrosis in terms of staining intensity, and the fibrotic area appeared
confined to the peri-portal space. Representative images of liver sections stained with Picro
Sirius red and anti-a-SMA antibodies are shown in Figure 14 and Figure 15, respectively.
These data suggest that human/mouse equivalent agonistic anti-MET antibodies could be
used in the clinic to treat pathological conditions associated with chronic liver damage,
characterized by progressive destruction and regeneration of the liver parenchyma and
leading to cirrhosis and fibrosis. Agonistic anti-MET antibodies may be used to reduce or
prevent fibrosis, leading to restoration of liver architecture and function. They may also be
used to suppress inflammation and immune reaction, often aggravating chronic liver
diseases.
Example 18: In vivo activity: Protection against acute kidney damage
Kidney epithelial cells express significant levels of MET and are very sensitive to HGF
stimulation (reviewed by Mizuno et al. Front Biosci. 13, 7072-7086, 2008). Therefore, we
tested whether human/mouse equivalent agonistic anti-MET antibodies displayed
protective effects in a mouse model of acute kidney failure. To this end, we induced tubular
damage in 7 week-old female BALB/c mice (Charles River) by i.p. injection of a single
bolus of HgCI2 (3 mg/kg). Soon after HgCI2 intoxication, mice were randomized into 4 arms
which were subjected to treatment with 7 1G3, 7 1D6, 7 1G2 or vehicle only (PBS).
Antibodies were administered by i.p. injection every 24 hours at a dose of 10 mg/kg. Each
arm comprised 6 mice that were sacrificed 72 hours after HgCI2 injection. At autopsy, blood
and kidneys were collected for analysis. Blood urea nitrogen (BUN) and creatinine (CRE)
plasma levels were determined by standard clinical biochemistry methods. Kidneys were
processed for histological analysis using standard protocols.
As shown in Figure 16, HgCI2 injection in control mice caused a sharp increase in the
levels of BUN and CRE. In the control arm, BUN and CRE increased 6 and 12 times,
respectively. In all antibody arms, these increases were significantly reduced (71 G3, 52%,
and 54%; 7 1D6, 39% and 30%; 7 1G2, 45% and 44%, respectively). The most potent
antibody in terms of kidney protection was 7 1D6.
Histological examination of kidneys revealed that HgCI2 caused a widespread tubular
damage characterized by proximal tubule dilatation, atrophy and necrosis. The glomerular
structures collapsed and detached from the surrounding stroma, substantially incrementing
the peri-glomerular space. In the antibody-treated arms, proximal tubule cells were less
necrotic and the histological architecture of glomeruli appeared intact. Representative
images of kidney sections stained with hematoxylin and eosin are shown in Figure 17.
We propose that human/mouse equivalent agonistic anti-MET antibodies may be used in
the clinic to treat pathological conditions associated with acute kidney failure, which may be
caused for example by ischemic or nephrotoxic injury, hypovolemic shock, obstruction of
the urinary collection system, atherosclerosis, sepsis, diabetes mellitus, autoimmune
diseases, or rhabdomyolysis. Agonistic anti-MET antibodies may be useful to prevent or
reverse acute renal failure, protect tubular epithelial cells from apoptosis, accelerate
epithelial cell regeneration and restore kidney function.
Example 19: In vivo activity: Protection against acute colonic damage, reduction of
inflammation and promotion of regeneration in a mouse model of ulcerative colitis
It is well established that intestinal epithelial cells express MET and that HGF plays a
pivotal role in the homeostasis and regeneration of the gastro-enteric tract (reviewed by
Nakamura et al., J Gastroenterol Hepatol. 1, 188-202, 201 1) . We therefore tested whether
human/mouse equivalent agonistic anti-MET antibodies could promote gut protection and
regeneration in a mouse model of ulcerative colitis. To this end, we exposed 7 week-old
female BALB/c mice (Charles River) to dextran sodium sulphate (DSS) in the drinking
water for 10 days. On day 10 , DSS treatment was interrupted and mice were put back on
normal water. Starting from day 1, mice were randomized into 7 arms of 7 mice each which
received treatment with 7 1G3, 7 1D6, 7 1G2 (at a dose of 1 mg/kg or 5 mg/kg) or vehicle
only (PBS). Antibodies were administered three times a week by i.p. injection. An
additional, eighth control arm contained 7 mice that received no DSS or antibody and
served as healthy control. Mice were sacrificed on day 12 , i.e. 2 days after DSS
administration was interrupted. At autopsy, colons were collected, washed through, and
their length was determined using a ruler. Following measurement, colons were embedded
in paraffin and processed for histological analysis.
During the whole course of the experiment, mouse weight was monitored on a regular
basis, and the clinical symptoms of ulcerative colitis were assessed by determining fecal
blood, rectal bleeding and stool consistency. Quantification was achieved using a standard
scoring system used in pre-clinical models (Kim et al., J Vis Exp. 60, pii: 3678, 2012): each
parameter scored from 0 (absence of the symptom) to 3 (maximal manifestation of the
symptom). Scores relative to the single parameters were summed together to give rise to
the Disease Activity Index (DAI) ranging from 0 to 9 .
As shown in Figure 18, exposure to DSS in the PBS arm caused a weight loss of up to
25%; the DAI increased to a score of 4 or higher; and the length of the colon was reduced
by up to 40%. Remarkably, all antibodies analyzed reversed these effects in a dose-
dependent fashion, displaying significant activity already at the lower dose tested. 7 1D6
was the most potent antibody: after a transient decline, it brought body weight back at
normal values, comparable to those observed in the PBS group; it curbed the DAI increase,
substantially inhibiting all the clinical symptoms; and it prevented colon shortage, limiting it
to negligible variations.
Colon sections were stained with hematoxylin and eosin and examined by microscopy. As
shown in Figure 19, DSS administration caused profound damage to the colonic mucosa.
The epithelial layer appeared eroded and infiltrated with lymphocytes. The colonic mucosa
was disseminated with cryptic abscess sites and was heavily colonized by foamy
macrophages, responsible for tissue destruction. Peri-visceral lymph nodes appeared
enlarged. The muciparous glands were characterized by atrophy and displayed marked
mucinous depletion, which was substituted with inflammatory infiltrate including foamy
macrophages, lymphocytes and neutrophils. Several ulcers were visibly invaded by
granulocytic or macrophage exudate, leading to the total disappearance of the glandular
component. Remarkably, mice treated with both DSS and agonistic anti-MET antibodies
displayed much milder symptoms of degeneration and inflammation. Specifically, elements
of acute inflammation were absent, including macrophages and granulocytes; the mucosa
appeared only marginally injured, displaying sparse glandular distortion and rarefaction;
mucin secretion was restored, and erosions and ulcers were completely absent. Although
these protective effects were dose-dependent in all antibody groups, they were already
evident at 1 mg/kg, indicating that the concentrations of antibodies reached with this dose
are very close to saturation (see plasma stability in Example 15). In this model as well, the
most effective antibody appeared to be 7 1D6.
Example 20: In vivo activity: Protection against acute colonic damage, reduction of
inflammation and immune suppression in a mouse model of inflammatory bowel disease
Prompted by the above results, we also tested whether agonistic anti-MET antibodies
displayed a therapeutic effect in a more specific mouse model of inflammatory bowel
disease. To this end, we induced acute colon injury in 7 week-old female C57BL/6 mice
(Charles River) by intra-rectal injection of 2,4,6-trinitrobenzenesulfonic acid (TNBS)
dissolved in ethanol. The TNBS/ethanol combination is known to induce colorectal
inflammation through both immunological and erosive processes (reviewed by Jones-Hall
and Grisham, Pathophysiology 2 1 , 267-288, 2014). TNBS dissolved in 50% ethanol was
administered by enema at a dose of 5 mg/mouse. Soon after TNBS administration, mice
were randomized into 4 arms of 6 mice each which received treatment with purified 7 1G3,
7 1D6, 7 1G2 or vehicle only (PBS). Antibodies were administered every second day by i.p.
injection at a dose of 1 mg/kg. An additional, fifth control arm contained 6 mice that
received no TNBS or antibody and served as healthy control. Mouse weight was monitored
daily. Mice were sacrificed 5 days after TNBS administration. At autopsy, colons were
collected and measured as described above. Following measurement, colons were
embedded in paraffin and processed for histological analysis.
As shown in Figure 20, exposure to TNBS caused a weight loss of approximately 15% and
reduced colon length by more than 20%. These effects, although more moderate compared
to those caused by DSS, were significantly different from those observed in all antibody
arms. In fact, treatment with 7 1G3, 7 1D6 and 7 1G2 inhibited TNBS-induced weight loss
and colon shortening almost completely, making the antibody-treated animals hardly
distinguishable from the healthy control mice.
Colon sections were stained with hematoxylin and eosin and examined by microscopy. As
shown in Figure 2 1 , TNBS administration caused the onset of the typical signs of
lymphocytic colitis, characterized by enlarged peri-visceral lymph nodes, appearance of
lymphocytic aggregation in the sub-mucosa and mucosa, and increased lymphocyte
infiltration. Several full-depth ulcers were visible, associated with stromal hyper-proliferation
and infiltration by lymphocytes and neutrophils. All these pathological processes were
strongly inhibited in the agonistic anti-MET antibodies arms, which displayed reduced
lymphocytic infiltration and reduced mucosal damage. Even where lymphocytes were
present, they were not associated with muciparous depletion or epithelial injury.
These results and the data reported in the previous example indicate that human/mouse
equivalent agonistic anti-MET antibodies may be employed in the clinic to treat pathological
conditions associated with ulcerative colitis or more in general with an inflammatory bowel
disease. Treatment with agonistic anti-MET antibodies may reduce intestinal lesions,
promote epithelial cell proliferation and reduce inflammatory cell infiltration, thus improving
the clinical course of the disease.
Example 2 1 : In vivo activity: Promotion of glucose uptake and cooperation with insulin in a
mouse model of type I diabetes
HGF has been reported to promote insulin-dependent glucose uptake in cultured mouse
skeletal muscle cells (Perdomo et al., J Biol Chem. 283, 13700-1 3706, 2008). We therefore
tested whether our agonistic anti-MET antibodies could reduce high blood glucose levels in
a mouse model of type I diabetes. To this end, we induced pancreatic β-cell degeneration
in 7 week-old female BALB/c mice (Charles River) by i.p. injection of streptozotocin (STZ;
Sigma Aldrich). STZ was injected at a dose of 40 mg/kg every day for 5 consecutive days.
One week after the last injection, blood glucose levels under fasting conditions were
determined using standard glucose strips (GIMA). At this time, STZ-treated mice displayed
a mean basal glycemy two times higher compared to untreated mice (240 mg/dL vs. 120
mg/dL). Mice were randomized into 4 arms of 7 mice each based on basal glycemy, which
received treatment with purified 7 1G3, 7 1D6, 7 1G2 or vehicle only (PBS), respectively.
Antibodies were administered two times a week by i.p. injection at a dose of 1 mg/kg. An
additional, fifth control arm contained 7 mice that received no STZ or antibody and served
as healthy control. Blood glucose concentration in fasting conditions was monitored over
time for 5 weeks. At the end of week 5 , we performed a glucose tolerance test (GTT) and
an insulin tolerance test (ITT). A GTT consists in administering glucose to a fasting animal
by oral gavage and then measuring blood glucose levels at different time points. An ITT
consists in administering insulin to a partially fasting animal by i.p or i.v. injection and then
measuring blood glucose levels at different time points.
As shown in Figure 22A, basal blood glucose levels in STZ-treated mice continued to
increase for the whole duration of the experiment. This is due to chronic pancreas
inflammation, which progressively aggravates organ injury. In contrast, antibody-treated
animals displayed steadily decreasing glycemic levels which eventually reached a plateau
after the second week of treatment. Antibody administration did not completely normalize
glycemy but lowered it by up to 25%, thus bringing it about half way between the levels
observed in STZ-treated mice and in control mice. Considering that in this model
hyperglycemy is due to the absence of β-cell-derived insulin, we wondered whether lower
glucose levels in the antibody arms was due to increased insulin levels. However, ELISA
assays on blood samples revealed that this is not the case (not shown). In a GTT, mice
receiving antibody treatment -while starting from lower blood glucose levels- failed to
display a normal glucose uptake curve (Figure 22B). In contrast, antibody-treated mice did
display a more rapid response to insulin in an ITT (Figure 22C). Fifteen minutes after
insulin injection, glucose blood levels in mice subjected to chronic antibody treatment
dropped to approximately 30-40% relative to time zero, which is significantly less than what
observed in both STZ-treated mice and control animals (Figure 22D). These results
suggest that agonistic anti-MET antibodies promote glucose uptake in the absence of
insulin. They also suggest that agonistic anti-MET antibodies and insulin, when both are
present, cooperate in mediating glucose uptake.
This hypothesis was tested in cell-based assays using mouse skeletal muscle cells. C2C1 2
mouse myoblast cells (obtained from American Tissue Type Collection) were induced to
differentiate into myocytes as recommended by the provider and then incubated with
human/mouse equivalent agonistic anti-MET antibodies (71 G3, 7 1D6, 7 1G2). After 24
hours, antibody-treated cells were divided into 3 arms, which were subjected to acute
stimulation with 0 nM, 100 nM or 1000 nM human recombinant insulin (Sigma Aldrich) for 1
hour in the presence of the fluorescent glucose analogue 2-(N-(7-Nitrobenz-2-oxa-1 ,3-
diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG; Life Technologies). 2-NBDG uptake was
determined by flow cytometry.
As shown in Figure 23, 7 1G3, 7 1D6 and 7 1G2 promoted glucose uptake in a dose-
dependent fashion. Combination of insulin and agonistic anti-MET antibodies resulted in a
co-operative effect and promoted higher glucose uptake compared to both insulin alone
and antibodies alone. These data are consistent with the finding that HGF and insulin c o
operate in regulating glucose metabolism in cultured cells (Fafalios et al. Nat Med. 17,
1577-1 584, 201 1) , and confirm our hypothesis that agonistic anti-MET antibodies are
capable of enhancing both insulin-independent and -dependent glucose uptake.
Example 22: In vivo activity: blood glucose level normalization and insulin resistance
overcoming in a mouse model of type I I diabetes
Prompted by the observation that human/mouse equivalent agonistic anti-MET antibodies
could cooperate with insulin in promoting glucose uptake, we tested their therapeutic
potential in a mouse model of type I I diabetes. Type I I diabetes mellitus is characterized by
high blood glucose levels, hyperinsulinemia, and insulin resistance. One of the most
characterized mouse models of type I I diabetes is represented by db/db mice, a
C57BLKS/J strain bearing a point mutation in the leptin receptor gene lepr. This mutation
results in loss of satiety sense and thus in unlimited feeding, leading to obesity and the
above mentioned type I I diabetes clinical hallmarks (reviewed by Wang et al. Curr Diabetes
Rev. 10, 131-145, 2014).
Female db/db mice were obtained from Charles River (JAX™ Mice Strain BKS.Cg-
Dock +l+Lep ) at the age of 7 weeks. One week later, animals were randomized into 4
arms of 5 mice each, which received treatment with purified 7 1G3, 7 1D6, 7 1G2 or vehicle
only (PBS), respectively. Antibodies were administered two times a week by i.p. injection at
a dose of 1 mg/kg. Blood glucose concentration in fasting conditions was monitored every
14 days for 8 weeks. After 7 weeks of treatment, i.e. when mice were 15 weeks old, a
glucose tolerance test (GTT) and an insulin tolerance test (ITT) were performed.
As shown in Figure 24, the mean basal blood glucose concentration in the PBS arm at the
time of randomization was approximately 230 mg/dL, which definitely corresponds to
diabetic levels. These values tended to increase over time and at the end of the
experiment, i.e. 8 weeks later, the mean blood glucose concentration in the PBS arm was
approximately 330 mg/dL. In contrast, in the arms receiving antibody treatment, basal
glycemy in fasting conditions decreased constantly over time. At the end of the experiment,
the mean blood glucose concentration in the 7 1G3, 7 1D6 and 7 1G2 arms was 173 mg/dL,
138 mg/dL and 165 mg/dL, respectively.
After 7 weeks of treatment, i.e. when mice were 15 weeks old, we tested their acute
response to glucose and insulin challenge. It should be kept in mind that these mice, in
contrast to mice treated with STZ (see example 2 1) , are hyperinsulinemic and display high
blood glucose levels because they are insulin-resistant. In fact, when challenged with
glucose in a GTT, mice of the PBS arm failed to display a normal glucose uptake profile. All
mice showed a sharp increase in glycemy that remained elevated for the whole duration of
the test. Symmetrically, when subjected to an ITT, the same mice showed a paradoxical
response to insulin, displaying a slight and transient increase in glucose levels. This
paradoxical response is a hallmark of insulin resistance, at least in pre-clinical models.
Mice of the antibody arms, while starting from lower basal levels, also did not display a
normal glucose uptake profile in a GTT, thus suggesting that agonistic anti-MET antibodies
are unable to neutralize an acute burst in blood glucose levels. However, remarkably,
antibody treatment did dramatically improve response to insulin in an ITT, reversing the
paradoxical effect observed in the PBS arm and making the ITT profile look more similar to
that displayed by non-diabetic mice (C57BLKS/J; Charles River). We conclude that long-
term treatment with agonistic anti-MET antibodies ameliorates type I I diabetes in db/db
mice and partially overcomes insulin resistance.
Based on these results and those presented in the previous example, we suggest that
human/mouse equivalent agonistic anti-MET antibodies may be used in the clinic to treat
pathological conditions associated with high blood glucose levels. These may include type I
diabetes mellitus, type I I diabetes mellitus, or other diabetes-like pathologies that are
characterized by high glucose and/or insulin resistance (e.g. metabolic syndrome).
Example 23: In vivo activity: fatty liver amelioration in a mouse model of non-alcoholic
steatohepatitis
Targeted genetic deletion of MET in the liver has been shown to lead to the development of
severe non-alcoholic steatohepatitis (NASH) in mice (Kroy et al. J Hepatol. 6 1, 883-890,
2014). In an independent study (Kosone et al., Am J Physiol Gastrointest Liver Physiol.
293, G204-21 0 , 2007), HGF ameliorated high fat diet-induced fatty liver in mice by
activating microsomal triglyceride transfer protein (MTP) and apolipoprotein B (ApoB), thus
minimizing fatty acid storage.
Hyperinsulinemic db/db mice are also widely used as a model of NASH and, more in
general, of fatty liver diseases. On a normal diet, these mice accumulate a remarkable
amount of lipids in their hepatocytes, leading to liver steatosis, fibrosis and chronic liver
failure. This condition can be further aggravated by putting mice on a high fat diet
(reviewed by Anstee and Goldin, Int J Exp Pathol. 87, 1- 16 , 2006).
Prompted by the above observations and considerations, we tested whether human/mouse
equivalent agonistic anti-MET antibodies could ameliorate moderate hepatic steatosis in
db/db mice kept on a normal diet. To this end, we obtained female db/db mice as described
above. When animals were 8 weeks old, they were randomized into 4 arms of 6 mice each,
which received treatment with purified 7 1G3, 7 1D6, 7 1G2 or vehicle only (PBS),
respectively. Antibodies were administered two times a week by i.p. injection at a dose of 1
mg/kg. After 8 weeks of treatment, mice were sacrificed and subjected to autopsy. Livers
were extracted, embedded in paraffin and processed for histological examination. Blood
was collected for analysis of hepatic function markers.
Liver sections were stained with hematoxylin and eosin or with Picro Sirius red to highlight
fibrosis. As shown in Figure 25, livers from the PBS arm displayed a remarkable steatosis,
typically concentrated around the central veins. Hepatocytes appeared dramatically
enlarged and full of lipids. Fatty hepatocytes were mixed together with normal hepatocytes,
and steatosis occupied up to 60% of the peri-central space. In contrast, livers from
antibody-treated animals contained remarkably less fatty cells and appeared overall quite
normal. As shown in Figure 26, Picro Sirius red staining evidenced a moderate peri-portal
fibrosis in the PBS group, characterized by thickening of the stromal layer around the
hepatic triads (portal vein, hepatic artery and bile duct), sometimes expanding into the
interlobular space. Remarkably, liver sections from all the antibody arms displayed a much
lower fibrosis -if any. Analysis of the liver function markers AST and ALT in the plasma
confirmed these observations (see Figure 27). In fact, animals treated with agonistic anti-
MET antibodies displayed exceptionally low plasma concentrations of AST and ALT, about
2.5 times lower than the PBS group and 2 times lower than the mean AST and ALT levels
in normal mice.
These data suggest that human/mouse equivalent agonistic anti-MET antibodies could be
used in the clinic to treat NASH or other pathological conditions associated with fatty liver.
Agonistic anti-MET antibodies may be used to inhibit lipid accumulation in the hepatocytes,
preventing or reversing hepatosteatosis, and suppressing the vicious cycle that occurs
between fatty acid accumulation and macrophage infiltration. Chronic inflammation
invariably leads to deposition of extracellular matrix. Therefore, agonistic anti-MET
antibodies can also be employed to reduce steatosis-associated fibrosis.
Example 24: In vivo activity: wound healing in diabetic mice
A clinically relevant complication of diabetes is represented by increased ulceration and
impaired healing of wounds. Since HGF has been implicated in wound healing (Nakamura
et al., J Gastroenterol Hepatol. 1, 188-202, 201 1) , we sought to determine whether
human/mouse equivalent anti-MET antibodies could promote the healing of wounds in a
diabetic background. To this end, we obtained db/db diabetic mice as described above. At
the age of 8 weeks, we subjected animals to anaesthesia and then cut a 0.8 cm-wide
circular wound in the right posterior flank using a circular punch blade for skin biopsies
(GIMA). The entire epidermal layer was removed. The day after surgery, mice were
randomized into 4 arms that received treatment with purified 7 1G3, 7 1D6 and 7 1G2 or
vehicle only (PBS). Antibodies were delivered every second day by i.p injection at a dose of
5 mg/kg. Wound diameter was measured every day using a calliper.
As shown in Figure 28, antibody treatment significantly accelerated wound closure and re-
epithelization. While the control arm repaired the experimental wound at an average rate of
5% per day, this value increased to 8% in the 7 1G3 arm, to 12% in the 7 1D6 arm, and to
11% in the 7 1G2 arm.
We suggest that human/mouse equivalent agonistic anti-MET antibodies could be used in
the clinic to treat diabetes-associated ulcers and wounds that typically display impaired
healing. Diabetes-associated sores represent an unmet medical need. In the United States,
diabetes is the leading cause of non-traumatic lower extremity amputations. Agonistic anti-
MET antibodies may be used to accelerate healing, improve re-epithelization and promote
vascularization of high blood glucose-induced sores.
Example 25: Cross-reactivity with Rattus norvegicus and Macaca fascicularis MET
Since the vast majority of animal models of human diseases employ the mouse as a host,
cross-reactivity with the mouse antigen is a pre-requisite for an antibody that needs to be
validated in pre-clinical systems. This was the rationale that prompted us to identify human-
mouse equivalent anti-MET antibodies. However, some pre-clinical procedures are
conducted preferably in larger rodents or in primates (e.g. organ transplantation and other
experimental practices requiring complex surgical interventions). Furthermore,
pharmacodynamics and pharmacokinetics studies are preferably conducted in higher
vertebrates, typically rats and monkeys. Finally and most importantly, toxicological
assessment of therapeutic antibodies are ideally performed in monkeys, or alternatively -if
this is not possible- in two different species of rodents. Therefore, cross-reactivity with rat
and monkey is also ideally desired.
To this end, we investigated whether our human/mouse equivalent anti-MET antibodies
cross-reacted with MET from other species, including rat (Rattus norvegicus) and
cynomolgus monkey {Macaca fascicularis). Rat MET ECD (NCBI # NP_1 13705.1 ; aa 1-
931) and monkey MET ECD (NCBI # XP 005550635.2; aa 1-948) were obtained by
standard protein engineering techniques. Human and mouse MET ECD were used as
controls. A restricted panel of antibodies representative of both SEMA binders (71 D6,
7 1C3, 7 1D4, 7 1A3, 7 1G2) and PSI binders (76H10, 7 1G3) was selected. The 5D5 prior art
antibody was used as control. MET ECD proteins were immobilized in solid phase (100
ng/well in a 96-well plate) and exposed to increasing concentrations (0-40 nM) of
antibodies (with human constant regions) in solution. Binding was revealed using HRP-
conjugated anti-human Fc antibodies (Jackson Immuno Research Laboratories). As shown
in Figure 29, all human/mouse equivalent antibodies tested bound to human, mouse, rat
and simian MET with similar affinity and capacity, while 5D5 bound to human and simian
MET only. We conclude that the 7 1D6, 7 1C3, 7 1D4, 7 1A3, 7 1G2, 76H10 and 7 1G3
antibodies bind with similar affinity and capacity to human MET, mouse MET, rat MET and
simian MET, at least as determined by ELISA.
Example 26: Fine epitope mapping
In order to finely map the epitopes of MET recognized by human/mouse equivalent anti-
MET antibodies we pursued the following strategy. We reasoned that, if an antibody
generated in llamas and directed against human MET cross-reacts with mouse MET, then
this antibody probably recognizes a residue (or several residues) that is (or are) conserved
between H. sapiens and M. musculus but not among H. sapiens, M. musculus and L
glama. The same reasoning can be extended to ft norvegicus and M. fascicularis.
To investigate along this line, we aligned and compared the amino acid sequences of
human (UniProtKB # P08581 ; aa 1-932), mouse (UniProtKB # P 16056.1 ; aa 1-931), rat
(NCBI # NP_1 13705.1 ; aa 1-931 ) , cynomolgus monkey (NCBI # XP_005550635.2; aa 1-
948) and llama MET (GenBank # KF042853.1 ; aa 1-931) among each other (Figure 30).
With reference to Table 12, we concentrated our attention within the regions of MET
responsible for binding to the 7 1D6, 7 1C3, 7 1D4, 7 1A3 and 7 1G2 antibodies (aa 3 14-372
of human MET) and to the 76H1 0 and 7 1G3 antibodies (aa 546-562 of human MET).
Within the former region of human MET (aa 314-372) there are five residues that are
conserved in human and mouse MET but not in llama MET (Ala 327, Ser 336, Phe 343, lie
367, Asp 372). These amino acids are indicated with a black box and the progressive
numbers 1-5 in Figure 30. Of these, four residues are also conserved in rat and
cynomolgus monkey MET (Ala 327, Ser 336, lie 367, Asp 372). Within the latter region of
human MET (aa 546-562) there are three residues that are conserved in human and
mouse MET but not in llama MET (Arg 547, Ser 553, Thr 555). These amino acids are
indicated with a black box and the progressive numbers 6-8 in Figure 30. Of these, two
residues are also conserved in rat and cynomolgus monkey MET (Ser 553 and Thr 555).
Using human MET as a template, we mutagenized each of these residues in different
permutations, generating a series of MET mutants that are fully human except for specific
residues, which are llama. A schematic representation of the mutants is shown in Figure
3 1 . Next, we tested the affinity of selected SEMA-binding mAbs (71 D6, 7 1C3, 7 1D4, 7 1A3,
7 1G2) and PSI-binding mAbs (76H1 0 and 7 1G3) for these MET mutants by ELISA. To this
end, the various MET proteins were immobilized in solid phase (100 ng/well in a 96-well
plate) and then exposed to increasing concentrations of antibodies (0-50 nM) solution. As
the antibodies used were in their human constant region format, binding was revealed
using HRP-conjugated anti-human Fc secondary antibody (Jackson Immuno Research
Laboratories). Wild-type human MET was used as positive control. The results of this
analysis are presented in Table 24.
Table 24. The epitopes of MET responsible for agonistic antibody binding represent
residues conserved among H. sapiens, . musculus, R. norvegicus, . fascicularis
but not among the same species and L glama. The relevance of residues conserved
among human, mouse, rat, cynomolgus monkey but not llama MET for binding to agonistic
mAbs was tested by ELISA. Wild-type (WT) or mutant (MT) human MET ECD was
immobilized in solid phase and exposed to increasing concentrations of mAbs in solution.
Binding was revealed using anti-human Fc secondary antibodies. All binding values were
normalized to the WT protein and are expressed as % binding (E
MAX
) compared to WT
MET. Each mutant (A-L) contained at least 2 of the mutations (1-8) showed in Figure 3 1 .
mAb binding (% WT MET ECD)
MT MUTATIONS SEMA BINDERS PSI BINDERS
71D6 71C3 71D4 1A3 71G2 76H10 71G3
WT - 100,0 100, 0 100, 0 100, 0 100,0 - -
A 1,2,3 103,3 99, 8 114,5 116, 8 92, 1 - -
B 4,5 0,0 0 , 0 0 , 0 0 , 0 0,0 - -
C 1,2,3,4,5 0,0 0 , 0 0 , 0 0 , 0 0,0 - -
D 1,2 128,0 101, 8 119, 6 127, 9 113,5 - -
E 2,3,4 43, 6 59, 6 57, 2 65, 4 41,4 - -
F 2,4,5 0,0 0 , 0 0 , 0 0 , 0 0,0 - -
G 3,4,5 0,0 0 , 0 0 , 0 0 , 0 0,0 - -
H 2,4 38, 6 61, 6 58, 7 76, 7 40,2 - -
I 6,7,8 - - - - - 100,0 100,0
J 6,7 - - - - - 89, 0 91,2
K 6 , 8 - - - - - 0,0 0,0
L 7,8 - - - - - 0,0 0,0
The results presented above provide a definite and clear picture of the residues relevant for
binding to our agonistic antibodies.
All the SEMA binders tested (71 D6, 7 1C3, 7 1D4, 7 1A3, 7 1G2) appear to bind to the same
epitope that contains 2 key amino acids conserved in human, mouse, cynomolgus and rat
MET but not in llama MET lying within blade 5 of the SEMA β-propeller: lie 367 and Asp
372. In fact, mutation of Ala 327, Ser 336 or Phe 343 did not affect binding at all; mutation
of lie 367 partially impaired binding; mutation of lie 367 and Asp 372 completely abrogated
binding. We conclude that both lie 367 and Asp 372 of human MET are crucial for binding
to the SEMA-directed antibodies tested. These two residues are indicated with an "S" (for
SEMA) in Figure 30.
Also the PSI binders tested (76H1 0 , 7 1G3) appear to bind to the same epitope. In contrast
to the SEMA epitope, however, the PSI epitope contains only one key amino acid also
conserved in human, mouse, cynomolgus and rat MET but not in llama MET: Thr 555. In
fact, mutation of Arg 547 or Ser 553 did not affect binding at all, while mutation of Thr 555
completely abrogated it. We conclude that Thr 555 represents the crucial determinant for
binding to the PSI-directed antibodies tested. This residue is indicated with a "P" (for PSI)
in Figure 30.
Example 27: Uniqueness of human/mouse equivalent agonistic antibodies
The fine epitope mapping results presented in Example 2% 26 provide a molecularly
detailed demonstration that the agonistic antibodies presented by this invention possess
unique features not shared by any of the prior art molecules. This uniqueness is best
understood by performing the following analysis.
For most of the prior art antibodies discussed in Examples 12-14 there is no information
available on the precise epitopes that they recognize on MET. However, we know that
these epitopes must be different than the ones recognized by our antibodies because none
of the prior art molecules cross-reacts with mouse MET. An illuminating example of this
diversity is provided by 5D5/Onartuzumab, the only prior art anti-MET antibody annotated
with detailed molecular information on its interaction with MET. 5D5/Onartuzumab
recognizes 4 different residues that lie within blade 5 of the SEMA β-propeller, very close to
the amino acids responsible for interacting with our SEMA-binding antibodies (Merchant et
al., Proc Natl Acad Sci USA 110 , E2987-2996, 2013). These residues, indicated with an
"0" (for Onartuzumab) in Figure 30, correspond to Gin 328, Arg 331 , Leu 337 and Asn
338.
It is interesting to note that none of these residues is conserved between H. sapiens and M.
musculus. This is fully consistent with the notion that 5D5/Onartuzumab was generated
using a mouse as host, and explains why it does not cross-react with mouse MET
(Merchant et al., vedi supra, and our data presented in Figure 6 and Figure 29).
Furthermore, none of these residues is conserved either between H. sapiens and ft
norvegicus, but all of them are conserved between H. sapiens and M. fascicularis. This
explains why 5D5/Onartuzumab does not bind to rat MET but it does bind to cynomolgus
monkey MET (Figure 29).
In contrast to 5D5/Onartuzumab and to all other prior art molecules discussed here, our
human/mouse equivalent antibodies were generated using a llama as host and were
explicitly screened for their ability to cross-react with both human and mouse MET. Since
most of the few amino acids that are conserved between H. sapiens and M. musculus but
not among H. sapiens, M. musculus and L. glama (indicated in a black box in Figure 30)
are also conserved in ft norvegicus and M. fascicularis, chance determined that the
selected antibodies are also cross-reactive with rat and monkey.
In conclusion, both the immunization strategy and the screening design make the
antibodies of this invention unique. On one hand, the species used for immunization (L
glama) is sufficiently distant from H. sapiens, M. musculus, R. norvegicus and M.
fascicularis to guarantee the existence of enough mismatches among the amino acid
sequences of llama MET compared to MET from the other species (see Figure 30). These
mismatches are crucial, because an immunized host cannot raise antibodies against an
epitope that it recognizes as 'self. On the other hand, the human/mouse double screening
protocol forces the selection of those antibodies that recognize epitopes conserved
between these two species. This step is also essential because without two-species
panning one would simply select the antibodies that are most represented or display higher
affinity, but are not necessarily cross-reactive. The introduction of both these criteria (the
fifth species and the 'double dipping' protocol) allowed us to identify antibodies with new,
unique features.
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CLAIMS:
1. An antibody, or an antigen binding fragment thereof, which binds human MET protein
(hMET) with high affinity and binds mouse MET protein (mMET) with high affinity, wherein
the antibody or an antigen binding fragment thereof is a hMET agonist and a mMET
agonist.
2 . The antibody or antigen binding fragment thereof of claim 1, wherein the antibody or
antigen binding fragment thereof comprises at least one heavy chain variable domain (VH)
and at least one light chain variable domain (VL), wherein said VH and VL domain, when
tested as a Fab fragment, exhibit an off-rate (k
off
measured by Biacore) for hMET in the
range of from 1 x 0 3 s 1 to 1 x 0 2 s 1 , optionally 1 x 10~3 s 1 to 6 x 10~3 s , and exhibit an
off-rate (k
off
measured by Biacore) for mMET in the range of from 1 x 10~3 s 1 to 1 x 10~2 s 1 ,
optionally 1 x 10~3 s 1 to 6 x 10~3 s~1 .
3 . The antibody or antigen binding fragment thereof of claim 1 or 2 , wherein the antibody or
antigen binding fragment thereof has equivalent affinity for hMET and mMET.
4 . The antibody or antigen binding fragment thereof of any preceding claim, wherein the
antibody or antigen binding fragment thereof induces phosphorylation of hMET and induces
phosphorylation of mMET.
5 . The antibody or antigen binding fragment thereof of claim 4 , wherein the antibody or
antigen binding fragment induces phosphorylation of hMET with an EC
50
(as measured by
phospho-MET ELISA) of less than 3.0 nM, optionally less than 2.0 nM and induces
phosphorylation of mMET with an EC
50
(as measured by phospho-MET ELISA) of less than
3.0 nM, optionally less than 2.0 nM.
6 . The antibody or antigen binding fragment thereof of claim 4 or 5 , wherein the antibody or
antigen binding fragment thereof induces phosphorylation of hMET and mMET
equivalently.
7 . The antibody or antigen binding fragment thereof of claims 4-6, wherein the antibody or
antigen binding fragment thereof exhibits high phosphorylation potency for hMET and
exhibits high phosphorylation potency for mMET.
8 . The antibody or antigen binding fragment thereof of claim 7 , wherein the antibody or
antigen binding fragment thereof induces phosphorylation of hMET with an EC5o of less
than 1nM and/or an E
max
(as a percentage of HGF-induced activation in a phospho-MET
ELISA) of at least 80%.and induces phosphorylation of mMET with an EC
50
of less than
1nM and/or an E
max
(as a percentage of HGF-induced activation in a phospho-MET ELISA)
of at least 80%.
9 . The antibody or antigen binding fragment thereof of claims 1-6, wherein the antibody or
antigen binding fragment thereof exhibits low phosphorylation potency for hMET and
exhibits low phosphorylation potency for mMET.
10. The antibody or antigen binding fragment thereof of claim 9 , wherein the antibody or





(as a percentage of HGF-induced activation in a phospho-MET ELISA) of
60-80% and induces phosphorylation of mMET with EC
50
of 1nM-5nM and/or an E
max
(as a
percentage of HGF-induced activation in a phospho-MET ELISA) of 60-80%.
11. The antibody or antigen binding fragment thereof of any preceding claim, wherein the
antibody or antigen binding fragment thereof induces an HGF-like cellular response when
contacted with a human cell and induces an HGF-like cellular response when contacted
with a mouse cell.
12 . The antibody or antigen binding fragment thereof of claim 11, wherein the antibody or
antigen binding fragment thereof fully induces an HGF-like cellular response when
contacted with a human cell and when contacted with a mouse cell.
13. The antibody or antigen binding fragment thereof of claim 11 or 12, wherein full
induction of HGF-like cellular response is measurable as one, any two, or all of:
(i) in a cell scattering assay, the antibody or antigen binding fragment thereof
induces cell scattering comparable to maximal HGF-induced scattering when the antibody
or antigen binding fragment thereof is at a concentration of 0.1-1 .0 nM;
(ii) in an anti-apoptotic cell assay, the antibody or antigen binding fragment
thereof exhibits an EC5o of less than 1.1x that of HGF, and/or with an Emax (measured as a
% of total ATP content of non-apoptotic control cells) of greater than 90% that observed for
HGF; and/or
(iii) in a branching morphogenesis assay, cells treated with the antibody exhibit
greater than 90% of the number of branches per spheroid induced by the same (non-zero)
concentration of HGF.
14. The antibody or antigen binding fragment thereof of claim 11, wherein the antibody or
antigen binding fragment thereof partially induces an HGF-like cellular response when
contacted with a human cell and when contacted with a mouse cell.
15. The antibody or antigen binding fragment thereof of 14, wherein partial induction of an
HGF-like cellular response is measurable as:
(i) in a cell scattering assay, the antibody or antigen binding fragment thereof
induces cell scattering of at least 25% that induced by 0.1 nM homologous HGF when the
antibody concentration is 1 nM or lower;
(ii) in anti-apoptotic cell assay, the antibody or antigen binding fragment thereof
exhibits an EC
50
no more than 7.0x that of HGF and/or an E
max
cellular viability of at least
50% that observed for HGF; and/or
(iii) in a branching morphogenesis assay, cells treated with the antibody exhibit
at least 25% the number of branches per spheroid induced by the same (non-zero)
concentration of HGF;
and the antibody or antigen binding fragment does not fully induce an HGF-like
cellular response.
16. The antibody or antigen binding fragment thereof of any preceding claim, wherein the
antibody or antigen binding fragment thereof is a HGF competitor.
17. The antibody or antigen binding fragment thereof of claim 16 , wherein the antibody or
antigen binding fragment thereof competes with hHGF binding to hMET with an IC
50
of no
more than 5nM and/or an l
max
of at least 50% and competes with mHGF binding to mMET
with an IC
50
of no more than 5nM and/or an l
max
of at least 50%.
18. The antibody or antigen binding fragment thereof of claim 16 or 17, wherein the
antibody or antigen binding fragment thereof competes with hHGF and mHGF equivalently.
19 . The antibody or antigen binding fragment thereof of any one of claims 16-1 8 , wherein
the antibody or antigen binding fragment thereof is a full HGF competitor.
20. The antibody or antigen binding fragment thereof of claim 19 , wherein the antibody or
antigen binding fragment thereof competes with hHGF with an IC
50
of less than 2 nM and/or
an l
max
of greater than 90% and competes with mHGF with an IC
50
of less than 2 nM and/or
an l
max
of greater than 90%.
2 1 . The antibody or antigen binding fragment thereof of claims 16-18, wherein the antibody
or antigen binding fragment thereof is a partial HGF competitor.
22. The antibody or antigen binding fragment thereof of claim 2 1, wherein the antibody or
antigen binding fragment thereof competes with hHGF with an IC
50
of 2-5nM and/or an l
max
of 50%-90% and competes with mHGF with an IC
50
of 2-5nM and/or an \
max
of 50%-90%.
23. An antibody or antigen binding fragment thereof which recognizes an epitope of human
MET located in a region from amino acid residue 123 to residue223 of human MET, from
amino acid residue 224 to residue31 1 of human MET, from residue 314to residue 372 of
human MET or from residue 546 to residue562 of human MET.
24. An antibody or antigen binding fragment thereof which recognizes an epitope in the
extracellular domain of MET that comprises one or more amino acids conserved across
human and mouse MET.
25. An antibody or antigen binding fragment thereof which recognizes an epitope of human
MET comprising the amino acid residue Ile367 and/or Asp372 of human MET, optionally
wherein the epitope is located in the region from amino acid residue 314 to residue 372 of
human MET.
26. An antibody or antigen binding fragment thereof which recognizes an epitope of human
MET comprising the amino acid residue Thr555 of human MET optionally wherein the
epitope is located in the region from amino acid residue 546 to residue 562 of human MET.
27. An antibody or antigen binding fragment thereof which comprises a heavy chain
variable domain comprising H-CDR1 , H-CDR2 and H-CDR3, and a light chain variable
domain comprising L-CDR1 , L-CDR2 and L-CDR3, wherein:
H-CDR1 comprises an amino acid sequence selected from SEQ ID NO:2, 9 , 16, 23, 30, 37,
44, 5 1 , 58, 65, and 72;
H-CDR2 comprises an amino acid sequence selected from SEQ ID NO:4, 11, 18 , 25, 32,
39, 46, 53, 60, 67, and 74;
H-CDR3 comprises an amino acid sequence selected from SEQ ID NO:6, 13 , 20, 27, 34,
4 1 , 48, 55, 62, 69, and 76,
L-CDR1 comprises an amino acid sequence selected from SEQ ID NO:79, 86, 93, 100,
107, 114, 12 1 , 128, 135, 142, and 149;
L-CDR2 comprises an amino acid sequence selected from SEQ ID NO:81 , 88, 95, 102,
109, 116, 123, 130, 137, 144, and 151 ; and
L-CDR3 comprises an amino acid sequence selected from SEQ ID NO:83, 90, 97, 104,
111, 118, 125, 132, 139, 146, and1 53.
28. An antibody according to any one of claims 23-27 that is an antibody or antigen binding
fragment according to any one of claims 1-22.
29. [71 G2] An antibody or antigen binding fragment which comprises a heavy chain
variable domain comprising H-CDR1 , H-CDR2 and H-CDR3, and a light chain variable
domain comprising L-CDR1 , L-CDR2 and L-CDR3, wherein:
H-CDR1 comprises the amino acid sequence shown as SEQ ID NO:44,
H-CDR2 comprises the amino acid sequence shown as SEQ ID NO:46,
H-CDR3 comprises the amino acid sequence shown as SEQ ID NO:48,
L-CDR1 comprises the amino acid sequence shown as SEQ ID NO:121 ,
L-CDR2 comprises the amino acid sequence shown as SEQ ID NO:123, and
L-CDR3 comprises the amino acid sequence shown as SEQ ID NO:125.
30. [71 G2] The antibody or antigen binding fragment according to claim 23, wherein the
heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:1 67, or a
sequence at least 90%, 95%, 97% or 99% identical thereto, and the light chain variable
domain comprises the amino acid sequence of SEQ ID NO:168, or a sequence at least
90%, 95%, 97% or 99% identical thereto.
3 1 . The antibody or antigen binding fragment according to claim 29 or 30 that is an
antibody or antigen binding fragment according to any one of claims 1-22.
32. [71 D6] An antibody or antigen binding fragment which comprises a heavy chain variable
domain comprising H-CDR1 , H-CDR2 and H-CDR3, and a light chain variable domain
comprising L-CDR1 , L-CDR2 and L-CDR3, wherein:
H-CDR1 comprises the amino acid sequence shown as SEQ ID NO:30,
H-CDR2 comprises the amino acid sequence shown as SEQ ID NO:32,
H-CDR3 comprises the amino acid sequence shown as SEQ ID NO:34,
L-CDR1 comprises the amino acid sequence shown as SEQ ID NO:107,
L-CDR2 comprises the amino acid sequence shown as SEQ ID NO:109, and
L-CDR3 comprises the amino acid sequence shown as SEQ ID NO:1 11.
33. [71 D6] The antibody or antigen binding fragment according to claim 25, wherein the
heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:1 63, or a
sequence at least 90%, 95%, 97% or 99% identical thereto, and the light chain variable
domain comprises the amino acid sequence of SEQ ID NO:164, or a sequence at least
90%, 95%, 97% or 99% identical thereto.
34. The antibody or antigen binding fragment according to claim 32 or 33 that is an
antibody or antigen binding fragment according to any one of claims 1-22.
35.[71G3] An antibody or antigen binding fragment which comprises a heavy chain variable
domain comprising H-CDR1 , H-CDR2 and H-CDR3, and a light chain variable domain
comprising L-CDR1 , L-CDR2 and L-CDR3, wherein:
H-CDR1 comprises the amino acid sequence shown as SEQ ID NO:9,
H-CDR2 comprises the amino acid sequence shown as SEQ ID NO:1 1,
H-CDR3 comprises the amino acid sequence shown as SEQ ID NO:1 3 ,
L-CDR1 comprises the amino acid sequence shown as SEQ ID NO:86,
L-CDR2 comprises the amino acid sequence shown as SEQ ID NO:88, and
L-CDR3 comprises the amino acid sequence shown as SEQ ID NO:90.
36. [71 G3] The antibody or antigen binding fragment according to claim 27, wherein the
heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:1 57, or a
sequence at least 90%, 95%, 97% or 99% identical thereto, and the light chain variable
domain comprises the amino acid sequence of SEQ ID NO:158, or a sequence at least
90%, 95%, 97% or 99% identical thereto.
37. The antibody or antigen binding fragment according to claim 35 or 36 that is an
antibody or antigen binding fragment according to any one of claims 1-22.
38. An affinity variant or human germlined variant of an antibody or antigen binding
fragment according to any of claims 1-37.
39. The antibody or antigen binding fragment of any preceding claim which contains the
hinge region, CH2 domain and/or CH3 domain of a human IgG, optionally lgG1 .
40. An antibody according to any preceding claim comprising a CH2 and/or CH3 domain
having a sequence at least 90%, 95%, 97% or 99% identical to a human IgG, preferably
lgG1 , optionally wherein the CH2 and/or CH3 domain has been modified in order to reduce
or substantially eliminate one or more antibody effector functions.
4 1. The antibody or antigen-binding fragment of any preceding claim wherein the VH
and/or VL domains or one or more of the CDRs are derived from an animal of the
Camelidae family.
42. The antibody or antigen-binding fragment of claim 4 1 wherein the animal is a llama.
43. An isolated polynucleotide which encodes the antibody or antigen binding fragment of
any of claims 1-42.
44. An expression vector comprising the polynucleotide of claim 43 operably linked to
regulatory sequences which permit expression of the antibody or antigen binding fragment
thereof in a host cell or cell-free expression system.
45. A host cell or cell-free expression system containing the expression vector of claim 43.
46. A method of producing a recombinant antibody or antigen binding fragment thereof
which comprises culturing the host cell or cell free expression system of claim 45 under
conditions which permit expression of the antibody or antigen binding fragment and
recovering the expressed antibody or antigen binding fragment.
47. A pharmaceutical composition comprising an antibody or antigen binding fragment
according to any of claims 1 to 42 and at least one pharmaceutically acceptable carrier or
excipient.
48. An antibody or antigen binding fragment according to any one of claims 1-42, or the
pharmaceutical composition of claim 47 for use in therapy.
49. A method of treating or preventing liver damage in a human patient, optionally acute
liver damage or chronic liver damage, which comprises administering to a patient in need
thereof a therapeutically effective amount of a MET agonist antibody.
50. A method according to claim 49, wherein the MET agonist antibody is an antibody or
antigen binding fragment according to any of claims 1-42.
5 1. A method of treating or preventing kidney damage in a human patient, optionally acute
kidney damage, which comprises administering to a patient in need thereof a
therapeutically effective amount of a MET agonist antibody.
52. A method according to claim 5 1 , wherein the MET agonist antibody is an antibody or
antigen binding fragment according to any of claims 1-42.
53. A method of treating or preventing inflammatory bowel disease in a human patient,
optionally ulcerative colitis, which comprises administering to a patient in need thereof a
therapeutically effective amount of a MET agonist antibody.
54. A method according to claim 53, wherein the MET agonist antibody is an antibody or
antigen binding fragment according to any of claims 1-42.
55. A method of treating or preventing diabetes in a human patient, optionally type I or type
I I diabetes, which comprises administering to a patient in need thereof a therapeutically
effective amount of a MET agonist antibody.
56. A method according to claim 55, wherein the MET agonist antibody is an antibody or
antigen binding fragment according to any of claims 1-42.
57. A method of treating or preventing non-alcoholic steatohepatitis in a human patient,
which comprises administering to a patient in need thereof a therapeutically effective
amount of a MET agonist antibody.
58. A method according to claim 57, wherein the MET agonist antibody is an antibody or
antigen binding fragment according to any of claims 1-42.
59. A method of treating or promoting wound healing in a human patient, optionally a
patient having diabetes, which comprises administering to a patient in need thereof a
therapeutically effective amount of a MET agonist antibody.
60. A method according to claim 59, wherein the MET agonist antibody is an antibody or
































A . CLASSIFICATION O F SUBJECT MATTER
INV. C07K16/28
ADD.
According to International Patent Classification (IPC) or to both national classification and IPC
B . FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
C07K A61K
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal , BIOSIS, EMBASE, WPI Data
C . DOCUMENTS CONSIDERED TO B E RELEVANT
Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
WO 98/00543 Al (GENENTECH INC [US] ) 1-60
8 January 1998 (1998-01-08)
page 5 , l i ne 25 - l i ne 31
WO 96/38557 Al (GENENTECH INC [US] ; 1-60
SCHWALL RALPH H [US] ; TABOR KELLY HELEN
[US] ) 5 December 1996 (1996-12-05)
the 1A3 and 6G1 anti bodi es
W0 2004/108766 A2 (UNI DEGLI STUDI DEL 1-60
PI EM0NTE 0 [IT] ; PRAT MARIA GI0VANNA [IT] )
16 December 2004 (2004-12-16)
exampl e 4
US 2014/193431 Al (PARK YOUNG WOO [KR] ET 1-60
AL) 10 July 2014 (2014-07-10)
exampl e 4
-/-
X| Further documents are listed in the continuation of Box C . See patent family annex.
* Special categories of cited documents :
"T" later document published after the international filing date or priority
date and not in conflict with the application but cited to understand
"A" document defining the general state of the art which is not considered the principle or theory underlying the invention
to be of particular relevance
"E" earlier application or patent but published o n or after the international "X" document of particular relevance; the claimed invention cannot be
filing date considered novel or cannot be considered to involve an inventive
"L" documentwhich may throw doubts on priority claim(s) orwhich is step when the document is taken alone
cited to establish the publication date of another citation or other "Y" document of particular relevance; the claimed invention cannot be
special reason (as specified) considered to involve an inventive step when the document is
"O" document referring to an oral disclosure, use, exhibition or other combined with one o r more other such documents, such combination
means being obvious to a person skilled in the art
"P" document published prior to the international filing date but later than
the priority date claimed "&" document member of the same patent family
Date of the actual completion of the international search Date of mailing of the international search report
10 October 2017 30/10/2017
Name and mailing address of the ISA/ Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016 Mari noni J-C
C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT
Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
A BARDELLI C ET AL: "Agoni st Met anti bodi e s 1-48
defi ne the s i gnal l i ng threshol d requi red
for a ful l mi togeni c and i nvasi v e program
of Kaposi ' s Sarcoma cel l s " ,
BIOCHEMICAL AND BIOPHYSICAL RESEARCH
COMMUNICATIONS, ELSEVI ER, AMSTERDAM, NL,
vol . 334, no. 4 ,
9 September 2005 (2005-09-09) , pages
1172-1179 , XP027459158,
ISSN : 0006-291X, D0I :
10. 1016/J . BBRC.2005 .07 .020
[retri eved on 2005-07-29]
the whol e document
X W0 2011/150454 Al (UNIV M0NASH [AU] ; 1-60
LUDWIG INST FOR CANCER RES LTD [CH] ; JOHNS
TERRANCE) 8 December 2011 (2011-12-08)
c l aims 2 , 22-26
X W0 2012/138599 A2 (UNIV WASHINGTON STATE 49-52 ,
RES FDN [US] ; HARDING JOSEPH W [US] ; 55 ,56,
WRIGHT JOHN) 11 October 2012 (2012-10-11) 59 ,60
page 4 1 , l i ne 28 - page 42 , l i ne 10
X VARGAS G A ET AL: "HEPAT0CYTE GROWTH 49-52
FACTOR I N RENAL FAI LURE: PROMISE AND
REALITY" ,
KIDNEY INTERNATIONAL, NATURE PUBLISHING
GROUP, LONDON , GB,
vol . 57 , no. 4 , 1 Apri l 2000 (2000-04-01) ,
pages 1426-1436, XP001181170,
ISSN : 0085-2538, DOI :
10. 1046/J . 1523-1755 . 2000. 00987 . X
t i t l e
A WO 2007/090807 Al (UNIV DEGLI STUDI TORINO 1-60
[IT] ; C0M0GLI0 PAOLO MARIA [IT] ; VIGNA
ELISA [ ) 16 August 2007 (2007-08-16)
A KUNIO MATSUMOTO ET AL: "HGF-Met Pathway 49-52
i n Regenerati on and Drug Di scovery" ,
BIOMEDICINES,
vol . 2 , no. 4 ,
3 1 October 2014 (2014-10-31) , pages
275-300, XP055412657 ,
DOI : 10.3390/bi omedi c i nes2040275
-/--
C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT
Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
J . MELLADO-GI L ET AL: "Di srupti on of 55 ,56
Hepatocyte Growth Factor/c-Met Si gnal i ng
Enhances Pancreati c -Cel l Death and
Accel erates the Onset of Di abetes" ,
DIABETES,
vol . 60, no. 2 ,
27 October 2010 (2010-10-27) , pages
525-536, XP055412664,
US
ISSN : 0012-1797 , D0I : 10.2337/db09-1305
t i t l e
GIOVANNI PACCHIANA ET AL: "Monoval ency 1-60
Unl eashes the Ful l Therapeuti c Potenti a l
of the DN-30 Anti -Met Anti body" ,
JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN
SOCI ETY FOR BIOCHEMISTRY AND MOLECULAR
BIOLOGY,
vol . 285 , no. 46,
12 November 2010 (2010-11-12) , pages
36149-36157 , XP002621766,
ISSN : 0021-9258, D0I :
10. 1074/JBC. MHO. 134031
[retri eved on 2010-09-10]
the whol e document
0 2005/016382 Al (PFIZER PROD INC [US] ; 1-50
ABGENIX INC [US] ; MICHAUD NEI L R [US] ;
KAJIJI SH) 24 February 2005 (2005-02-24)
paragraphs [0122] , [0123] , [0180] ,
[0195] , [0245]
Patent document Publication Patent family Publication
cited in search report date member(s) date
WO 9800543 Al 08-01 -1998 AT 465257 T 15-05-2010
AU 729029 B2 25-01-2001
CA 2258153 Al 08-01-1998
DK 0922102 T3 16-08-2010
EP 0922102 Al 16-06-1999
P 2000515735 A 28-11-2000
US 6099841 A 08-08-2000
WO 9800543 Al 08-01-1998
ZA 9705851 B 04-01-1999
WO 9638557 Al 05-12 -1996 AU 713862 B2 09-12-1999
CA 2223269 Al 05-12-1996
EP 0832224 Al 01-04-1998
EP 1746160 A2 24-01-2007
I L 118476 A 31-10-2000
P H11506327 A 08-06-1999
US 5686292 A 11-11-1997
US 6207152 Bl 27-03-2001
US 6468529 Bl 22-10-2002
US 2009148457 Al 11-06-2009
US 2011280870 Al 17-11-2011
US 2012321628 Al 20-12-2012
US 2014056921 Al 27-02-2014
WO 9638557 Al 05-12-1996
ZA 9604383 B 01-12-1997
WO 2004108766 A2 16-12 -2004 AT 466031 T 15-05-2010
CA 2524329 Al 16-12-2004
DK 1641828 T3 02-08-2010
EP 1641828 A2 05-04-2006
US 2006140940 Al 29-06-2006
WO 2004108766 A2 16-12-2004
US 2014193431 Al 10-07 -2014 KR 20120134938 A 12-12-2012
US 2014193431 Al 10-07-2014
WO 2012165925 A2 06-12-2012
W0 2011150454 Al 08-12 -2011 AU 2011261161 Al 10-01-2013
EP 2576622 Al 10-04-2013
EP 2808344 Al 03-12-2014
P 2013534515 A 05-09-2013
US 2013171063 Al 04-07-2013
WO 2011150454 Al 08-12-2011
W0 2012138599 A2 11-10 -2012 AU 2012240424 Al 17-10-2013
CA 2832113 Al 11-10-2012
CN 103582490 A 12-02-2014
EP 2709650 A2 26-03-2014
ES 2622385 T3 06-07-2017
J P 6173298 B2 02-08-2017
J P 2014511858 A 19-05-2014
NZ 616210 A 31-07-2015
US 2013165392 Al 27-06-2013
US 2014088004 Al 27-03-2014
US 2017049843 Al 23-02-2017
WO 2012138599 A2 11-10-2012
W0 2007090807 Al 16-08 -2007 AT 514715 T 15-07-2011
page 1 of 2
Patent document Publication Patent family Publication
cited in search report date member(s) date
AU 2007213804 Al 16-08 2007
BR PI0707480 A2 03- 05 2011
CA 2638889 Al 16-08 2007
CN 101379192 A 04- 03 2009
CY 1111884 Tl 04- 11 2015
DK 1981981 T3 26- 09 2011
EA 200870234 Al 27- 02 2009
EP 1981981 Al 22- 10 2008
EP 2192188 Al 02-06 2010
ES 2368864 T3 23- 11 2011
I L 192879 A 27-02 2014
P 5306828 B2 02-10 2013
P 2009526010 A 16-07 2009
KR 20090013745 A 05- 02 2009
PT 1981981 E 04-10 2011
SG 169382 Al 30-03 2011
SG 169383 Al 30- 03 2011
SI 1981981 Tl 31- 01 2012
US 2009285807 Al 19-11 2009
US 2012134996 Al 31-05 2012
O 2007090807 Al 16-08 2007
ZA 200806559 B 27-12 2012
W0 2005016382 Al 24-02-2005 A R 047717 Al 15 -02 -2006
BR PI0413272 A 1 -10 -2006
CA 2534563 Al 24 -02 -2005
EP 1660127 Al 31 -05 -2006
GB 2404660 A 09 -02 -2005
GT 200400149 A 22 -02 -2005
HN 2004000285 A 27 -04 -2006
P 2007501013 A 25 -01 -2007
NL 1026776 C2 02 -08 -2005
PA 8608401 Al 03 -03 -2005
PE 07272005 Al 01 -10 -2005
T W 200523269 A 16 -07 -2005
US 2005054019 Al 1 -03 -2005
US 2010040629 Al 18 -02 -2010
US 2012321614 Al 2 -12 -2012
US 2014086914 Al 27 -03 -2014
UY 28453 Al 28 -02 -2005
WO 2005016382 Al 24 -02 -2005
page 2 of 2
